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Abstract 
 
Understanding the molecular mechanisms involved in fibroblast-mediated tissue 
contraction is essential for developing future therapeutics for anti-scaring and 
fibrosis treatment not only for eyes, but also for a wide range of fibrotic diseases. 
The small Rho GTPase Rac1 is a master regulator of actin dynamics, which plays 
an essential role in protrusive activity, tissue repair and wound healing. A genome 
wide microarray study was performed with/without the transient treatment of human 
conjunctival fibroblasts with Rac1 inhibitor NSC23766 in a collagen gel contraction 
model to unveil the signalling events underlying contractile activity and the 
contribution of Rac1 activation. Through a comprehensive analysis that combined a 
pilot parallel study of scarring in an in vivo model in rabbit following glaucoma 
filtration surgery, and previously obtained microarray data of human ocular fibrotic 
diseases (including trachoma and thyroid-associated orbitopathy), it was identified 
that the contraction process consisted of two phases: an early phase that exhibited 
a classic serum/wound response profile with upregulation of genes related to 
inflammation, matrix remodelling, and transcription activation; and a late stage when 
the hyperactive signal receded and the gene profile progressed to promote fibrosis. 
The transient treatment with NSC23766 altered gene expression, and the early 
inhibition of Rac1 blocked the fibroblasts from entering the contractile phenotype as 
a whole. Interestingly, NSC23766 did not supress the mRNA expression of Matrix 
Metalloproteinase (MMP) 1, 3 and 10 during contraction, but reduced their 
enzymatic activity. The link between the activation of the Rho GTPase and MMP 
expression was subsequently investigated using MMP1 as an example. The results 
showed Rac1, Cdc42 and RhoA differently regulated MMP1 expression and 
secretion in fibroblasts during contraction, suggesting that the rate-limiting step for 
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modulating MMP is the release in the extracellular medium rather than expression 
levels, drawing some interesting new prospects for therapies. 
  
 5 
 
Acknowledgments 
I would like to thank both of my primary and secondary supervisors, Dr. Maryse 
Bailly and Prof. Sir. Peng T. Khaw, for providing ultimate support, guidance, and 
mentoring throughout my PhD. Many thanks to Lady Peggy Khaw who very kindly 
provided help and guidance. I much appreciate Dr. Victoria Tovell’s contribution to 
the samples preparation work for the human conjunctival fibroblasts microarray. My 
thanks to Dr. David Simpson (Queen's University Belfast) for advice on techniques 
to analyse the microarray data. Thanks to Dr. Daniel Paull who performed the in 
vivo microarray and Dr. Jian-Liang Li (Sanford Burnham Prebys Medical Discovery 
Institute) who analysed the in vivo data. Many thanks to Ms. Diana Sefic-Svara who 
helped me a lot with the microscopy work. Thanks to Dr. Y. Itoh (University of 
Oxford) who kindly provided the in-house produced anti-MMP1 antibody. Thanks to 
Prof. Gregg B. Fields (Florida Atlantic University) who kindly provided the full-length 
MMP1 vector. Thanks to all of my group members (past and current) including Dr. 
Caroline Fittchet, Ms. Kasia Kozdon, Dr. Cynthia Yu-Wai-Man and Dr. Y-Hui Yang 
for the general support and help kindly provided. I would especially like to thank Dr. 
Zanetta Kechagia and Dr. Garima Sharma--without your company, those late nights 
and weekends in the lab would have been so long and lonely.   
 
Thanks to my parents, without whose love and support I would not be able to do 
anything. Thanks to Jun who is so supportive to my work and life. 
 
 
 
 
 6 
 
Table of Contents 
 
Declaration ................................................................................................................ 2 
Abstract ..................................................................................................................... 3 
Acknowledgments ..................................................................................................... 5 
Abbreviations ........................................................................................................... 11 
List of Figures .......................................................................................................... 13 
List of Tables ........................................................................................................... 18 
Chapter 1 Introduction .......................................................................................... 21 
1.1 Wound healing ............................................................................................... 21 
1.1.1 Blood clotting and inflammation .............................................................. 21 
1.1.2 Tissue growth (Proliferation) ................................................................... 22 
1.1.3 Tissue remodelling (maturation) .............................................................. 24 
1.2 Fibrosis and scarring...................................................................................... 25 
1.2.1 Molecular mechanisms of fibrosis ........................................................... 26 
1.2.2 Ocular Scarring ....................................................................................... 33 
1.3 Fibroblast-mediated contraction..................................................................... 37 
1.3.1 Fibroblasts ............................................................................................... 37 
1.3.2 Cell-mediated contraction........................................................................ 38 
1.3.3 Matrix degradation .................................................................................. 42 
1.4 Small Rho GTPases ...................................................................................... 48 
1.4.1 Small Rho GTPases and their regulators ................................................ 48 
1.4.2 Rac1, Cdc42 and RhoA .......................................................................... 51 
 7 
 
1.5 Aims and objectives ....................................................................................... 55 
Chapter 2 Material and methods .......................................................................... 56 
2.1 Fibroblast cell culture ..................................................................................... 56 
2.1.1 Human conjunctival samples................................................................... 56 
2.1.2 Cell culture .............................................................................................. 57 
2.2 Collagen contraction assay ............................................................................ 57 
2.2.1 Contraction assay with inhibitors ............................................................. 58 
2.2.2 Cell viability assay ................................................................................... 59 
2.3 Real-time PCR ............................................................................................... 59 
2.3.1 RNA isolation .......................................................................................... 59 
2.3.2 Reverse transcription .............................................................................. 60 
2.3.3 qPCR ....................................................................................................... 60 
2.4 Microarrays .................................................................................................... 62 
2.4.1 The in vitro microarray............................................................................. 62 
2.4.2 The in vivo microarray ............................................................................. 63 
2.5 MMP activity assay ........................................................................................ 64 
2.6 MMP1 ELISA ................................................................................................. 64 
2.7 siRNA ............................................................................................................. 65 
2.8 Protein extraction ........................................................................................... 66 
2.8.1 Protein extraction from 2D culture ........................................................... 66 
2.8.2 Protein extraction from 3D culture ........................................................... 67 
2.9 Western blotting ............................................................................................. 67 
2.10 Subcellular fractionation .............................................................................. 69 
 8 
 
2.11 Cell staining and microscopy ....................................................................... 70 
2.11.1 2D fluorescent imaging ......................................................................... 70 
2.11.2 Collagen gel imaging ............................................................................. 71 
2.12 Statistical analysis ....................................................................................... 73 
Chapter 3 The ‘molecular portrait’ of fibroblast-mediated contraction in vitro
 ............................................................................................................................... .74 
3.1 Gene expression profiling reveals global but transient gene activation during 
contraction ........................................................................................................... 74 
3.2 Early contraction: a classical wound healing/serum response ....................... 78 
3.3 Late contraction gene expression profile ....................................................... 87 
3.4 Gene expression profile changes induced by NSC23766 treatment ............. 96 
3.5 Relevance to in vivo contraction profile ......................................................... 99 
3.6 Relevance to ocular fibrotic disease profile ................................................. 106  
3.7 Validation of the in vitro contraction profile signatures ................................. 112 
3.8 Discussion ................................................................................................... 116 
Chapter 4 The involvement of the Rho GTPases in contraction ..................... 122 
4.1 The variable response of fibroblasts to NSC23766 treatment ..................... 122 
4.2 The Characterisation of other Rac inhibitors ................................................ 123 
4.3 The role of Rho GTPases Rac1, Cdc42 and RhoA in contraction ............... 131 
4.4 Role of ERK, P38 MAPK and PI3K signalling in contraction ....................... 133 
4.5 Role of Rac2, Racgap1, Arhgap5 and Arhgef3 in contraction ..................... 134 
4.6 Discussion ................................................................................................... 140 
Chapter 5 Matrix metalloproteinase 1 (MMP1) in the contraction ................... 146 
 9 
 
5.1 The expression of matrix metalloproteinases (MMPs) during in vitro 
contraction ......................................................................................................... 146 
5.2 Effect of NSC23766 treatment on MMPs’ expression and enzymatic activity
 ........................................................................................................................... 148 
5.3 Treatment with NSC23766 altered MMP1 expression and secretion .......... 151 
5.4 NSC23766 treatment led to intracellular accumulation of MMP1 in both 2D- 
and 3D-cultured cells ......................................................................................... 153 
5.4.1 MMP1 expression and secretion in 2D- and 3D-cultured fibroblasts .... 153 
5.4.2 The localisation of MMP1 in the cells .................................................... 154 
5.5 The effect of NSC23766 treatment on MMP1 secretion was not due to a direct 
inhibition of GTPase dynamin ............................................................................ 161 
5.6 Small Rho GTPases Rac1, Cdc42 and RhoA differentially regulated MMP1 
expression and secretion ................................................................................... 164 
5.7 ERK, P38 MAPK and PI3K signalling differentially regulated MMP1 
expression and secretion ................................................................................... 168 
5.8 Regulation of GTPases activation in MMP1 secretion ................................. 171 
5.9 Discussion ................................................................................................... 173 
Chapter 6 Discussion and future directions ..................................................... 181 
6.1 Signalling pathways characterised in contraction ........................................ 182 
6.2 A model for the role of small GTPases in contraction .................................. 184 
6.3 A model for the regulation of MMP1 expression and secretion during 
contraction ......................................................................................................... 187 
6.4 Future direction ............................................................................................ 190 
Bibliography ........................................................................................................... 192 
 10 
 
Appendix ............................................................................................................... 210 
Gene symbols and descriptions ......................................................................... 210 
 
  
 11 
 
Abbreviations 
2D Two-dimensional space     
3D Three-dimensional space     
Akt Protein Kinase B      
APMA 4-aminophenylmercuric acetate    
BSA Bovine serum albumin     
cDNA Complementary DNA     
CID Corrected integrated density      
CNS Central nervous system     
DAVID The Database for Annotation, Visualization and Integrated Discovery 
DMSO Dimethyl sulfoxide      
DNA Deoxyribonucleic acid     
DPBS Dulbecco's phosphate-buffered saline     
ECM Extracellular matrix      
EGF Epidermal growth factor      
ELISA Enzyme-linked immunosorbent assay    
ERK Extracellular-signal-regulated kinase    
FBS Fetal bovine serum      
FES Floppy eye syndrome     
GAP GTPase-activating proteins     
GDI Guanine nucleotide dissociation inhibitor   
gDNA Genomic DNA      
GDP Guanosine diphosphate     
GEF Guanine nucleotide exchange factors    
GFP Green fluorescent protein     
GFS Glaucoma filtration surgery     
GTP Guanosine triphosphate     
His-tag Polyhistidine-tag      
HTF Human Tenon's fibroblast     
IC50 The half maximal inhibitory concentration   
IOP Intraocular pressure     
mAChRs Muscarinic acetylcholine receptors     
MAPK Mitogen-activated protein kinase    
MMP Matrix metalloproteinase     
mRNA Messenger RNA       
mTORC2 Mammalian target of rapamycin complex 2   
PBS Phosphate buffered saline     
PCA Principal component analysis     
PCR Polymerase chain reaction     
PDGF Platelet-derived growth factor    
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase   
RMA Robust multi-array average     
ROCK Rho-associated protein kinase     
qPCR Quantitative real time polymerase chain reaction    
 12 
 
SEM The standard error of the mean    
TBS Tris-buffered saline      
TBS-T Tris-buffered saline, 0.1% Tween 20    
TED Thyroid-associated orbitopathy    
TGFα Transforming growth factor alpha    
TGFβ Transforming growth factor beta    
  
 13 
 
List of Figures 
 
Chapter 1  
Figure 1.1 The phases of wound healing process. .................................................. 25 
Figure 1.2 Regulators of fibrosis. ............................................................................ 32 
Figure 1.3 The pathogenesis of glaucoma (outflow mechanism) compared to normal 
eye. .......................................................................................................................... 35 
Figure 1.4 Graphic illustration of glaucoma filtration surgery (GFS). ....................... 36 
Figure 1.5 The free-floating fibroblast-populated collagen gel contraction assay. .. 40 
Figure 1.6 The domain structural characterisation of the MMPs. ............................ 45 
Figure 1.7 The regulations of Rho GTPases by GEF, GAP and GDI. ..................... 50 
Figure 1.8 Rac1, Cdc42 and RhoA regulate actin cytoskeleton via their downstream 
effector proteins. ...................................................................................................... 52 
 
Chapter 3 
Figure 3.1 The distribution of normalised log2 probe set intensity values of the 
samples. .................................................................................................................. 76 
Figure 3.2 Principal Component Analysis (PCA) plot showing the separation of 
individual samples. .................................................................................................. 76 
Figure 3.3 Hierarchical clustering heatmap showing the differential gene 
expressions (log2 fold) during contraction at the time points day0, 3 and 5 
with/without NSC23766 treatment. .......................................................................... 77 
Figure 3.4 Paired comparisons of genes differentially expressed among day0, 3 and 
5 during the in vitro contraction. .............................................................................. 78 
Figure 3.5 Functional annotation by DAVID of the first 1000 genes 
up/downregulated during early contraction from day0 to 3. ..................................... 86 
 14 
 
Figure 3.6 Paired comparisons of the fibroblast serum responsive (SR) genes 
(genes that were identified in a study of transcriptional profile of human foreskin 
fibroblasts in response to serum that were regulated dynamically during the in vitro 
contraction. .............................................................................................................. 87 
Figure 3.7 Functional annotation of the genes regulated throughout the whole 
contraction process. ................................................................................................ 95 
Figure 3.8 Venn diagrams showing that majority of the early contraction gene 
signalling were suppressed by NSC23766 treatment. ............................................. 97 
Figure 3.9 Functional annotation analysis by DAVID showing the modulations of 
NSC23766 made on the early contraction gene signalling...................................... 98 
Figure 3.10 Characterisation of the functional gene clusters regulated during the in 
vivo wound healing study. ..................................................................................... 102 
Figure 3.11 Paired comparisons of the gene expression profiles of the in vivo and in 
vitro wounding models. .......................................................................................... 103 
Figure 3.12 Venn diagrams showing the common genes expressed between the in 
vitro contraction and trachoma, and the in vitro contraction and the thyroid-
associated orbitopathy (TED). ............................................................................... 108 
Figure 3.13 Annotated gene functional clusters (analysed by DAVID) of the common 
up/downregulated genes between the in vitro contraction and trachoma (a), and the 
ones of the in vitro contraction and TED (b). ......................................................... 111 
Figure 3.14 Validation of the in vitro early contraction profile signatures by qPCR.
 .............................................................................................................................. 114 
Figure 3.15 Validation of the in vitro late contraction profile signatures by qPCR. 115 
 
Chapter 4 
Figure 4.1 The variable responses of fibroblasts to NSC23766 treatment. ........... 125 
 15 
 
Figure 4.2 Characterisation of the inhibitory efficiency of a range of Rac inhibitors 
including NSC23766, W56, Z62954982, EHT1864 and Ehop-016, as well as the 
broad MMP inhibitor GM6001 and the Rho-associated protein kinase (ROCK) 
inhibitor H1152 (labelled as ‘ROCK’) on fibroblast-mediated collagen gel 
contraction. ............................................................................................................ 126 
Figure 4.3 Characterisation of the inhibition efficiency of the Rac inhibitors 
Simvastatin, NSC23766, EHT1864 and Ehop-016, as well as the broad MMP 
inhibitor GM6001 and the Rho-associated protein kinase (ROCK) inhibitor H1152 
(labelled as ‘ROCK’) on collagen contraction with eight different conjunctival 
fibroblasts. ............................................................................................................. 129 
Figure 4.4 Cell viability assay performed on the inhibitors treated contracting 
fibroblasts at day2 and day7. ................................................................................ 130 
Figure 4.5 Small Rho GTPases Rac1, Cdc42 and RhoA differently regulated the 
contractile activity of human conjunctival fibroblast HTF1785R. ........................... 132 
Figure 4.6 The ERK, P38 MAPK and PI3K signalling differently regulated the 
contractile activity of human conjunctival fibroblast HTF1785R. ........................... 136 
Figure 4.7 Illustrative diagram showing the potential regulatory roles of Rac1, Cdc42 
and RhoA, and ERK, PI3K and P38 signalling in contraction. ............................... 137 
Figure 4.8 Validation of the siRNA knockdown of Rac2, Racgap1, Arhgap5 and 
Arhgef3 respectively in HTF1785R using Western blot. ........................................ 138 
Figure 4.9 Collagen gel contraction kinetics of the Rac2, Racgap1, Arhgap5 and 
Arhgef3 knockdown HTF1785R cells respectively treated with/without NSC23766.
 .............................................................................................................................. 139 
 
Chapter 5 
Figure 5.1 mRNA expression levels of MMP1, 3 and 10 were upregulated during 
contraction, independently of treatment with NSC23766. ..................................... 149 
 16 
 
Figure 5.2 Transient treatment with NSC23766 significantly inhibited total MMP 
activity in the contraction medium. ........................................................................ 150 
Figure 5.3 NSC23766 significantly blocked MMP1 protein released in the culture 
medium during contraction. ................................................................................... 152 
Figure 5.4 NSC23766 increased MMP1 intracellular protein expression. ............. 152 
Figure 5.5 NSC23766 treatment led to accumulation of intracellular MMP1 in 
HTF1785R, which was stronger in collagen gels (3D) comparing to monolayers 
(2D). ...................................................................................................................... 156 
Figure 5.6 Immunofluorescence staining of MMP1 expression in HTF1785R cells 
cultured on tissue culture flask (2D). ..................................................................... 157 
Figure 5.7 Immunofluorescence staining of MMP1 in fibroblast cells HTF7071 and 
HTF9154 contracting in collagen gels at day3. ..................................................... 158 
Figure 5.8 Immunofluorescence staining of MMP1 in fibroblast cells HTF1785R 
contracting in the collagen gels at day3. ............................................................... 159 
Figure 5.9 NSC23766 treatment led to MMP1 accumulation in the cytoplasm. .... 160 
Figure 5.10 Dynamin inhibition significantly suppressed MMP1 protein secretion. 163 
Figure 5.11 Silencing of Rac1, Cdc42 or RhoA increased MMP1 expression. ..... 166 
Figure 5.12 Downregulation of Rac1, Cdc42 or RhoA increased MMP1 production, 
whilst only RhoA inhibition significantly prevented MMP1 secretion. .................... 167 
Figure 5.13 The inhibition of ROCK, a downstream mediator of RhoA, also 
increased MMP1 protein production in the cells, but had no effect on its secretion.
 .............................................................................................................................. 168 
Figure 5.14 The ERK, P38 MAPK and PI3K signalling differentially regulated MMP1 
expression and secretion. ..................................................................................... 170 
Figure 5.15 Silencing of Rac2, Arhgap5, Racgap1 or Arhgef3 increased MMP1 
expression in the cells but differently regulated its release in the medium. ........... 172 
Figure 5.16 Silencing of MMP1 by siRNA in conjunctival fibroblasts only mildly 
affected contraction. .............................................................................................. 174 
 17 
 
Chapter 6 
Figure 6.1 Conclusion of the annotated functional gene clusters that are associated 
with the activation or inhibition of the contractile activity. ...................................... 183 
Figure 6.2 Illustrative diagram showing the potential regulatory roles of numerous 
modulators in the conjunctival fibroblast-mediated contraction. ............................ 186 
Figure 6.3 A model for the potential mechanisms by which the expression and 
release of MMP1 are regulated during the conjunctival fibroblast-mediated 
contraction. ............................................................................................................ 189 
Figure 6.4 A putative model for the regulation of MMP1 trafficking by RhoA and 
Rac1, in cooperation with the Rab, Ral and Rap family of proteins. ..................... 191 
 
  
 18 
 
List of Tables 
 
Chapter 1  
Table 1.1 MMPs expression in the different structures of the eye (Wong et al., 
2002). ...................................................................................................................... 46 
 
Chapter 2 
Table 2.1 Isolated primary conjunctival fibroblasts and their donors’ information. .. 56 
Table 2.2 The inhibitors and their concentrations used in the study ....................... 58 
Table 2.3 Taqman Gene Expression Assays used in the qPCR experiments.  ...... 61 
Table 2.4 List of siRNA used for the gene silencing study. ..................................... 66 
Table 2.5 Primary antibodies used in the Western blot experiments. ..................... 69 
Table 2.6 Secondary antibodies used in the Western blot experiments. ................. 69 
 
Chapter 3 
Table 3.1 The symbol, definition and fold change of the first 100 genes upregulated 
in the early contraction from day0 to 3 (fold change>2 times, p value<0.05). ......... 79 
Table 3.2 The symbol, definition and fold change of the first 100 genes 
downregulated in the early contraction from day0 to 3 (fold change>2 times, p 
value<0.05) .............................................................................................................. 82 
Table 3.3 The symbol, definition and fold change of the first 100 genes upregulated 
in the late contraction from day3 to 5 (fold change>2 times, p value<0.05).. .......... 89 
Table 3.4 The symbol, definition and fold change of the first 100 genes 
downregulated in the late contraction from day3 to 5 (fold change>2 times, p 
value<0.05). ............................................................................................................. 92 
 19 
 
Table 3.5 The gene symbol, definition and fold changes of the first 20 common 
upregulation genes in the in vitro early contraction and in vivo profiles (fold 
change>1.2, p<0.05). ............................................................................................ 104 
Table 3.6 The gene symbol, definition and fold changes of the first 20 common 
downregulation genes in the in vitro early contraction and in vivo profiles (fold 
change>1.2, p<0.05). ............................................................................................ 104 
Table 3.7 The gene symbol, definition and fold change of the first 20 upregulated 
genes expressed exclusively in the in vivo wounding model (fold change>2, 
p<0.05). ................................................................................................................. 105 
Table 3.8 The gene symbol, definition and fold change of the first 20 downregulated 
genes expressed exclusively in the in vivo wounding model (fold change>2, 
p<0.05). ................................................................................................................. 105 
Table 3.9 The gene expression profiles of the common upregulated trachoma 
signature genes in the in vitro early (day0-3) and late (day3-5) contraction stages 
(fold change>1.2 times, p<0.05). ........................................................................... 109 
Table 3.10 The gene expression profiles of the common downregulated trachoma 
signature genes in the in vitro early (day0-3) and late (day3-5) contraction stages 
(fold change>1.2 times, p<0.05). ........................................................................... 110 
Table 3.11 The gene expression profiles of the common upregulated thyroid-
associated orbitopathy (TED) signature genes in the in vitro early (day0-3) and late 
(day3-5) contraction stages (fold change>1.2 times, p<0.05). .............................. 110 
Table 3.12 The gene expression profiles of the common downregulated thyroid-
associated orbitopathy (TED) signature genes in the in vitro early (day0-3) and late 
(day3-5) contraction stages (fold change>1.2 times, p<0.05). .............................. 111 
Table 3.13 Early contraction gene candidates selected for validation. .................. 113 
Table 3.14 Late contraction gene candidates selected for validation. ................... 113 
Table 3.15 Examples of the implications of the in vitro contraction signature genes 
in various fibrotic diseases and cancers. ............................................................... 121 
 20 
 
 
Chapter 4 
Table 4.1 Gene expression fold changes of Rac2, Racgap1, Arhgap5 and Arhgef3 
in the in vitro microarray of fibroblast-mediated contraction at day0-3, day3-5 and 
NSC23766 treated samples at day3 (p<0.05). ...................................................... 138 
 
Chapter 5 
Table 5.1 The gene expression fold changes of Matrix metalloproteinases (MMPs) 
regulated during (a) early contraction from day0 to 3 and (b) late contraction from 
day3 to 5. ............................................................................................................... 147 
Table 5.2 The gene expression fold changes of MMPs regulated in the NSC23766 
treated samples at (a) day3 and (b) day5 compared to untreated control samples.
 .............................................................................................................................. 147 
Table 5.3 Summary of the changes of MMP1 protein expression and secretion upon 
siRNA knockdown of small Rho GTPases Rac1, Cdc42, RhoA and Rac2, and GAPs 
and GEFs including Arhgap5, Racgap1 and Arhgef3............................................ 177 
Table 5.4 Summary of the regulation of the inhibitors of ERK (U0126), P38 MAPK 
(SB203580) and PI3K (LY294002) pathways on MMP1 expression and secretion 
respectively in contracting conjunctival fibroblasts HTF1785R. ............................ 178 
  
 21 
 
 
Chapter 1 Introduction 
 
1.1 Wound healing  
Wound healing is the process by which body tissue repairs itself after injury. It is a 
complicated but well-organised process. With the goal of restoring tissue 
homeostasis and architecture after insult, tissue repair starts immediately after 
wounding by synthesising a fibrous extracellular matrix (ECM) to replace lost or 
damaged tissue. The newly deposited ECM is then re-modelled over time to 
emulate normal tissue. The process is an orchestrated biological phenomena that 
consists of three sequential and predictable phases: blood clotting (homeostasis) 
and inflammation, tissue growth (proliferation), and tissue remodelling (maturation) 
(Figure 1.1) (Clark, 1996, Stadelmann et al., 1998, Singer and Clark, 1999). 
 
1.1.1 Blood clotting and inflammation 
Immediately after wounding, platelets in the blood are activated upon contact with 
the collagen exposed from damaged endothelium. They stick to the injury site by 
binding to the extracellular matrix via their collagen-specific glycoprotein surface 
receptors. The platelets change into amorphous shape and aggregate to form a 
plug to prevent further bleeding. A series of clotting factors released by platelets 
trigger the activation of the zymogen prothrombin into thrombin, which in turn 
catalyses the conversion of the soluble plasma protein fibrinogen into insoluble 
fibrous fibrin. The polymerized fibrin forms a mesh of fibres around the platelet plug 
to build a temporary clot (Pallister and Watson, 2011). The clot is also the main 
structural support for the wound until the deposition of newly formed collagen, which 
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serves to induce homeostasis and provides a matrix for the inflammatory cells. 
Meanwhile, platelets release mediators into the blood, including growth factors such 
as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), 
transforming growth factor beta (TGFβ) and numerous cytokines, which promote the 
recruitment of inflammatory leukocytes from the bloodstream to the site of injury. 
Within an hour of wounding, infiltrating neutrophils are attracted to the site. They 
phagocytose debris, remove contaminating bacteria by releasing free radicals, and 
cleanse the wound by producing proteases that break down the damaged tissue. 
Thereafter, they undergo apoptosis or are phagocytosed by macrophages, which 
are differentiated from monocytes and play important roles in amplifying 
inflammatory response and tissue debridement. Two days after injury, macrophages 
become the predominant cells in the wound, where they stimulate the re-
epithelialisation process, initiate the development of granulation tissue and release 
a variety of pro-inflammatory cytokines. These cytokines include IL-1 and IL-6, and 
growth factors such as fibroblast growth factor (FGF), EGF, TGFβ and PDGF, which 
lead to the next stage of the wound healing process (Rasche, 2001, Versteeg et al., 
2013, Midwood et al., 2004, Martin and Leibovich, 2005, Greenhalgh, 1998).  
 
1.1.2 Tissue growth (Proliferation) 
The proliferation phase commences even before the inflammatory phase has 
ended. In this stage, re-epithelialisation, neovascularisation, granulation tissue 
formation, collagen deposition and wound contraction occur. Following the release 
of growth factors and cytokines at the wound site, the epithelial cells migrate and 
proliferate, resulting in re-epithelialisation to achieve wound closure. 
Neovascularisation, which is the process of angiogenesis, starts concurrently with 
the migration and proliferation of fibroblasts, endothelial cells, and macrophages. 
The vascular endothelial growth factor (VEGF) and FGF secreted by macrophages 
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promote the formation of new blood vessels by endothelial cells. Neovascularisation 
is imperative for other stages in wound healing, as it provides the oxygen and 
nutrients that are required by active fibroblasts and epithelial cells.  
 
Simultaneously with angiogenesis, the formation of granulation tissue starts 
approximately four days after injury. Fibroblasts are attracted by the growth and 
chemotactic factors produced by macrophage and mast cells, and they infiltrate and 
accumulate at the site of the wound. Their numbers peak at one to two weeks post-
wounding, and eventually they become the main residential cells in the site. By 
depositing fibronectin and collagen, fibroblasts grow and form a new, provisional 
ECM that not only allows all the cells involved in the process to attach to, grow and 
differentiate, but also facilitates their further migration. Later this provisional matrix 
will be replaced with a matrix that closely resembles the previous non-injured tissue. 
At the same time, fibroblasts also secrete growth factors to attract other cell types to 
the wound site.  
 
A key phase of wound healing is contraction, which occurs approximately a week 
after injury, and initially starts without the involvement of myofibroblasts. Later on, 
upon the induction of TGFβ and PDGF, fibroblasts phenotypically differentiate into 
myofibroblasts that express alpha smooth muscle actin (α-SMA), which is normally 
found in smooth muscle cells. Myofibroblasts move along the fibronectin/fibrin 
provisional ECM to reach the wound borders, where they align themselves and form 
connections to the ECM to generate a constrictive mechanical force to cause wound 
closure, while fibroblasts continue to lay down collagen to reinforce the wound. At 
this stage, the wound closes more quickly due to the presence of myofibroblasts 
than it does in the first, non-differentiated fibroblast-dependent stage. Finally, the 
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wound edges are pulled together as the synthesis of new collagen and the 
degradation of the old matrix become equal, and the tensional homeostasis is 
restored. Fibroblasts gradually stop contracting and undergo apoptosis, which 
signals the beginning of the maturation phase (Falanga, 2005, Kondo and Ishida, 
2010, Chang et al., 2004, Stadelmann et al., 1998, Ruszczak, 2003, Mirastschijski 
et al., 2004, Deodhar and Rana, 1997, Hinz, 2006, Greenhalgh, 1998).  
 
1.1.3 Tissue remodelling (maturation) 
During the maturation period, the granulation tissue formed in the tissue growth is 
replaced by a framework of collagen and elastin fibres, which are saturated with 
proteoglycans and glycoproteins. The tissue then remodels with the synthesis of 
new collagen, and the rearrangement of the originally disorganised collagen fibres 
that are cross-linked and aligned along tension lines. The final product of this 
procedure is scar tissue, which is formed as a result of the continued synthesis and 
catabolism of collagen. The key regulators of the collagen degradation are matrix 
metalloproteinases (MMPs), which are secreted by macrophages, epidermal cells, 
and endothelial cells, as well as fibroblasts. The maturation phase lasts from a few 
weeks to a year or longer, depending on the type of the wound (Morton and Phillips, 
2016, Kondo and Ishida, 2010, Sethi et al., 2002).  
 
These steps of wound healing do not occur in series but rather considerably overlap 
with each other. Recently, a parallel model has been suggested that divides the 
wound healing process into two stages: an early phase that leads to the 
homeostasis and formation of the provisional matrix, and a cellular phase in which 
the multiple cell types work together to order inflammation, re-epithelisation and 
remodelling (Orgill, 2009).  
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Figure 1.1 The phases of wound healing process.   
Wound healing is a complicated but well-organised process including inflammation, 
proliferation, and maturation, with a number of cells and many cytokines, growth factors and 
proteases closely involved. The final product of this procedure is scar tissue, which forms as 
a result of the formation and contraction of a new fibrous extracellular matrix that replaces 
the previous lost or damaged tissue (figure adapted from (Kondo and Ishida, 2010)).  
 
 
1.2 Fibrosis and scarring 
Fibrosis is characterised by the production and accumulation of excessive fibrous 
connective tissue in response to wounding, and can be a reactive, benign, or 
pathological state (Birbrair et al., 2014). Derived through exaggerated wound 
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healing process, fibrosis causes the formation of scar tissue that is rich in 
extracellular matrix proteins, such as collagens and fibronectin, affecting normal 
tissue architecture and obstructing organ function (Neary et al., 2015). Currently a 
significant number of the world population is suffering from fibroproliferative 
diseases including pulmonary fibrosis, systemic sclerosis, liver cirrhosis, 
cardiovascular disease, progressive kidney disease and other chronic inflammation 
diseases. Fibrotic tissue remodelling can also promote cancer metastasis and 
increase chronic graft rejection in transplant recipients (Wynn, 2007, Wynn, 2008). 
In the developed world, these fibrotic-driven diseases account for up to 45% of all 
deaths (Lim and Kim, 2008). In the eye alone, deregulated tissue contraction and 
scarring are involved in either directly causing or failure of treatment of virtually 
every major blinding disease, for example glaucoma, cataract, macular 
degeneration and diabetes (Dahlmann et al., 2005, Friedlander, 2007). However, 
despite its enormous impact on human health, the detailed mechanisms by which 
‘the wound healing gone awry’ and whether fibrosis and scarring can be 
therapeutically perturbed are still poorly understood. A thorough investigation of the 
cellular components and underlying molecular mechanisms is urgently required to 
identify cures for the often devastating health conditions. 
 
1.2.1 Molecular mechanisms of fibrosis 
Tissue fibrosis is determined by two major processes: the synthesis and the 
degradation of the ECM, which regulate the net increase or decrease of the 
collagen within a wound (Pardo and Selman, 2006). During skin homeostasis, both 
processes are in balance but can be shifted under specific conditions, for example 
towards ECM synthesis upon wound healing. The molecular mechanisms of ECM 
synthesis are addressed in the current section (Figure 1.2). The other critical part of 
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the tissue remodelling—ECM degradation, and the central effector cell in fibrosis—
fibroblast, will be described in details in the later sections. 
 
1.2.1.1 Chronic infections 
 Persistent infection with bacteria, viruses, fungi or multicellular parasites drives 
chronic inflammation and the development of fibrosis. It triggers marked alterations 
in the activation status of fibroblasts and M2 macrophages, which are key cells 
involved in the remodelling process. The conserved pathogen-associated molecular 
patterns (PAMPs) are pathogen by-products including lipoproteins, bacterial DNA 
and double-stranded RNA that are recognised by pattern recognition receptors 
(PRRs) found on a wide variety of cells, including fibroblasts. The interactions 
between PAMPs and PRRs activate numerous pro-inflammatory cytokine and 
chemokine pathways, which maintain the cells at a state of activation as well as 
promoting fibroblasts to differentiate into collagen-producing myofibroblasts (Akira 
and Takeda, 2004, Meneghin and Hogaboam, 2007, Wynn, 2004). 
 
1.2.1.2 Origins of myofibroblasts 
Myofibroblasts can be derived from multiple sources, including resident 
mesenchymal fibroblasts, epithelial cells in the process of epithelial-mesenchymal 
transition (EMT) and endothelial cells through endothelial-mesenchymal transition 
(EndMT) (Willis et al., 2006, Zeisberg et al., 2007, Kalluri and Neilson, 2003). 
Furthermore, it is reported that bone marrow stem cells can differentiate into a 
unique circulating fibroblast-like cell type that has a fibroblast/myofibroblast-like 
phenotype and are now commonly called fibrocyte (Ebihara et al., 2006, Russo et 
al., 2006). Also, in liver fibrosis, the resident hepatic stellate cells (HSC) are found to 
contribute to the primary source of myofibroblasts (Iredale, 2007). With the induction 
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of the CXC chemokine receptor family such as chemokine receptor 4 (CXCR4), CC 
chemokine receptor 7 (CCR7) and the pro-fibrotic chemokine CC Motif Chemokine 
Ligand 2 (CCL2), these cells travel to the site of injury and participate with the 
resident mesenchymal cells in the reparative process (Phillips et al., 2004, Strieter 
et al., 2007, Moore et al., 2005).  
   
1.2.1.3 Cytokines and growth factors 
Cytokines are important cell signalling molecules, which include chemokines, 
interferons, interleukins, lymphokines and tumour necrosis factors. They are 
produced by a broad range of cells such as macrophages, lymphocytes, and mast 
cells, as well as endothelial cells, fibroblasts and various stromal cells (Thomson 
and Lotze, 2003). Many cytokines possess the ability to induce fibrogenesis. For 
instance, the pro-inflammatory cytokine interleukin 6 (IL-6) is involved in the 
pathogenesis of many fibrogenic diseases, due to its ability of regulating the 
synthesis of a broad spectrum of acute phase proteins (Choi et al., 1994, Klee et al., 
2016, Kobayashi et al., 2015). Moreover, the production of the pro-fibrotic cytokines 
including interleukin 13 (IL-13) and interleukin 4 (IL-4) is found to closely associate 
with the CC chemokine activity, which is also important in mediating fibrosis (Blease 
et al., 2000, Gao et al., 1997). IL-4 is showed to augment collagen expression in 
fibroblasts with a higher efficiency than TGFβ (Fertin et al., 1991). IL-13 shares 
many functional activities with IL-4, it can regulate fibrosis independently of IL-
4Ra/Stat6 signalling pathways and is identified as a dominant effector cytokine of 
fibrosis in several models of fibrosis (Zurawski et al., 1993, Blease et al., 2001, 
Jakubzick et al., 2004, Joshi et al., 2006). Similarly, interleukin 5 (IL-5), interleukin 
17 (IL-17) and interleukin 21 (IL-21) are found to perform distinct roles in the 
regulation of tissue remodelling and fibrosis (Emad and Emad, 2008, Gharaee-
Kermani and Phan, 1997, Brodeur et al., 2015, Lei et al., 2015).  
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Chemokines are leukocyte chemoattractants that function together with pro-fibrotic 
cytokines during fibrogenesis to recruit fibroblasts, macrophages and other key 
effector cells to the wounding site. Numerous chemokine signalling pathways, 
especially the CC and CXC chemokine receptor families, play important roles in the 
regulation of fibrosis. For example, monocyte chemotactic and activating factor 
(CCL2) and macrophage inflammatory protein 1α (CCL3) are chemotactic for 
mononuclear phagocytes including macrophages and epithelial cells, which are 
crucial pro-fibrotic mediators (Zhu et al., 2002, Smith et al., 1995). Other 
chemokines, such as macrophage inflammatory protein 1-β (CCL4), macrophage 
inflammatory protein 3α (CCL20), eosinophil chemotactic protein (CCL11) and 
macrophage-derived chemokine (CCL22), are all found to participate in the 
pathogenesis of fibrosis (Belperio et al., 2002, Ma et al., 2004).  
 
The transforming growth factor β (TGFβ) signalling is the major inducer of collagen 
synthesis by activated fibroblasts and myofibroblasts (Hinz, 2015). TGFβ is the most 
intensively investigated ECM regulator, which is linked to the development of 
fibrosis in numerous diseases (Sato et al., 2003, Border et al., 1992, Hills and 
Squires, 2011, Meng et al., 2012). It has three isotypes in mammals including 
TGFβ1, -2 and -3, all exhibit similar biological activity (Gorelik and Flavell, 2002). 
TGFβ is produced by a variety of cell types, with circulating monocytes and 
macrophages being the predominant cellular sources. The tissue fibrosis is primarily 
attributed to the TGFβ1 isoform (Letterio and Roberts, 1998). Upon binding to its 
type I and II receptors, TGFβ activates the canonical Smad3/4, the non-canonical 
TAK1/p38/JNK (Leask and Abraham, 2004, Trojanowska, 2009) and the 
NOX4/ROS pathways (Liao et al., 2001, Yan et al., 2009), resulting in the induction 
of fibrogenic genes including α-SMA (ACTA2), ECM components including collagen 
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type I (COL1A1) and matricellular proteins such as the connective tissue growth 
factor (CTGF) that increase the mechanical tension of the matrix (Cucoranu et al., 
2005, Leask, 2010). TGFβ induces fibroblasts to differentiate into myofibroblasts in 
an integrin-dependent fashion (Thannickal et al., 2003). 
 
Other potent matrix regulators, such as platelet-derived growth factor (PDGF), also 
play important roles in tissue fibrogenesis. PDGF is a growth factor that regulates 
cell growth and division. It in particular contributes to angiogenesis (Hannink and 
Donoghue, 1989). PDGF is also a vital mitogen for cells of mesenchymal origin, 
especially fibroblasts (Heldin, 1992). It is found to stimulate fibroblast-mediated 
contraction (Rhee and Grinnell, 2006), significantly enhance TGFβ1 synthesis in 
vitro (Zhao et al., 2013) and work together with TGFβ to promote fibrosis (Zhao et 
al., 2013). Both TGFβ and PDGF are found to be upregulated in normal wound 
healing (Kane et al., 1991, Andrae et al., 2008), and increase considerably in a 
variety of pathological fibrotic conditions (Bottinger and Bitzer, 2002, Wang et al., 
2005, van Steensel et al., 2010). 
 
1.2.1.4 Other factors 
A pro-fibrotic hormone to mention is the final product of the renin-angiotensin-
aldosterone system, angiotensin II (ANG II), which is found to play important roles in 
cardiac, renal and hepatic fibrosis (Watanabe et al., 2005, Mezzano et al., 2001). 
ANG II is produced by activated macrophages and fibroblasts. It induces NADPH 
oxidase activity, stimulates TGFβ1 production and triggers fibroblasts proliferation 
and secretion of collagen via binding to their angiotensin II type1 (AT1) receptor 
(Rosenkranz, 2004, Bataller et al., 2003). ANG II augments ECM accumulation by 
increasing TGFβ1 signalling via enhancing SMAD2 levels, amplifying the nuclear 
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translocation of phosphorylated SMAD3, and through an autocrine TGFβ activation 
(Rosenkranz et al., 2002, Tomasek et al., 2002).  
 
Furthermore, uncontrolled vascular proliferation, which often occurs prior to the 
development of fibrosis, is characterised in many fibrotic diseases, especially ocular 
fibrosis (Rattner and Nathans, 2006, Friedlander, 2007). Signalling pathways, for 
example the Wnt-b-catenin signalling, has been suggested as a major pathway 
leading to fibrosis. The increased expression and activity of its family member Wnt 
family member 10b (Wnt10b) has been detected in multiple fibrogenic models in 
vitro and in vivo (Wei et al., 2011, Wei et al., 2012).  
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Figure 1.2 Regulators of fibrosis.   
This figure illustrates the multiple contributors participating in the development of fibrosis. All 
of them converge onto fibroblast representing the central effector cell in the process. 
Fibroblasts can be derived from resident mesenchymal fibroblasts, which are recruited via 
their chemokine receptors. Fibroblasts can also transform from cells such as endothelial or 
epidermal cells, in the process of EMT. Oxidative stress, mechanical tension, pro-fibrotic and 
pro-inflammatory cytokines and growth factors all induce ECM synthesis in fibroblasts. 
Furthermore, immune cells are an important source of pro-fibrotic mediators. ECM 
deposition can be suppressed by MMP secretion. ANG II: angiotensin II, AT1R: angiotensin 
II type I receptor, CCR: CC chemokine receptor, CTGF: connective tissue growth factor, 
CXCR: CXC chemokine receptor, ECM: extracellular matrix, EMT: epithelial-to-
mesenchymal transition, IL: interleukin, MMP: matrix metalloproteinase, TIMP: tissue 
inhibitor of metalloproteinases, TGFβ: transforming growth factor β (figure adapted from (Do 
and Eming, 2016)).   
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1.2.2 Ocular Scarring 
Similar to the tissues elsewhere in the body, the presence of the normal 
vasculature, ECM and various cell types maintain the homeostasis in the eye. 
Following infection, inflammation or metabolic diseases, such homeostasis is 
disturbed and the consequent event is often fibrosis. Fibrosis in the eye is used to 
describe the wound-healing responses and the associated scar formation mediated 
by fibroblasts in the non-CNS (central nervous system) tissues. In the CNS, of 
which the neuro-retina is a part, the similar processes are mediated by glial cells 
and usually termed gliosis. Nevertheless, abnormal wound healing can lead to 
disastrous consequences for vision, as a result of mechanical disruption of the 
highly ordered tissue architecture and/or biological malfunctioning in the eye. For 
example, fibrosis of the cornea that occurs after corneal injury, surgery or secondary 
to infection causes corneal opacification and thereby loss of vision. Uncontrolled 
retinal angiogenesis, induced by diabetes-associated retinal hypoxia, leads to 
diabetic retinopathy (DR) with retinal fibrosis and traction retinal detachment. In the 
neuro-retina, similar fibrosis can occur due to the pathogenesis of age-related 
macular degeneration (AMD) (Friedlander, 2007, Yu-Wai-Man and Khaw, 2016). 
Moreover, conjunctival fibrosis is the major determinant of the surgical success after 
glaucoma filtration surgery (GFS) (Dahlmann et al., 2005). It is also the 
consequence of Chlamydia trachomatis infection that causes trichiasis (inward-
turned eyelids) and permanent blindness in trachoma (Resnikoff et al., 2004, Rajak 
et al., 2012). Collectively, these conditions of ocular fibrosis result in vision loss in 
millions of individuals worldwide. 
 
1.2.2.1 Glaucoma and glaucoma filtration surgery (GFS) 
Glaucoma is a progressive optic neuropathy affecting retinal ganglion cells and optic 
nerve axons (Nuzzi and Tridico, 2017). It is defined by characteristic optic disc 
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damage and visual field loss for that the intraocular pressure (IOP), which is the 
fluid pressure inside the eye, is a major modifiable risk factor. It can progress at 
variable rates and afflict all age groups, and is a significant global health problem 
and the second leading cause of blindness worldwide after cataract. Based on the 
status of the internal drainage system, the disease can be characterised into two 
major subtypes: the open-angle and closed-angle glaucomas, with the former being 
the most common type with a prevalence in the USA of 1.55% (Coleman and 
Brigatti, 2001). Risk factors for open-angle glaucoma are family history, IOP, aging, 
increased cup-to-disc ratio and thinner central corneas; and for closed-angle 
glaucoma are hyperopia, female gender and Asian ethnicity (Mantravadi and 
Vadhar, 2015). 
 
The underlying causes of glaucoma are still unclear. In a normal eye, the aqueous 
humour first flows from the ciliary processes into the posterior chamber, bounded 
posteriorly by the lens and anteriorly by the iris. It then goes through the pupil of the 
iris into the anterior chamber, bounded posteriorly by the iris and anteriorly by the 
cornea. Eventually, it drains through the trabecular meshwork via the scleral venous 
sinus (Schlemm's canal) into the scleral plexuses and general blood circulation 
(Walker et al., 1990). In open-angle glaucoma, due to the degeneration and 
obstruction of the trabecular meshwork, the flow of aqueous humour out of the eye 
is reduced, which results in a rise of the intraocular pressure (IOP). In closed-angle 
glaucoma, the aqueous fluid is not able to flow out of the trabecular network, as the 
iridocorneal angle is completely closed, which results in an increase of IOP that can 
be acute and associated with pain (Mozaffarieh et al., 2008) (Figure 1.3).  
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Figure 1.3 The pathogenesis of glaucoma (outflow mechanism) compared to normal 
eye.   
The figure illustrates the pathogenesis of glaucoma aqueous outflow compared to a normal 
eye, in which the aqueous humour flow is not able to drain through the trabecular meshwork 
via the Schlemm's canal into scleral plexuses and general blood circulation, so that it 
accumulates and increases the intraocular pressure (IOP), which results in damage to the 
optic nerve and eventually causes vision loss. In open-angle glaucoma, IOP is caused by 
the blockage of the trabecular meshwork; in close-angle glaucoma, the blockage occurs at 
the contact between the iris and trabecular meshwork, which obstructs outflow of the 
aqueous humour (figure cited from http://www.maskelloptometrists.com/glaucoma/).  
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Glaucoma can be managed by topical and oral medical therapies, laser modalities 
and surgeries with the goal of lowering IOP to avoid optical nerve damage (Parikh et 
al., 2008). The most commonly performed glaucoma filtration surgery (GFS) is the 
trabeculectomy, which aims to create a permanent drainage outflow channel for 
aqueous humour that connects the anterior chamber to the sub-Tenon’s space. 
Herein, a partial thickness flap with its base at the corneoscleral junction is made in 
the scleral wall, and a window opening is produced under the flap to remove a 
portion of the sclera, Schlemm's canal and trabecular meshwork. The flab is then 
sutured loosely back in place forming a ‘bleb’ on the surface of the eye, which 
allows fluid to flow out (Wells et al., 2004) (Figure 1.4).  
 
 
 
Figure 1.4 Graphic illustration of glaucoma filtration surgery (GFS).  
The glaucoma filtration surgery (GFS) creates a new opening that connects the anterior 
chamber to the sub-Tenon’s space, which allows the aqueous humour to leave the eye and 
therefore decrease the intraocular pressure (IOP) (figure cited from 
http://www.allaboutvision.com/conditions/glaucoma-surgery.htm). 
 
 37 
 
1.2.2.2 Conjunctival scarring after GFS 
Subconjunctival fibrosis and scarring at either the level of scleral flap or the ostium 
of the newly created drainage channel is the main reason that glaucoma filtration 
surgery (GFS) fails (Khaw et al., 2012). The successful prevention of the scarring 
after GFS determines the percentage of patients who achieve low final intraocular 
pressure (IOP) and virtually no disease progression. Fibroblasts from Tenon’s 
capsule are known to play an essential part in conjunctival scarring following the 
GFS, by their ability of remodelling the extracellular matrix (ECM) via both direct 
cell-mediated contractile activity and matrix metalloproteinases (MMPs)-mediated 
matrix degradation (Martin-Martin et al., 2011, Daniels et al., 2003). However, 
signalling events that regulate fibroblast-driven matrix contraction and remodelling 
remain unclear. The current anti-metabolites treatment used after GFS to inhibit 
fibrosis and scarring of trabeculectomy blebs are anti-cancer agents, such as 
mitomycin-C (MMC) and 5-fluorouracil (5-Fu). Unfortunately they are associated 
with severe complications including non-specific cytotoxicity, tissue damage, 
breakdown and infections, all of which are linked to sight-threatening risks (Yu-Wai-
Man and Khaw, 2015). Still there is a large unmet need to better understand the 
mechanisms underlying conjunctival fibrosis and scarring following ocular wound 
healing. The development of such anti-fibrotic therapies in the eye will also benefit 
other pathological conditions associated with contractile scarring. 
 
 
1.3 Fibroblast-mediated contraction 
1.3.1 Fibroblasts 
Fibroblasts are ubiquitous mesenchymal cells in the stroma of all epithelial organs. 
They are known to play an essential role in organ development, inflammation, 
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wound healing and fibrosis. In each anatomic site of the body, fibroblasts 
differentiate in a site-specific way and display distinct and characteristic 
transcriptional patterns, suggesting that they perform important duties in 
establishing and maintaining the positional identity in tissues and organs (Chang et 
al., 2002). Normal human fibroblasts require growth factors for proliferation in 
culture, which are usually supplied by fetal bovine serum (FBS). In the events of 
injury, upon exposure to the specific physiological signals within the soluble fraction 
of coagulated blood, serum, fibroblasts are activated and programmed to perform a 
broadly coordinated and multifaceted program including regulation of homeostasis, 
cell cycle progression, epithelial cell migration, inflammation, and angiogenesis (Iyer 
et al., 1999, Chang et al., 2004). With the help of other cellular participants, they not 
only execute central effector roles in the process of wound repair, but also act as 
the main regulator of fibrosis. At the end of the healing process, fibroblasts remodel 
the extracellular matrix via direct cell-mediated contractile activity, as well as 
degradation and synthesis to bring the margins of the wound together, leading to 
the formation of scar tissue. The initiation and maintenance of the fibrotic responses 
of contracting fibroblasts result from a complicated interaction among a network of 
growth factors, cytokines and hormones, and the cellular microenvironment that 
promotes the pathological responses to these stimuli, though the molecular 
mechanisms underneath remain unclear (Leask, 2010).   
 
1.3.2 Cell-mediated contraction 
Tissue contraction is a fundamental part of many important biological processes, 
including wound healing, in which abnormal contraction leads to fibrosis and 
scarring that associate with a wide range of debilitating pathological conditions. The 
resident fibroblasts are believed to play a key role in controlling this process, by 
generating substantial contractile forces on the extracellular matrix that are in part 
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regulated by the mechanical loading in the environment in which they reside. To 
maintain an active tensional homeostasis, fibroblasts consistently react to modify 
the endogenous matrix tension in the opposite direction to externally applied loads 
by changing in cell shape and attachment in a predictable manner (Eastwood et al., 
1998, Brown et al., 1998). However, the mechanisms by which they remodel their 
environment are still unclear. Bell's introduction of the fibroblast-populated collagen 
lattice (FPCL) has become the most commonly used in vitro model to study the 
reciprocal and adaptive interactions that occur between fibroblasts and surrounding 
matrix in the tissue-like environment (Bell et al., 1979, Grinnell, 2003). To create 
such a pseudo-physiological 3D environment, a suspension of trypsinised 
fibroblasts are added to pH neutralised type-I collagen solution with concentrated 
medium. After the collagen polymerises, the fibroblasts are dispersed throughout 
the resulting gel-like matrix, which is then allowed to free-float in the medium 
containing tissue culture dish. Stimulated by the serum or growth factors contained 
in the culture medium, the cells contract the matrix by applying force to the 
neighbouring collagen fibres. Through cycles of extension and retraction, they 
structurally reorganise the collagen architecture down to a fraction of its original 
size. The speed of contraction depends on the cell type, density and collagen 
concentration (Tomasek et al., 2002) (Figure 1.5). 
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Figure 1.5 The free-floating fibroblast-populated collagen gel contraction assay. 
 Collagen gel contraction assay with human conjunctival fibroblasts HTF7071 at Day0, 3 and 
5 in culture medium with 10% FBS (the contracting collagen gel at the centre of the well is 
labelled with white circle).  
 
 
There are three main cellular mechanisms proposed to be responsible for 
generating the FPCL contraction (Dallon and Ehrlich, 2008). The first one is cell 
tractional forces that are how fibroblasts generate sufficient force in order to bend 
individual collagen fibres bound to their surface to allow cell spreading and 
migration, which relate to cell migration or locomotion. The assumption is that these 
tractional forces are distributed throughout the matrix via the cross-linked collagen 
fibres, which lead to global remodelling and contraction of the whole environment 
(Meshel et al., 2005, Roy et al., 1997). Nevertheless, challenging data suggested 
that tractional forces may not be sufficient to induce matrix contraction in vitro as 
well as wound closure in vivo (Ehrlich and Rajaratnam, 1990, Roy et al., 1999).  
 
Another possible mechanism is that through differentiation into α-smooth muscle 
actin rich stress fibres expressing myofibroblast phenotype, the ‘modified’ cells 
enhance their contractility and become the ‘icon of fibrosis’ (Tomasek et al., 2002). 
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The myofibroblast was first defined by Gabbiani's group in 1971 in an experimental 
animal model of wound healing (Gabbiani et al., 1971, Majno et al., 1971). 
Subsequently, their presence has been identified in a variety of pathological 
connective tissue conditions including cancer and has been intensively studied 
(Gabbiani, 1992, Gabbiani, 1999, Desmouliere et al., 2004). However, 
myofibroblasts only appear at the later stage of wound healing in vivo, and 
differentiation into myofibroblasts in vitro requires specific conditions such as TGFβ, 
tension, and most importantly, time (Arora and McCulloch, 1994, Hinz, 2015, 
Grinnell et al., 1999, Desmouliere et al., 1993). Hence the transformation of 
myofibroblasts is unlikely to be the reason of early matrix contraction of FPCL in 
vitro and early wound closure in vivo (Grinnell, 1994, Dahlmann-Noor et al., 2007).  
 
The third mechanism of cell-mediated contraction proposed is the traction 
generated by cell protrusive activity without association with net cell locomotion. 
Previous studies have demonstrated that through the dynamic extension and 
retraction of pseudopodial extensions, non-motile cells can produce local tension in 
the matrix that leads to contraction (Roy et al., 1997, Sawhney and Howard, 2002, 
Sawhney and Howard, 2004). By performing protrusions and retractions by 
lamellipodia in the typical “hand-over-hand” cycle, fibroblasts can also reposition the 
individual collagen fibres placed on their upper surface in such case (Meshel et al., 
2005). The molecular machinery contributes to the process including assembly of 
actin filaments, myosin activity, as well as microtubules depolymerizing (Sawhney 
and Howard, 2004). Furthermore, the macroscopic matrix contraction has been 
linked to the stochastic nature of cell elongation initiation and of the time required for 
cells to reach a final morphology, but not cell migration (Freyman et al., 2001).  
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The host laboratory have investigated the cellular mechanisms underlying force 
generation and matrix contraction using primary human ocular fibroblasts in the 
standard collagen matrix. The former studies have identified factors that affect early 
matrix contraction including cell size, intrinsic level of actin dynamics and genuine 
contractile force, dynamic cell protrusive activity, and net pericellular matrix 
displacement. It was reported that protrusive activity is the main cell behaviour 
observed within the first 24 hrs of matrix deformation (Dahlmann-Noor et al., 2007). 
Furthermore, it has been proposed that fibroblasts remodel the collagen matrix by 
two major mechanisms, one via local active collagen fibre alignment through cellular 
protrusive activity, and the other through matrix degradation. We found that cells 
with a rounded morphology and proliferative profile display low intrinsic cellular 
force, whereas those with an elongated morphology express higher levels of 
protrusive activity that leads to efficient matrix remodelling and contraction (Martin-
Martin et al., 2011). 
 
1.3.3 Matrix degradation   
1.3.3.1 Matrix metalloproteinases (MMPs) 
The degradation of the excessive ECM during tissue remodelling is tightly controlled 
by the production of matrix metalloproteinases (MMPs) and their regulators by 
multiple stromal cells, including fibroblasts (Kessenbrock et al., 2010). Dysregulation 
of such procedure causes fibrosis or non-healing wounds. MMPs are a family of 
zinc-dependent endopeptidases that were first described more than half a century 
ago in the tail of a tadpole undergoing metamorphosis (Gross and Lapiere, 1962). 
They are collectively capable of cleaving essentially all ECM components, thus play 
a crucial role in almost every physiological process that involving matrix remodelling 
throughout the mammalian life span, from embryo implantation (Alexander et al., 
1996) to cell death or necrosis (Egeblad and Werb, 2002, Currie et al., 2007). Also, 
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they perform a primary function in wound healing and tissue repair, organ 
development, regulation of inflammatory processes and in pathological conditions 
such as cancer metastasis and tumour invasion (Page-McCaw et al., 2007, Parks et 
al., 2004, Egeblad and Werb, 2002). The expression of MMPs is transcriptionally 
regulated by growth factors, hormones, cytokines and cellular transformation 
(Nagase and Woessner, 1999).  
 
MMPs are secreted from the cells or anchored to the cell surface, in order to 
catalyse membrane proteins and proteins in the secretory pathway or extracellular 
space (Parks et al., 2004). To date, 24 different vertebrate MMPs have been 
identified, of which 23 are found expressed in humans. Structurally, MMPs generally 
consist of three domains that are common to almost all of them, which include a 
pro-peptide, a catalytic domain and a hemopexin-like C-terminal domain that is 
linked to the catalytic domain via a flexible hinge region (Visse and Nagase, 2003) 
(Figure 1.6). Initially, MMPs are expressed in an enzymatically inactive state as 
‘pro-MMP’, due to a cysteine residue of the pro-domain that binds the zinc ion of the 
catalytic site. Upon breaking down of this interaction by a mechanism called 
‘cysteine switch’, which usually occurs as a result of the proteolytic removal of the 
pro-domain, or chemical modification of the cysteine residue, the pro-enzyme 
becomes a proteolytically active ‘active-MMP’. The pro-domain has a consensus 
sequence that can be proteolytically cleaved by convertases, which happens 
intracellularly by furin, extracellularly by other MMPs or serine proteinases, 
depending on the difference of the sequences (Sternlicht and Werb, 2001).  
 
Based on the specificity, sequence similarity and domain organisation, vertebrate 
MMPs can be divided into six groups. These are (1) Collagenases, including MMP1, 
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8, 12 and 18 that are able to cleave interstitial collagens I, II, and III. (2) 
Gelatinases, such as MMP2 and 9 that digest the denatured collagens—gelatins. 
(3) Stromelysins, including MMP3 and 10, which have similar substrate specificities 
and digest ECM components. MMP3 activates several pro-MMPs, whose action is 
important for the generation of fully active MMP-1 (Suzuki et al., 1990). (4) 
Matrilysins, including MMP7 and 26 that are also called endometase, which do not 
have a hemopexin domain. Apart from ECM components, MMP7 also processes a 
number of cell surface molecules such as pro–α-defensin, Fas-ligand, pro–tumour 
necrosis factor (TNF)-α and E-cadherin. (5) Membrane-type (MT) MMPs, such as 
MMP14, 15, 16, 24, 17 and 25 can also digest a number of ECM molecules. 
MMP14 (MT1-MMP) exhibits collagenolytic activity on type I, II and III collagens, 
and plays a critical role in angiogenesis, tumour invasion and metastatic cancer cell 
migration (Ohuchi et al., 1997, Pepper, 2001, Friedl and Wolf, 2008). (6) Other 
MMPs, including MMP12, 19, 20, 22, 23 and 28 that are not classified in the former 
categories. MMP12 is mostly expressed by macrophages and is essential for 
macrophage migration (Shipley et al., 1996). MMP28 is mainly expressed in 
keratinocytes, which may play a role in tissue homeostasis and wound repair 
(Marchenko and Strongin, 2001, Lohi et al., 2001, Saarialho-Kere et al., 2002).  
 
 
 45 
 
 
Figure 1.6 The domain structural characterisation of the MMPs.  
The structural features of matrix metalloproteinases (MMPs) are illustrated, showing the 
minimal domain structures. S, signal peptide; Pro, pro-domain; Cat, catalytic domain; Zn, 
active-site zinc; Hpx, hemopexin-like C-terminal domain; Fn, fibronectin domain; V, 
vitronectin insert; I, type I transmembrane domain; II, type II transmembrane domain; G, a 
glycosylphosphatidylinositol (GPI) anchor; Cp, cytoplasmic domain; Ca, cysteine array 
region; Ig, IgG-like domain. The black band between pro-domain and catalytic domain 
represents the furin cleavage (figure adapted from (Visse and Nagase, 2003)). 
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In the eye, overexpression of MMPs has been shown to associate with aberrant 
wound healing and scarring diseases in all ocular structures from the anterior 
segment to the retina, which include corneal endothelium, stroma, lens, trabecular 
meshwork, uveoscleral outflow and conjunctiva (Wong et al., 2002) (Table 1.1). It 
has been reported that application of the broad-range MMP inhibitor GM6001 
efficiently prevented human conjunctival fibroblast-mediated collagen lattice 
contraction in vitro, as well as reducing the production of collagen by those 
fibroblasts (Daniels et al., 2003). Also, in the in vivo rabbit model of glaucoma 
filtration surgery, inhibition of MMPs led to a dramatic reduction of scarring, with 
retention of normal tissue morphology (Wong et al., 2003). Furthermore, previous 
studies have demonstrated that treatment with GM6001 consistently decreased cell 
dynamics in 3D-culture, which correlated with a significant reduction of early matrix 
contraction in vitro and ex vivo (Martin-Martin et al., 2011, Tovell et al., 2011). 
These results suggest that MMP inhibition potentially prevents conjunctival 
fibroblast-mediated tissue contraction and scarring.  
 
Table 1.1 MMPs expression in the different structures of the eye (Wong et al., 2002).  
* Bovine corneal endothelium. 
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1.3.3.1.1 MMP1 
MMP1 (Collagenase-1) is the founding member of the MMPs family, which was first 
purified to homogeneity as a protein in 1962 (Gross and Lapiere, 1962). It cleaves 
interstitial collagens I, II and III at a specific site three-fourths from the N-terminus, 
and also digests a number of other ECM and non-ECM molecules (Visse and 
Nagase, 2003). It is not only involved in the breakdown of ECM in numerous normal 
physiological processes, but also exaggeratedly accumulated in many pathological 
conditions. Elevated expression of MMP1 has been implicated in diseases 
characterised by excessive ECM degradation, such as chronic ulcerations 
(Saarialho-Kere et al., 1993, Pilcher et al., 1997, Pilcher et al., 1999), rheumatoid 
arthritis (Walakovits et al., 1992, Mateos et al., 2012) and lung emphysema (Mercer 
et al., 2004, Imai et al., 2001); as well as in the fibrotic conditions, which by contrast 
associate to over-deposition of ECM substrates, including pulmonary fibrosis (Zuo 
et al., 2002, Pardo and Selman, 2006, Herrera et al., 2013) and various of cancers 
(McColgan and Sharma, 2009, Tao et al., 2015, Nguyen et al., 2015, Pietruszewska 
et al., 2016).  
 
The mechanism by which MMP1 is produced and expressed by the cell is not clear. 
The expression of MMP1 is inducible under certain circumstances, not only by 
soluble factors such as growth factors, cytokines and chemical agents, but also 
through cell-matrix and cell-cell interactions. For example, via ligation of the α2β1 
integrin with collagen, MMP1 is largely expressed in migrating keratinocytes, which 
therefore becomes a reliable marker of activated keratinocytes in wounded human 
skin in a variety of conditions (Rohani et al., 2014). Particular signalling pathways 
also lead to expression of MMP1, such as blocking of α5β1 integrin by soluble 
antibody, which results in a disruption of the actin cytoskeleton and an augmented 
expression of MMP1 in rabbit synovial fibroblasts (Werb et al., 1989). This is due to 
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the activation of the small Rho GTPase Rac1 that induces the activation of NF-kB 
by generating reactive oxygen species (ROS), which further results in an induction 
of IL1A, an autocrine inducer of MMP1 (Kheradmand et al., 1998). Furthermore, 
MAP kinase pathways also play a role in the regulation of MMP1, as ERK1/2, 
stress-activated protein kinase (SAPK)/JNK and p38 MAPK that all independently 
trigger the expression of MMP1 in human skin fibroblasts (Reunanen et al., 1998).  
 
MMP1 is significantly expressed by fibroblasts during tissue contraction. Increased 
mRNA level of MMP1 is detected in the conjunctiva of patients with recurrent 
trichiasis one year after trachoma surgery (Burton et al., 2010). In primary trachoma 
fibroblast-mediated collagen gel contraction, MMP1 is found to be dramatically 
upregulated comparing to other MMPs (Li et al., 2013). Most importantly, MMP1 
was found to be significantly upregulated during conjunctival fibroblast-mediated 
contraction in vitro (Tovell et al., 2012). 
 
 
1.4 Small Rho GTPases 
1.4.1 Small Rho GTPases and their regulators 
The family of small Rho GTPases belong to the Ras superfamily and are highly 
conserved in all eukaryotic organisms. In mammals 22 Rho GTPases are identified 
that are related in primary sequence. Each one of them acts as a molecular switch 
to control distinct biochemical pathways. They contribute to various cellular activities 
including regulation of gene transcription, cell cycle, microtubule dynamics, vesicle 
transport and numerous enzymatic activities, as well as controlling the assembly of 
filamentous actin and the organisation of the actin cytoskeleton (Ridley, 2006).  
 49 
 
Most of the Rho GTPases bind to guanosine triphosphate (GTP) and guanosine 
diphosphate (GDP), and have intrinsic GTPase activity. In their GDP-bound 
conformation they are generally assumed to be inactive, as they do not bind effector 
proteins; whilst when bound to GTP they are active and able to transduce signals 
through interacting with downstream target proteins. This inter-conversion is tightly 
regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating 
proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs). Generic Rho 
GTPases anchor to the membrane with a prenyl group near the carboxyl terminus. 
GEFs and GAPs are often constitutively or inducibly associated with membranes. 
GEFs promote the release of GDP to allow binding of GTP on monomeric GTPases,  
thus playing an activation role; whereas GAPs accelerate the hydrolysis of GTP to 
GDP that turns the GTPases’ activity off. The GDIs bind to the C-terminal lipid 
groups on GTPases to prevent their membrane binding and interaction with the 
membrane-associated proteins, thus also performing an inhibitory role (Tybulewicz 
and Henderson, 2009) (Figure 1.7).  
 
There are 85 Rho GTPases’ GEFs identified in the mammalian genome. Many of 
them were originally characterised as oncogenes after transfection of immortalized 
fibroblast cell lines with cDNA expression libraries (Cerione and Zheng, 1996). Most 
of the GEFs belong to the Dbl subfamily, which contain a Dbl homology (DH) 
domain that has catalytic activity. Other subgroups include the Dock family whose 
catalytic activity resides in a Dock homology region 2 (DHR2), and those do not 
contain either of the domain (Cote and Vuori, 2002, Schmidt and Hall, 2002). 
Similarly, a large family of GAPs are identified that are typified by a conserved 
RhoGAP domain, which contains the catalytic activity of the enzymes (Tcherkezian 
and Lamarche-Vane, 2007). The reasons for the large number of GEFs and GAPs 
relative to Rho GTPases are unclear. Some GEFs or GAPs are specific for only one 
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or a few GTPases respectively, whereas others have a broader specificity. How 
GEFs and GAPs are themselves regulated is still unknown, which is very likely the 
key point of understanding the mechanisms that underlie the spatial and temporal 
activation of GTPases within a cell in response to outside influence. 
 
 
 
Figure 1.7 The regulations of Rho GTPases by GEF, GAP and GDI.   
GEFs (Guanine nucleotide exchange factors) activate Rho GTPases by accelerating their 
GDP/GTP exchange rates. GAPs (GTPase-activating proteins) increase the intrinsic activity 
of Rho GTPases, causing GTP to be hydrolysed to GDP and phosphate (Pi). GDIs (Rho 
guanine nucleotide dissociation inhibitors) to the prenyl group of Rho GTPases’ thereby 
inhibit their membrane-binding and interaction with effector proteins (figure adapted from 
(Tybulewicz and Henderson, 2009)).   
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1.4.2 Rac1, Cdc42 and RhoA 
The best-known members of the Rho GTPases family are Rac1, Cdc42 and RhoA, 
originally identified through their effect on actin polymerisation. Each of them 
controls a signalling pathway that associates with membrane receptors to the 
assembly and disassembly of actin cytoskeleton and of linking integrin adhesion 
complexes. Rac1 induces plasma membrane protrusions known as lamellipodia, 
Cdc42 triggers filopodial extensions at the cell periphery, and RhoA stimulates focal 
adhesion and formation of stress fibres. Therefore they play vital regulatory roles in 
any cellular process that involves the activity of filamentous actin (Hall, 1998, Hall, 
2005).  
 
Regulation of the actin cytoskeleton downstream of Rac1, Cdc42 and RhoA is 
mediated by several effector proteins (Figure 1.8). Rac1 activates the WASP 
(Wiskott–Aldrich syndrome protein)-related WAVE (WASP-family verprolin 
homologous protein) family of proteins that lead to new actin polymerisation 
branching off from the sides of existing filaments through the ARP2/3 protein 
complex. Cdc42 activates the same pathway through the WASP. Both Rac1 and 
Cdc42 activate DIAP3 (members of the Diaphanous-related formins, also known as 
mDIA2), which causes the nucleation and extension of non-branching actin 
filaments. Also, these two GTPases activate the PAK (p21 activated kinases) family 
kinases, which in turn phosphorylate and activate LIMK (LIM domain kinase), a 
kinase that phosphorylates and inhibits cofilin, an actin depolymerising protein. The 
inhibition of cofilin promotes the stability of polymerized actin. LIMK is also activated 
by ROCK (Rho-associated protein kinase), a kinase effector that is downstream of 
RhoA. ROCK phosphorylates and suppresses the myosin light chain phosphatase 
(MLCP), which as a result leads to an increased phosphorylation of the myosin light 
chain (MLC), which strengthens the association between MLC and actin filaments. 
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MLC can also be phosphorylated via inhibition of the MLC kinase (MLCK) by PAK 
(Millard et al., 2004, Hall, 2005, Tybulewicz and Henderson, 2009, Taylor et al., 
2011).  
 
 
Figure 1.8 Rac1, Cdc42 and RhoA regulate actin cytoskeleton via their downstream 
effector proteins.  
The downstream effectors of Rac1, Cdc42 and RhoA including: WASP (Wiscott-Aldrich 
syndrome protein)-WAVE (WASP-family verprolin-homologous protein) proteins, DIAP3 
(Diaphanous-related formins, also known as mDIA proteins), and kinases such as PAKs 
(p21 activated kinases) and ROCK (RHO-associated protein kinases). WASP-WAVE 
proteins stimulate the activation of the ARP2/3 complex, lead to the branching of new actin 
filaments. Activation of DIAP3 stimulates the extension of parallel actin filaments. PAKs and 
ROCKs contribute to the stabilization of actin filaments via phosphorylation of LIMKs (LIM 
domain kinases), which in turn inactivate cofilin, ROCK also stimulates the phosphorylation 
of myosin regulatory light chain (MLC) via suppressing MLCP (myosin light chain 
phosphatase), thus contributes to the contractility of actin–myosin (figure adapted from 
(Tybulewicz and Henderson, 2009)).  
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In contracting fibroblasts, the cytoskeletal components are reorganized in order to 
produce a tensile strength (Ehrlich and Rajaratnam, 1990). Rac1 is shown to 
promote the assembly of a peripheral actin meshwork in these cells, which causes 
membrane protrusions (lamellipodia/membrane ruffles) in response to growth 
factors stimulation such as PDGF (platelet-derived growth factor) or insulin (Ridley 
and Hall, 1992, Ridley et al., 1992). The activity of Rac1 is reported to be required 
for controlling cell mobility, tissue repair, wound healing and fibrogenic responses in 
vitro and in vivo (Liu et al., 2009, Nobes and Hall, 1999). The expression of Rac1 
was shown to associate with matrix remodelling in fibroblasts in the context of 
tumour-promoting stroma and fibrotic diseases, whilst its inactivation reversed the 
elevated contractile phenotype of cancer-associated fibroblasts (Hooper et al., 
2010, Xu et al., 2009), suggesting that signalling through Rac1 is one of the major 
components in fibroblast-mediated contraction. Recently, it was demonstrated that 
transient inhibition of Rac1 by its inhibitor NSC23766 dramatically reduced human 
conjunctival fibroblasts mediated contraction in vitro, as well as ex vivo tissue 
contraction, suggesting a critical role for Rac1 in early matrix contraction and ocular 
scarring (Tovell et al., 2012).  
 
Cdc42 induces peripheral actin-rich microspikes (filopodia) through a number of 
kinase and non-kinase effector proteins (Nobes and Hall, 1995, Kozma et al., 1995). 
It regulates the myotonic dystrophy kinase-related Cdc42-binding kinases (MRCKs), 
which are key regulators of the actin stress fibre contractility (Zhao and Manser, 
2015). Interacting through the Par polarity complex and other targets, Cdc42 
performs vital functions in cell migration by establishing cell migratory polarity and 
migratory persistence (Ridley, 2015). Also, it is in particular involved in fibroblasts 
migrating in 3D matrix, which is driven by localised protrusions known as 
invadopodia, via acting through its target N-WASP and several Cdc42 GEFs (Spuul 
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et al., 2014). In primary mouse embryonic fibroblast-mediated matrix remodelling, 
Cdc42 deficiency reduced the collagen gel contraction that associated with cell 
morphological changes, decreased focal adhesion complex formation, blocked 
MMP9 production and altered fibronectin deposition patterning, suggesting that it 
plays an essential role in regulating cell-matrix interaction (Sipes et al., 2011).  
 
RhoA is shown to promote the assembly of contractile actin and myosin filaments 
(stress fibres) in fibroblasts in response to LPA (lysophosphatidic acid) addition 
(Ridley and Hall, 1992). The RhoA-ROCK pathway plays important roles in the 
formation of actin stress fibres and focal adhesions, as well as regulating 
actomyosin cytoskeletal organisation, cell adhesion, morphology, motility, 
contraction and cytokinesis (Takai et al., 1995). The anti-scarring property of the 
ROCK inhibitor has been tested in the human conjunctival fibroblast-populated 
collagen lattice in vitro and rabbit glaucoma filtration surgery model in vivo, which 
showed promising results in preventing fibroblasts contractile activity and increasing 
the survival rate of the GFS blebs compared to the control ones (Honjo et al., 2007). 
 
Moreover, Rac1, Cdc42 and RhoA contribute to modulate multiple aspects of wound 
healing including matrix degradation. They have been reported to participate in the 
regulation of MMP1 expression in various fibroblast cells, though the effects 
appeared to be cell-type and origin dependent. For example, activation of Rac1 or 
RhoA induced the expression of MMP1 through the ROS/NF-kB/IL1A pathway in 
response to the integrin-mediated disruption of actin cytoskeleton in rabbit synovial 
fibroblasts (Kheradmand et al., 1998, Werner et al., 2001, Werner and Werb, 2002); 
and silencing of Cdc42, but not that of Rac1 or RhoA, induced a significant increase 
of MMP1 secretion in human skin fibroblasts, which was dependent on ERK1/2 
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pathways (Deroanne et al., 2005). However, these studies were all performed with 
fibroblasts cultured in 2D format. No studies have explored the regulations of Rac1, 
Cdc42 or RhoA on MMP1 expression and secretion in the model of 3D-cultured 
contracting fibroblasts. 
 
1.5 Aims and objectives 
In a previous study, it was found that transient inhibition of small Rho GTPase Rac1 
by its inhibitor NSC23766 significantly prevented tissue contraction and matrix 
degradation during fibroblast-mediated contraction in vitro and ex vivo (Tovell et al., 
2012), suggesting that Rac1 could be a master regulator of contractile scarring. 
Therefore, the main aim of the study is to identify the regulatory roles that Rac1 
performs in the contraction, which includes three objectives:  
 
1. To characterise the gene expression profiles underlying fibroblast-mediated 
contraction and the involvement of Rac1, comparing it to in vivo studying 
and published studies of human ocular fibrotic diseases. 
 
2. To evaluate the anti-scarring potential of a range of Rac inhibitors and 
further explore the regulatory roles of Rho GTPases Rac1, Cdc42, RhoA, 
and Rac2, and their regulators in contraction. 
 
3. To investigate the connection between Rho GTPases’ activation and MMP 
expression using MMP1 as an example.  
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Chapter 2 Material and methods 
 
 
2.1 Fibroblast cell culture 
2.1.1 Human conjunctival samples 
Human conjunctival fibroblasts were isolated from conjunctival biopsy samples or 
whole eye globes in accord with the tenets of the Declaration of Helsinki and with 
local ethics approval. The conjunctival biopsies were kept in sterile culture medium 
and refrigerated prior of processing, and processed within 48 hrs of sample arrival. 
The whole eye globes were incubated in 1000 IU/ml penicillin and 1000µg/ml 
streptomycin (Invitrogen) in sterile PBS for 10-20 min, and then dissected to obtain 
conjunctival tissue. The primary fibroblast cells used in this study and the originated 
donors’ information are listed in Table 2.1. 
Table 2.1 Isolated primary conjunctival fibroblasts and their donors’ information.  
*HTF7071 was established by Dr. Victoria Tovell. **HTF2320, the age and sex of its donor 
are not known. 
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2.1.2 Cell culture 
The biopsies were transferred to a sterile flat surface (15cm diameter tissue culture 
dish) and cut into small pieces, which were then placed in the 3cm diameter tissue 
culture dishes and incubated with 100-200µl of 0.05% collagenase in DPBS (Gibco, 
Thermo Fisher Scientific) for 10-20 min at 37ºC with 5% CO2. To prevent the tissue 
fragments from floating in the culture medium, a sterile coverslip was placed on top 
of them, and 0.8ml of Dulbecco's modified Eagle's medium (DMEM) with high 
glucose (Gibco, Thermo Fisher Scientific), supplemented with 10% fetal bovine 
serum (FBS) (Sigma-Aldrich), 100 IU/ml penicillin, 4.5g/L l-Glutamine and 100µg/ml 
streptomycin (Invitrogen) was added to the dish. The medium was changed 2-3 
times per week, until the cells have expanded to over 50% confluency (usually in 2-
4 weeks).The cells were then trypsinised with trypsin-EDTA 0.25% (Gibco, Thermo 
Fisher Scientific) and plated into a T25 tissue culture flask (Corning, Sigma-Aldrich) 
with 5ml of medium (passage 1). The cells were passaged again 1:3 when the 
confluency reached 80-90%. Stock of cells at passage 2 to 6 were kept in liquid 
nitrogen in 10% DMSO v/v (Sigma-Aldrich) in FBS. The fibroblast cells used in this 
study were aged from passage 3 to 8.  
 
2.2 Collagen contraction assay 
The collagen contraction assay was performed to characterise the ability of 
fibroblasts to contract the extracellular matrix (ECM). 1x105 fibroblast cells were 
suspended in 100μl of serum free medium (DMEM with 100 IU/ml penicillin, 4.5g/L l-
Glutamine and 100µg/ml streptomycin), and added to a mixture of 1ml type I 
collagen solution (2.05 mg/ml in 0.6% acetic acid, First Link Ltd) and 160μl 
concentrated medium (10x DMEM, Sigma-Aldrich, l-Glutamine, Invitrogen, sodium 
bicarbonate 0.75%, Sigma-Aldrich), which had been adjusted to pH 7.2 by addition 
of 80-90μl of sterile 1M NaOH (Sigma-Aldrich). And then, the cell-collagen solution 
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was quickly casted into the inner well of MatTek dish (MatTek Corporation) as 
150μl/well and set at 37ºC with 5% CO2 for 10-15 min. The polymerized gels were 
detached from the edge of the well by sliding a pipette tip around it to allow free 
floating, and 2ml of culture medium with/without treatment was added per dish. Gel 
contraction was monitored daily for 3-5 days depended on experimentation by 
digital photography. Gel areas were measured using ImageJ software 
(http://rsb.info.nih.gov/ij/), and the contraction was plotted as a percentage of gel 
area normalised to original area (day 0 measurement).   
 
2.2.1 Contraction assay with inhibitors 
The inhibitors were added in the culture medium of the contraction assay after the 
initial gel polymerisation. For treatment within a specific time, the medium with 
inhibitor as well as the control medium were replaced with fresh culture medium 
after the time. The inhibitors used in this study are listed in Table 2.2: 
Table 2.2 The inhibitors and their concentrations used in the study.  
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2.2.2 Cell viability assay  
The alamarBlue reagent (Thermo Fisher Scientific) was used to evaluate cell 
viability. It contains resazurin, which is a blue dye that is cell permeable and non-
fluorescent. Upon entering cells, resazurin is reduced to resorufin that produces 
very bright red fluorescence via the reduction reactions of metabolically active cells. 
Viable cells continuously convert resazurin to resorufin, thereby generating a 
quantitative measure of cell viability. The alamarBlue reagent was added to the gel 
contraction culture as 10% of the total volume (200µl in 2ml medium), and followed 
by an incubation at 37ºC for 4 hrs. And then, 100µl of the medium was taken from 
each sample and transferred to a 96-well plate. The fluorescence intensity was 
measured at Ex/Em=530/590nM using a plate reader (Fluostar Optima). Each 
experiment was performed with triplicate wells. 
 
2.3 Real-time PCR 
2.3.1 RNA isolation 
Contraction gels with/without transient 24hrs treatment of NSC23766 were 
harvested at day0, 3 and 5, and placed straight into TRIzol Reagent (Invitrogen) at 
4°C for 1 hr (3 gels:1ml TRIzol). The day0 gels were obtained after 1hr of initial gel 
polymerisation in serum free medium. After the gels were completely dissolved with 
vortexing if necessary, 0.2 mL of chloroform per 1ml TRIzol was added and the 
solution was incubated for 2-3 min at room temperature after a vigorously shaking 
by hand for 15 sec. The samples were then centrifuged at 12000 x g for 15 min at 
4°C to achieve phase separation. The aqueous phase that contained RNA was 
transferred to a new 1.5ml tube (Eppendorf) and 2 volumes of 100% ethanol 
(Sigma-Aldrich) was added. The mixture was transferred to an RNeasy spin column 
placed in a 2 ml collection tube (RNeasy Kit; Qiagen) and spun for 15s at 8000 x g 
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at room temperature. After discarding the flow-through, 700µl of Buffer RW1 and 
500µl of Buffer RPE were added to the column respectively, each following a 15s 
centrifugation at 8000 x g at room temperature. A final wash of 500µl Buffer RPE 
was repeated, and the column was spin again for 2 min at 8000 x g to thoroughly 
wash the membrane. The column was placed in a new 1.5 ml collection tube 
(Qiagen) and 40µl of RNase-free water (Qiagen) was added directly to the column 
membrane. After a short incubation of 3-5 min at room temperature, the column was 
centrifuged for 1 min at 8000 x g to elute the RNA. The concentration of the RNA 
samples was measured using NanoDrop Spectrophotometer (Thermo Fisher 
Scientific).  
 
2.3.2 Reverse transcription 
Reverse transcription was carried out using QuantiTect Reverse Transcription Kit 
(Qiagen) to obtain cDNA samples. The RNA samples were briefly incubated in 
gDNA Wipeout Buffer at 42°C for 2 min to remove remaining genomic DNA. And 
then, a reverse-transcription master mix that contained Quantiscript Reverse 
Transcriptase, 5x Quantiscript RT Buffer, and RT Primer Mix was added to the 
template RNA according to manufacturer’s instructions. The reactions were 
incubated at 42°C for 30 min, and 95°C for 3 min to inactivate the transcriptase. The 
cDNA samples obtained were proceed directly to real-time PCR, or stored at -80°C 
for long-term storage. 
 
2.3.3 qPCR 
The mRNA expression levels of the genes of interest were measured by qPCR 
using Taqman Gene Expression Assays (Thermo Fisher Scientific) (Table 2.3), 
which rely on the 5´-3´ exonuclease activity of Taq polymerase to cleave a dual-
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labelled probe during hybridization to the complementary target sequence and 
fluorophore-based detection. 10ng of cDNA was added into the reaction mix made 
of 12.5µl of Taqman gene expression master mix (Thermo Fisher Scientific), 1.25µl 
of Taqman assays (identification numbers listed below), and 6.25µl of RNase free 
water (Qiagen) to achieve a final volume of 25µl on the MicroAmp optical 96-well 
reaction Plate (Applied Biosystems). The plate was sealed with MicroAmp optical 
adhesive film (Applied Biosystems) and read in the HT7900 Fast Real-Time PCR 
system (Applied Biosystems) using the standard protocol: hold at 50°C for 2 min, 
hold at 95°C for 10 min, followed by repeating 40 cycles of 95°C for 15 sec for 
annealing and 60°C for 1 min for elongation. The reactions were performed in 
triplicate wells and the HPRT1 gene (hypoxanthine phosphoribosyl transferase 1) 
was used as an endogenous control for normalizing the sample concentration. The 
2(-ΔΔCT) method was applied to quantify the mRNA expression levels (Livak and 
Schmittgen, 2001).  
 
Table 2.3 Taqman Gene Expression Assays used in the qPCR experiments. 
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2.4 Microarrays 
2.4.1 The in vitro microarray  
Independent parallel sets of RNA samples isolated from contraction gels of 
conjunctival fibroblast cells HTF7071 at day0, 3 and 5 were prepared as described 
previously. Day0 gels were cultured in serum free medium and harvested 1 hour 
after gel polymerization. The gels harvested at day3 and 5 were cultured in normal 
medium with 10% serum (FBS) and treated with/without transient treatment of 
NSC23766 for the first 24 hours after gel polymerization. Accordingly, the sample 
groups were labelled as Day0, Day3 and Day5, and Day3NSC and Day5NSC. 
Initially all the samples were triplicated and processed by Dr. Tovell. However, two 
replicates from Day0 and Day5 group respectively had inadequate amount of RNA, 
thus were re-prepared by myself. Nevertheless, the replacement samples that I 
processed were isolated from gels made with serum containing medium, thus 
exhibited a different gene expression profile comparing to the Tovell’s ones due to 
the early serum stimulation. Therefore, the final analysis was performed with only 
Tovell’s samples in which the Day0 and Day5 groups only had duplicate replicates. 
  
The samples were assessed for quality, integrity, quantity and purity using a 
bioanalyser (QC model 2100; Aglient, Santa Clara, CA) and reverse-transcribed to 
cDNA, labelled and hybridised to the array chip, and then analysed on the 
GeneChip Human Gene 1.0 ST transcriptome-level cDNA platform (Affymetrix, 
Santa Clara, CA) at the UCL Genomics microarray laboratory, Institute of Child 
Health (London, UK) following the standard Affymetrix protocols. Arrays were 
scanned on a GeneChip 3000 7G Scanner (Affymetrix) and the ‘.DAT’ files collected 
were converted to ‘.CEL’ files using 2100 Bioanalyzer (Agilent), which were 
subsequently processed using the Robust Multi-array Average (RMA) normalization 
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methodology (Irizarry et al., 2003). Due to the small sample size, a moderate t-test 
was conducted. The gene expression levels, annotations, the principal component 
analysis (PCA), and clustering heatmaps were obtained by analysing the ‘.CEL’ files 
through Altanalyze v2.0.9 (http://www.altanalyze.org/) (Emig et al., 2010). Genes 
that were differently expressed were filtered as fold change>1.2 times and a 
significance of p<0.05. The identification of the functional-related enrichment gene 
clusters was carried out by the Database for Annotation, Visualization and 
Integrated Discovery Bioinformatics v6.8 (DAVID; http://david.abcc.ncifcrf.gov/ ) 
(Huang da et al., 2009a, Huang da et al., 2009b).  
 
2.4.2 The in vivo microarray  
The raw data of the microarray profiling of in vivo wounding model in rabbit was 
obtained from Dr. Daniel Paull who performed the study using rabbits (2-2.5kg, 12-
14 weeks old, Harlan UK) that underwent glaucoma filtration surgery (GFS) on the 
left eye, and with the right eye used as un-operated control. GFS created a fornix-
based conjunctival ﬂap with a drainage channel that connected the anterior 
chamber to the sub-Tenon’s space underneath, together those formed a ‘bleb’ on 
the surface of the eye. Five days after surgery, conjunctival samples (approximately 
2 × 2mm in size) of both eyes were taken from the centre of the bleb and RNA was 
extracted using the RNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions as described before. The quality was assessed using the 2100 
Bioanalyzer (Agilent) and RNA 6000 Nano Chip Kit (Agilent), and then the samples 
were hybridised to the arrays all following Agilent standard protocols. The 
microarray was undertaken using a custom designed, rabbit specific, Agilent 8 × 
15k 60-mer oligonucleotide arrays (Agilent AMADID# 017130). The data was 
analysed with the Limma package with Bioconductor (Ritchie et al., 2015), which 
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applied a modified t-test using a Bayesian approach. Genes that were differently 
expressed were filtered as fold change>1.2 times and a significance of p<0.05. 
 
2.5 MMP activity assay 
The total (both pro and active forms) and active (only active form) activities of the 
MMPs’ in the contraction medium were determined using the MMP activity assay kit 
(Abcam ab112147). It uses a fluorescence resonance energy transfer (FRET) 
peptide as a MMP substrate, which upon cleavage by MMPs releases the 
fluorescence. 25µl of culture medium was removed from each control and 
NSC23766 treated gel contraction culture at Day0, Day3 and Day5, and added to 
96-well plate that contained 25µl of 2mM APMA (4-aminophenylmercuric acetate) 
working solution that activates the pro MMPs or 25 µl of Assay buffer as non-
stimulated control and incubated at 37°C for 3hrs. And then, 50µl of the MMP Red 
Substrate was added to the reaction and incubated at room temperature for 1hr. 
The fluorescence intensity was measured at Ex/Em=540/590nM using a plate 
reader (Fluostar Optima). The assay was performed in triplicate wells. 
 
2.6 MMP1 ELISA 
The MMP1 protein secreted into the culture medium by fibroblasts was measured 
using MMP1 Human ELISA (Enzyme-Linked Immunosorbent Assay) Kit (Abcam 
ab100603) that quantitatively measured the Human MMP1 pro and active forms in 
cell culture supernatants. 100µl of the culture medium was removed from gel 
contraction culture at desired time points and eight MMP1 protein standards ranging 
from 0 to 18000 pg/ml were added into the ELISA plate respectively for incubation 
for 2.5hrs. The solution was discarded and the wells were washed with 300 µl of 
wash solution/well for 4 times. And then, 100 µl of Biotinylated MMP1 Detection 
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Antibody and 100µl of HRP-streptavidin solution were added to each well 
respectively and each incubated for 1hr with a washing step followed as previously 
described. 100µl/well of the one-step TMB-ELISA substrate solution was added to 
the plate and incubated for 30 min in the dark. Finally, 50µl of stop solution was 
added to each well and the absorbance was read immediately at 450 nm on the 
plate reader (Fluostar Optima). The whole experiment was performed at room 
temperature and each sample was assessed in triplicate wells. The plate was 
incubated with gentle shaking on a plate shaker.  
 
2.7 siRNA 
The silencing of the genes of interest was achieved using siRNA SMARTpools 
(Dharmacon) that contained a mixture of 4 siRNAs targeting the same human gene. 
Either HiPerfect Transfection Reagent (Qiagen) or Lipofectamine RNAiMAX 
Transfection Reagent (Thermo Fisher Scientific) was used depending on the gene 
of target. Two non-target (NT) siRNAs were initially tested as negative control, 
including the Allstars negative control siRNA (Qiagen), and the siGENOME non-
targeting siRNA #1 (Dharmacon). However, each of them had their own side-
effects, for example the siGENOME one decreased the contractile activity of 
fibroblasts, and the Allstars one slightly increased MMP1 production in the cells. In 
the end, the Allstars NT siRNA (Qiagen) was applied in most of the experiments. 
The details of the siRNAs and their working concentrations used are listed in Table 
2.4. The concentration and transfection reagent used for NT siRNA were matching 
the ones applied for the target siRNA. The cells were transfected with the fast-
forward transfection method. Firstly, 0.8x105 cells were seeded on 6cm petri dish in 
4ml of culture medium. When the cells were attached to the bottom of the dish (2-
3hrs after the seeding), a transfection complex that consisted of siRNA, transfection 
reagent and serum-free culture medium (or Opti-MEM (Thermo Fisher Scientific) if 
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using RNAiMAX) was added drop-wise on the cell culture. The petri dish was gently 
swirled to ensure uniform distribution of the complex. The cells were incubated at 
37ºC with 5% CO2 and medium unchanged. 72 hrs after transfection, cells were 
harvested and seeded into collagen contraction assay, as well as lysed for 
immunoblotting to confirm the protein downregulation.  
 
Table 2.4 List of siRNA used for the gene silencing study, with the catalogue number, 
working concentration and the transfection reagent applied. 
 
2.8 Protein extraction 
2.8.1 Protein extraction from 2D culture 
Total protein extraction of cells seeded on tissue culture plate (2D format) was 
performed by lysing cells in ice cold Radioimmunoprecipitation assay (RIPA) buffer 
(150mM NaCl, 0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate (SDS), 50mM Tris-HCl pH8.0 (all from Sigma-Aldrich), cOmplete 
protease inhibitor cocktail (Roche)) on ice. The cells were then scraped from the 
plate using a cell scraper (VWR) and lysing on ice for 15-20 min, followed by a 
centrifugation at 11000 rpm at 4 ºC for 15 min. The insoluble pellet was discarded 
and the supernatant was stored at -80 ºC.  
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2.8.2 Protein extraction from 3D culture 
To extract protein from cells seeded in collagen gels (3D format), the gel was first 
digested. Triplicate collagen gels from contraction assay were carefully transferred 
to a 15ml conical centrifuge tube (Sigma-Aldrich) that contained 500µl of 0.05% 
Collagenase D (Roche) in DPBS ( Thermo Fisher Scientific) using pipette tip. The 
tube was placed in the incubator at 37 ºC for no longer than 30 min until the gels 
were just dissolved. 3ml of DPBS was added to the tube to dilute the collagenase 
and the solution was centrifuged at 1400 rpm at 4 ºC for 7 min. The supernatant 
was carefully aspirated without disturbing the cell pellet. Finally, the cells were 
resuspend in 50µl of ice cold RIPA buffer, lysed on ice for 10 min, centrifuged at 
11000 rpm at 4 ºC for 15 min, and the supernatant containing the cellular protein 
was stored at -80 ºC.  
 
2.9 Western blotting 
The concentrations of the protein samples were determined using the bicinchoninic 
acid (BCA) assay (Thermo Fisher Scientific). 10µl of the protein samples and 
protein standards (ranging from 0.125 to 2mg/ml) were added to 50µl of assay 
reagent on flat-bottom 96-well plate (Thermo Fisher Scientific) and incubated at 37 
ºC for 30 min. The absorbance was read at 562nm using a plate reader (Fluostar 
Optima). The protein samples were then normalised to same concentration by 
adding RIPA buffer, and 5x sample buffer (Thermo Fisher Scientific) and boiled in 
the heat block at 90 ºC for 5 min for denaturation. 5µg of the samples were loaded 
on 8-16% precast polyacrylamide Tris-Glycine or 4-12% Bis-Tris Plus mini gels 
(Thermo Fisher Scientific) and ran with Tris-HEPES SDS or MOPS SDS running 
buffer (Thermo Fisher Scientific) respectively depending on the size of the protein of 
interest at 200V for 20-40 min until optimal separation obtained. The wet transfer 
method was applied to transfer the proteins on the gel to polyvinylidene difluoride 
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(PVDF) membrane (Thermo Fisher Scientific). The membrane was soaked in 
methanol (VWR) for activation for a few seconds, then quickly rinsed in water, and 
equilibrated in transfer buffer (25mM Tris-HCl pH8.3, 192mM Glycine, 20% v:v 
methanol) with filter paper (Thermo Fisher Scientific) and foam pads (Bio-Rad). The 
transfer sandwich was assembled in the order of foam pads/filter paper/PVDF 
membrane/gel/filter paper/foam pads, which was subsequently placed in the Mini 
Trans-Blot cell apparatus (Bio-Rad) and transferred at 110V for 1hr. The membrane 
was blocked in Blotto buffer (5% reduced-fat milk in TBS-T (0.1% Tween-20 in Tris-
buffered saline)) for 1hr at room temperature and followed by overnight incubation 
at 4 ºC in primary antibody (Table 2.5). Then, after 3 times x10 min each washing in 
TBS-T, the membrane was incubated in secondary horseradish peroxidase (HRP)-
conjugated antibody (Jacksons ImmunoResearch) (Table 2.6) in Blotto buffer for 
2hrs, followed with 3 times x10 min each washing in TBS-T. Lastly, the membrane 
was placed in the transparent plastic layflat sheet (Scientific Laboratory Supplies), 
incubated in Pierce ECL Plus Substrate (Thermo Fisher Scientific) for 3-5 min, and 
developed in the dark room using Fujifilm Corporation RX NIF Sheet X-ray Film 
(Thermo Fisher Scientific) in the X-ray developer with varied exposure time 
depending on the signal strength. The film was scanned with a high resolution 
scanner and image was analysed using ImageJ software (http://rsb.info.nih.gov/ij/). 
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Table 2.5 Primary antibodies used in the Western blot experiments.  
 
Table 2.6 Secondary antibodies used in the Western blot experiments.  
 
 
2.10 Subcellular fractionation  
Parallel sets of fibroblast cells were seeded as 1.2x105 cells/dish on 6cm petri dish 
in 4ml of culture medium with/without the treatment of 50µM NSC23766 for the first 
24hrs and cultured for 3 days. To separate nucleus and cytoplasm, cells were 
typsinised, spun down and resuspended in 300µl of ice-cold fractionation buffer 
(sucrose 250mM, HEPES PH7.4 20mM, KCl 10mM, MgCl2 2mM, EDTA 1mM, 
EGTA 1mM, DTT 5mM (all from Sigma-Aldrich), cOmpleteTM protease inhibitor 
cocktail (Roche)). The cells suspension was passed through a 25 gauge needle for 
10 times using a 1ml syringe, and then left on ice for 20 min, following by 
centrifugation at 3000 rpm at 4 ºC for 5 min to separate the nuclei and the 
cytoplasm components. The cytoplasm components in the supernatant were 
clarified by centrifugation at 8000 rpm at 4 ºC for 10 min to discard any insoluble 
pellet. The nuclear pellet remained was washed with 500µl of ice cold fractionation 
buffer, and dispersed with a pipette and passed through a 25 gauge needle for 10 
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times, followed by a centrifugation at 3000 rpm at 4 ºC for 10 min to remove any 
cytoplasm contamination. The supernatant was discarded and the pellet was 
resuspended in 300µl of ice cold RIPA buffer added with 10% glycerol, and then 
sonicated briefly for 10 sec. It was subsequently centrifuged again at 8000 rpm at 4 
ºC for 10 min to discard any insoluble pellet. The whole cell lysate was obtained by 
lysing equal number of cells in 600µl of ice cold RIPA buffer according to the 
standard protein extraction protocol describe previously. The sample loading of 
whole cell, nuclear and cytoplasmic lysates for electrophoresis was equal in volume 
(20µl for each sample).    
 
2.11 Cell staining and microscopy 
2.11.1 2D fluorescent imaging 
Three 13mm diameter coverslips (VWR) were placed in 3cm tissue culture dish, and 
treated with 1M HCl for 5 min, washed with sterile PBS, followed by incubation of 
70% ethanol for 5 min, and a final wash in sterile PBS. 1x105 cells were seeded per 
dish in 2ml of culture medium, and cultured at 37ºC with 5% CO2 overnight. The 
next day, the medium was aspirated and the dish was rinsed quickly with warm 
PBS, followed by fixation in 3.7% formaldehyde (Sigma-Aldrich) in PBS for 7 min, 
permeabilization in 0.5% Triton-X100 (Sigma-Aldrich) in PBS for 20 min, and 
incubation in 0.1M Glycine (Sigma-Aldrich) in PBS for 10 min. The dish was then 
washed with 1% BSA (Thermo Fisher Scientific) in TBS pH8.0 for 5 min, and the 
coverslips were transferred onto a glass plate covered with parafilm and blocked 
with 50µl of rhodamine-phalloidin (Thermo Fisher Scientific) 1:50 in 1% BSA plus 
1% FBS in TBS pH8.0 in a humidified chamber in the dark for 20 min. Then, the 
phalloidin block was replaced with 50µl of primary antibody (anti-MMP1 antibody) 
1:50 in 1% BSA in TBS pH8.0 and incubated for 1hr in the dark. The coverslips 
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were washed for 30 min with 1% BSA in TBS pH8.0 with a minimum of 3 changes of 
buffer, followed by incubation of 50µl of secondary antibody (Alexa Fluor® 488-
AffiniPure Donkey Anti-Rabbit IgG (H+L), Stratech) 1:50 in 1% BSA in TBS pH8.0 
for 1hr in the dark, and wash again for 30 min with 1% BSA in TBS pH8.0 as 
previously described. After carefully blotting the extra liquid, the coverslips were 
inverted onto the Fluoroshield mounting medium (Abcam ab1041135) drop on the 
glass slide (VWR) using forceps, and the edges were sealed by nail polish. The 
slides were stored at 4ºC in the dark and images were carried out on a Nikon Ti-E 
microscope with CoolSNAP HQ2 camera (Photometrics, Tucson, AZ, USA), using a 
x20 air objective (20x Plan Fluor ELWD ADM with correction collar). The images 
were imported into ImageJ software and the cells were manually traced for the 
calculation of cell area and integrated density. Corrected integrated density (CID) 
was calculated based on the equation: CID=Integrated density - (cell area x 
background integrated density).  
 
2.11.2 Collagen gel imaging 
Collagen contraction assays were terminated at the desired time point. The culture 
medium was removed by aspirating, and the gels were fixed with pre-warmed 
(37ºC) 3.7% formaldehyde (Sigma-Aldrich) in PBS for 30 min, followed with 
permeabilisation with 2ml of 0.5% Triton-X100 (Sigma-Aldrich) in PBS for 30 min, 
and 1 time rinse and incubation with 0.1M Glycine (Sigma-Aldrich) in PBS for 30 
min. The gels were then transferred into eppendorf tubes (Eppendorf) with 50µl of 
0.5µM labelled phalloidin (Thermo Fisher Scientific) (approximately 1:20 of the stock 
phalloidin) in TBS pH8.0 with 1% BSA plus 1% FBS, and incubated in the dark for 
30 min. The gels were transferred to another eppendorf tube with 50µl of 1:50 anti-
MMP1 primary antibody (ab38929, Abcam; or in-house produced anti-MMP1 
antibody provided by Dr. Yoshi Itoh from Oxford University) in TBS pH8.0 with 1% 
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BSA, and incubated overnight at 4ºC in the dark. The primary antibody was 
removed by gentle pipetting, and the eppendorf tubes were filled with TBS pH8.0 
with 1% BSA, and placed in a 50ml centrifuge tube (Thermo Fisher Scientific) that 
wrapped in foil paper on the rotating wheel for 10 min washes for 3 times. The gels 
were then transferred to fresh eppendorf tubes with 50µl 1:50 of the secondary 
antibody (Alexa Fluor® 488-AffiniPure Donkey Anti-Rabbit IgG (H+L), Thermo 
Fisher Scientific) in TBS pH8.0 with 1% BSA and incubated for 2-3 hrs in the dark at 
room temperature, following with 3 x 15 min washes as described previously. The 
last wash was made in TBS pH8.0 instead of TBS pH8.0 with 1% BSA. The gels 
were placed back to the centre of the original Mattek dishes, and mounted by 
adding 200µl of Fluoroshield mounting medium (Abcam ab1041135) or freshly 
made mounting medium (N-propyl gallate 6g/L in glycerol 50% in TBS pH8.0) and 
covered with coverslip.  
 
The gels were imaged using Biorad Radiance confocal microscope (Zeiss Axiovert 
S100/Biorad Radiance 2000) with a long working distance objective (ZEISS LD 
plan- Neofluoar 63x0.75) to visualise cells (red, green HeNe laser 540/565nm) and 
matrix (confocal reflection microscopy). The 3D re-construction was processed 
using Volocity software (PerkinElmer). In addition, imaging of the gels was also 
performed using Nikon Ti-E microscope with CoolSNAP HQ2 camera 
(Photometrics, Tucson, AZ, USA) with 20x objective (20x S Plan Fluor ELWD 0.45 
Ph1). The composite images were captured with a z-stacking of 2µm per layer and 
the projection process was performed using the Nikon NIS elements software. 
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2.12 Statistical analysis 
The statistical analysis was performed using Microsoft Excel 2013. Data is 
presented as means averaged from at least triplicate experiments ± standard error 
of the mean (SEM). Student’s t-test was performed using 2-tailed paired tests to 
establish significant differences and individual p value was displayed. In the case of 
different experimental value applied, it is indicated in the figure’s legend.  
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Chapter 3 The ‘molecular portrait’ of fibroblast-mediated 
contraction in vitro  
 
3.1 Gene expression profiling reveals global but transient gene activation 
during contraction  
To identify the molecular pathways underlying fibroblast-mediated matrix contraction 
following serum stimulation, and the role of small Rho GTPase Rac1 in contraction, 
a microarray platform (Affymetrix human gene 1.0 ST) was used to analyse the 
gene expression profiles of human conjunctival fibroblasts during contraction at time 
point day0 (30min after initial gel polymerisation in the serum free condition), day3 
(peak contraction rate) and day5 (contraction plateau) with/without transient 
treatment with Rac1 inhibitor NSC23766 for 24 hrs in the standard free-floating 
collagen gel contraction assay (Tovell et al., 2011). As explained in Chapter 2 
(2.4.1), all the groups contained triplicate samples, except Day0 and Day5 those 
had duplicate samples. The raw Affymetrix CEL files were processed using the 
Robust Multi-array Average (RMA) normalization methodology (Irizarry et al., 2003), 
and data analysis was performed using AltAnalyze 2.0.9 
(http://www.altanalyze.org/). A moderated t-test was conducted due to the small 
sample size. The data was evaluated to be of high quality according to the density 
plot that showed the distribution of normalised log2 probe set intensity values of the 
samples (Figure 3.1). It confirmed a very good overlapping to allow comparisons 
that in line with the principle of “lower variability data with all other things being 
equal, should be judged to be of higher quality” (Gentleman, 2005). The Principal 
Component Analysis (PCA), which uses an orthogonal transformation to convert 
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samples of possibly correlated variables into a set of values of linearly uncorrelated 
variables, also demonstrated a very good level of similarities between the 
experimental replicates. The PCA plot also indicated that the Day3 samples were 
clearly separated from the others, whilst the NSC23766 treated ones were very 
close to the Day5 samples. Furthermore, little variation was shown between the 
Day5NSC and Day5 untreated samples (Figure 3.2). The gene expression patterns 
across all the samples were visualised by hierarchical clustering, which suggested a 
similar result to the PCA plot: among the three time points tested, the Day3 samples 
exhibited a strikingly strong and altered gene expression profile that implicated 
massive gene changes, which receded at day5. However, with NSC23766 
treatment, this hyperactive gene cascade was supressed (Figure 3.3).  
 
The differentially expressed genes among the contraction at day0, 3 and 5 non-
treated group were compared by drawing a Venn diagram, which is an interactive 
tool for comparing lists with Venn Diagrams. There were over 10,000 genes being 
differentially regulated during the whole contraction process (p<0.05, fold 
change >1.2 times). Approximately half of the genes that went up from day0 to day3 
(1672 of a total of 3162) also went down from day3 to day5 (1672 of a total of 2721). 
The same was true for the 1656 genes that both went down during day0 to day3 
and backed up later on from day3 to day5, suggesting a major but transient 
activation of the fibroblasts during contraction, which receded after 3 days (Figure 
3.4). 
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Figure 3.1 The distribution of normalised log2 probe set intensity values of the 
samples. 
The density plot showed the density of the probe intensities was of good overlapping 
between the samples. Each line represented a different array in the experiment (Day0--J, B; 
Day3--G, L, D; Day5--J, A; Day3NSC--F, K, C; Day5NSC--H, K, M).  
 
Figure 3.2 Principal Component Analysis (PCA) plot showing the separation of 
individual samples. 
The PCA plot demonstrated a very good level of similarities between the experimental 
replicates. In terms of sample variation, Day3 samples were the most separated among all, 
whilst the Day3NSC, Day5NSC, and Day5 samples sit in a similar position. The Day0 
samples showed a modest variability from the others.  
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Figure 3.3 Hierarchical clustering heatmap showing the differential gene expressions 
(log2 fold) during contraction at the time points day0, 3 and 5 with/without NSC23766 
treatment.  
The expression pattern of each gene is displayed as a horizontal strip. The gene expression 
level (log2 fold) in each sample replicate is represented by a colour, according to the colour 
scale at the top left. Each column of the heatmap represents the expression pattern of a 
sample replicate, with the sample name labelled at the bottom. The sample groups are 
represented by the colour bar on the top of the heatmap, according to the colour scale at the 
bottom left. The figure illustrates that the Day3 sample group showed a strikingly strong and 
altered gene expression profile that exhibited a massive gene regulation towards opposite 
direction comparing to the others, whereas with the treatment of NSC23766, this hyperactive 
regulation was receded.  
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Figure 3.4 Paired comparisons of genes differentially expressed among day0, 3 and 5 
during the in vitro contraction.  
During the 5-day serum stimulated in vitro contraction, over 10,000 genes were captured 
during the process. More than 3000 genes were regulated up and down dynamically, with 
1672 genes being upregulated from day0 to 3 changed to the opposite direction from day3 
to 5, whilst 1656 downregulation genes from day0 to 3 reactivated again at day3 to 5. 
 
 
3.2 Early contraction: a classical wound healing/serum response  
According to the gene expression profiles, the fibroblast-mediated in vitro 
contraction was divided into two stages: early contraction (from day0 to 3) and late 
contraction (from day3 to 5). The most dramatic gene expression changes (over 60 
times) were observed in the early contraction upregulation profile, which included 
inflammatory factors (F2EL1, LIF, PTGS2), cytokines (IL8, IL36B, IL11), growth 
factors (HBEGF, PTHLH) and matrix metalloproteinases (MMPs) (MMP1, MMP10), 
underlying a classical “response to wounding” profile (Iyer et al., 1999) (Table 3.1). 
Meanwhile, genes related to cell migration (CD34, PEX2, TGFBR3) and membrane 
integrity (ADAM22, FGFR2, LDLR) were found greatly suppressed, with the most 
downregulated gene being affected less than 20 fold (Table 3.2). 
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Table 3.1 The symbol, definition and fold change of the first 100 genes upregulated in 
the early contraction from day0 to 3 (fold change>2 times, p value<0.05). 75 of them 
were downregulated at day3 in the NSC23766 treated samples comparing to the 
untreated control samples. 25 genes that did not show downregulation were coloured 
in blue. The serum response genes that were identified in a study of transcriptional 
profile of human foreskin fibroblasts in response to serum (Iyer et al., 1999) were 
labelled in bold character (12 genes). 
Symbol Definition FoldChng 
IL1RN interleukin 1 receptor antagonist  63.56 
CXCR4 chemokine (C-X-C motif) receptor 4  62.13 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 60.46 
F2RL1 coagulation factor II (thrombin) receptor-like 1  47.90 
MMP1 matrix metallopeptidase 1 (interstitial collagenase)  38.73 
RNA5SP242 RNA, 5S ribosomal pseudogene 242  34.76 
IL8 interleukin 8  29.98 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1  29.46 
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1  28.78 
HBEGF heparin-binding EGF-like growth factor  27.53 
TFPI2 tissue factor pathway inhibitor 2  25.80 
RAD54L RAD54-like (S. cerevisiae)  25.25 
KRTAP3-2 keratin associated protein 3-2  25.21 
LSMEM1 leucine-rich single-pass membrane protein 1  23.49 
CD163L1 CD163 molecule-like 1  23.22 
MMP10 matrix metallopeptidase 10 (stromelysin 2)  22.09 
MFSD2A major facilitator superfamily domain containing 2A  21.00 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)  20.46 
TSPAN13 tetraspanin 13 20.36 
LPXN leupaxin  20.00 
ANGPTL4 angiopoietin-like 4  18.87 
HS3ST2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2  18.43 
LIF leukaemia inhibitory factor  18.31 
UPP1 uridine phosphorylase 1  16.98 
C12orf50 chromosome 12 open reading frame 50  16.81 
PAX8-AS1 PAX8 antisense RNA 1 16.63 
HAS2 hyaluronan synthase 2 15.56 
TEX26 testis expressed 26 15.46 
RNU6ATAC2P RNA, U6atac small nuclear 2, pseudogene  14.52 
ZNF267 zinc finger protein 267  13.09 
VTRNA1-3 vault RNA 1-3  13.07 
LEKR1 leucine, glutamate and lysine rich 1  12.79 
RNU6ATAC3P RNA, U6atac small nuclear 3, pseudogene  12.40 
ADTRP androgen-dependent TFPI-regulating protein  12.24 
MT1G metallothionein 1G  11.79 
MIR222 microRNA 222  11.61 
PTHLH parathyroid hormone-like hormone  11.54 
GEM GTP binding protein overexpressed in skeletal muscle 11.46 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64)  11.35 
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CDCP1 CUB domain containing protein 1  11.27 
PMEPA1 prostate transmembrane protein, androgen induced 1  11.27 
STC1 stanniocalcin 1  11.23 
SLC16A6 
solute carrier family 16, member 6 (monocarboxylic acid 
transporter 7) 11.08 
PRSS3 protease, serine, 3  10.99 
RP11-170L3.8 n/a 10.71 
USP38 ubiquitin specific peptidase 38  10.63 
C5orf45 chromosome 5 open reading frame 45  10.51 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2  10.49 
LIMD1-AS1 LIMD1 antisense RNA 1  10.48 
TMEM100 transmembrane protein 100  10.45 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 10.44 
SIK1 salt-inducible kinase 1  10.13 
TNC tenascin C  10.08 
CCL20 chemokine (C-C motif) ligand 20  9.91 
MT1H metallothionein 1H  9.80 
PRSS3P2 protease, serine, 3 pseudogene 2  9.77 
NCKAP1L NCK-associated protein 1-like  9.75 
GABARAP GABA(A) receptor-associated protein  9.71 
S100A2 S100 calcium binding protein A2  9.71 
MT1F metallothionein 1F  9.68 
MIR31HG MIR31 host gene (non-protein coding)  9.64 
E2F7 E2F transcription factor 7  9.58 
SLC39A14 solute carrier family 39 (zinc transporter), member 14  9.51 
MT1M metallothionein 1M  9.29 
CSRNP1 cysteine-serine-rich nuclear protein 1  9.27 
CREB5 cAMP responsive element binding protein 5  9.20 
SLC22A3 
solute carrier family 22 (extraneuronal monoamine 
transporter), member 3  9.19 
SCUBE2 signal peptide, CUB domain, EGF-like 2  9.07 
TEX35 testis expressed 35  9.00 
IL36B interleukin 36, beta  9.00 
BCL2L10 BCL2-like 10 (apoptosis facilitator)  8.96 
RYBP RING1 and YY1 binding protein  8.95 
DGKI diacylglycerol kinase, iota  8.92 
SEL1L2 sel-1 suppressor of lin-12-like 2 (C. elegans)  8.87 
LINC01270 long intergenic non-protein coding RNA 1270 8.85 
IL11 interleukin 11  8.84 
C3orf67 chromosome 3 open reading frame 67  8.84 
HIST2H3C histone cluster 2, H3c  8.82 
MIR103A2 microRNA 103a-2  8.73 
DEFB107A defensin, beta 107A  8.70 
DEFB107B defensin, beta 107B  8.70 
PTPRR protein tyrosine phosphatase, receptor type, R  8.67 
DACT1 
dapper, antagonist of beta-catenin, homolog 1 (Xenopus 
laevis)  8.65 
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NFATC2 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2  8.62 
PTGS2 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)  8.39 
ACTN2 actinin, alpha 2  8.34 
RCAN1 regulator of calcineurin 1  8.29 
ETV4 ets variant 4  8.21 
PLEK2 pleckstrin 2  8.20 
ADNP2 ADNP homeobox 2  8.10 
C3orf35 chromosome 3 open reading frame 35 8.07 
CXCL1 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)  8.03 
KLF10 Kruppel-like factor 10 8.01 
RNU6ATAC10P RNA, U6atac small nuclear 10, pseudogene  8.00 
TAGLN3 transgelin 3  7.99 
PLAUR plasminogen activator, urokinase receptor  7.91 
TMEM217 transmembrane protein 217  7.84 
IER3 immediate early response 3  7.83 
IDI2 isopentenyl-diphosphate delta isomerase 2  7.81 
DEC1 deleted in esophageal cancer 1  7.61 
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Table 3.2 The symbol, definition and fold change of the first 100 genes downregulated 
in the early contraction from day0 to 3 (fold change>2 times, p value<0.05). 58 of them 
were upregulated at day3 in the NSC23766 treated samples comparing to the 
untreated control samples. The genes that did not show upregulation were coloured 
in blue. The serum response genes that were identified in a study of transcriptional 
profile of human foreskin fibroblasts in response to serum (Iyer et al., 1999) were 
labelled in bold character (9 genes). 
Symbol Definition FoldChng 
C10orf10 chromosome 10 open reading frame 10  -16.46 
GOLGA8O golgin A8 family, member O -12.71 
FMO2 flavin containing monooxygenase 2 (non-functional) -11.21 
SLC40A1 
solute carrier family 40 (iron-regulated transporter), member 
1  -10.70 
LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial)  -10.33 
LMO3 LIM domain only 3 (rhombotin-like 2)  -10.26 
ALPK1 alpha-kinase 1 -9.56 
TFAP2B 
transcription factor AP-2 beta (activating enhancer binding 
protein 2 beta)  -9.47 
SLC25A27 solute carrier family 25, member 27  -9.15 
VWA5A von Willebrand factor A domain containing 5A  -9.12 
OSR2 odd-skipped related 2 (Drosophila) -8.76 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 -8.61 
SKP2 
S-phase kinase-associated protein 2, E3 ubiquitin protein 
ligase  -7.90 
BTN3A3 butyrophilin, subfamily 3, member A3  -7.52 
NCAPH non-SMC condensin I complex, subunit H  -7.27 
ARHGAP28 Rho GTPase activating protein 28  -7.20 
KLF2 Kruppel-like factor 2 (lung)  -7.08 
RASSF4 Ras association (RalGDS/AF-6) domain family member 4  -7.07 
KIT 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog  -7.07 
HLTF helicase-like transcription factor  -6.81 
HNMT histamine N-methyltransferase  -6.78 
ADAM22 ADAM metallopeptidase domain 22  -6.76 
EYA2 eyes absent homolog 2 (Drosophila)  -6.73 
FANCA Fanconi anemia, complementation group A  -6.65 
AL953854.2 n/a -6.36 
PRUNE2 prune homolog 2 (Drosophila)  -6.35 
DENND3 DENN/MADD domain containing 3  -6.34 
CC2D2A coiled-coil and C2 domain containing 2A  -6.23 
SPEG SPEG complex locus  -6.21 
TRPM3 
transient receptor potential cation channel, subfamily M, 
member 3  -6.20 
LRIG3 leucine-rich repeats and immunoglobulin-like domains 3  -6.13 
CRELD1 cysteine-rich with EGF-like domains 1  -6.12 
OSBPL5 oxysterol binding protein-like 5 -6.01 
DMAP1 DNA methyltransferase 1 associated protein 1  -5.96 
RNY3P6 RNA, Ro-associated Y3 pseudogene 6 -5.94 
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NLGN1 neuroligin 1  -5.88 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8  -5.84 
PPP1R12B protein phosphatase 1, regulatory subunit 12B  -5.81 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3  -5.81 
MRVI1 murine retrovirus integration site 1 homolog  -5.73 
DBC1 deleted in bladder cancer 1  -5.70 
RIMS1 regulating synaptic membrane exocytosis 1  -5.68 
MPP7 
membrane protein, palmitoylated 7 (MAGUK p55 subfamily 
member 7)  -5.68 
TMEM14E transmembrane protein 14E  -5.61 
IRAK1BP1 interleukin-1 receptor-associated kinase 1 binding protein 1  -5.52 
CABLES1 Cdk5 and Abl enzyme substrate 1  -5.50 
LDLR low density lipoprotein receptor  -5.49 
AC025171.1 n/a -5.48 
PPM1K protein phosphatase, Mg2+/Mn2+ dependent, 1K  -5.47 
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide  -5.43 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2  -5.40 
PRKG2 protein kinase, cGMP-dependent, type II  -5.38 
RN7SKP56 RNA, 7SK small nuclear pseudogene 56  -5.36 
ANG angiogenin, ribonuclease, RNase A family, 5  -5.35 
ACACB acetyl-CoA carboxylase beta  -5.31 
TMEM182 transmembrane protein 182  -5.30 
PRELP proline/arginine-rich end leucine-rich repeat protein  -5.14 
C11orf74 chromosome 11 open reading frame 74  -5.14 
ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9  -5.13 
PARP9 poly (ADP-ribose) polymerase family, member 9  -5.10 
CCBE1 collagen and calcium binding EGF domains 1  -5.03 
DTX3L deltex 3-like (Drosophila)  -5.02 
PEX2 peroxisomal biogenesis factor 2  -5.01 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2  -4.97 
FGFR2 fibroblast growth factor receptor 2 -4.93 
LMOD1 leiomodin 1 (smooth muscle)  -4.91 
CCDC7 coiled-coil domain containing 7  -4.90 
ACAD11 acyl-CoA dehydrogenase family, member 11  -4.87 
TTLL1 tubulin tyrosine ligase-like family, member 1  -4.81 
INVS inversin  -4.80 
LPIN1 lipin 1 -4.80 
LPCAT3 lysophosphatidylcholine acyltransferase 3  -4.79 
SELENBP1 selenium binding protein 1  -4.77 
SLC9A9 
solute carrier family 9, subfamily A (NHE9, cation proton 
antiporter 9), member 9  -4.74 
UBL4B ubiquitin-like 4B  -4.73 
MAN1C1 mannosidase, alpha, class 1C, member 1  -4.69 
ANXA3 annexin A3  -4.69 
PGAP2 post-GPI attachment to proteins 2  -4.67 
MTMR4 myotubularin related protein 4  -4.64 
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RTP4 receptor (chemosensory) transporter protein 4  -4.64 
ATL3 atlastin GTPase 3 -4.63 
JUP junction plakoglobin  -4.62 
SNORD48 small nucleolar RNA, C/D box 48 -4.53 
C2CD5 C2 calcium-dependent domain containing 5  -4.51 
C5orf30 chromosome 5 open reading frame 30  -4.50 
GLRB glycine receptor, beta  -4.50 
KANK2 KN motif and ankyrin repeat domains 2 -4.49 
CCL28 chemokine (C-C motif) ligand 28  -4.49 
PARP4 poly (ADP-ribose) polymerase family, member 4  -4.49 
CD34 CD34 molecule -4.46 
CRYZ crystallin, zeta (quinone reductase) -4.45 
CCDC158 coiled-coil domain containing 158 -4.42 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1  -4.41 
TGFBR3 transforming growth factor, beta receptor III  -4.40 
TLR3 toll-like receptor 3  -4.40 
GOLGA8M golgin A8 family, member M -4.39 
ZMYM1 zinc finger, MYM-type 1  -4.37 
MITF microphthalmia-associated transcription factor  -4.37 
DMKN dermokine  -4.37 
ZNF277 zinc finger protein 277  -4.35 
 
 
To identify the important biological pathways underlying early contraction, DAVID 
(the Database for Annotation, Visualization and Integrated Discovery v6.8) 
functional annotation analysis was performed on the first 1000 genes 
up/downregulated respectively from day0 to 3. The top functional clusters of the 
upregulated genes according to enrichment score (p<0.01) included ion binding, 
response to wounding, regulation of transcription, cell motion and cytokine activity 
(Figure 3.5a); and the ones of the downregulated genes included cofactor binding, 
sterol metabolism and metal ion binding (Figure 3.5b). 
 
Fibroblast-mediated gel contraction is reliant on the presence of serum or growth 
factors (Winkles, 1998, Cordeiro et al., 2000, Denk et al., 2003). Previous study has 
shown that fibroblasts in response to serum stimulation at least partially 
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recapitulated a classical wound response in vitro (Iyer et al., 1999). To evaluate the 
contribution of serum stimulation to the contraction profile of our model, we 
compared the early contraction gene expression profile to the transcriptional profile 
of human foreskin fibroblasts in response to serum (517 genes captured in total, 
with 479 of which with known annotation) (Iyer et al., 1999). We found that nearly 
half of the serum response genes (228 out of 479 genes) were captured in our early 
contraction gene expression profile, with 87 of which (44 within the first 1000 most 
upregulated genes) showing upregulation and 141 (60 within the first 1000 most 
downregulated genes) showing downregulation (Figure 3.6). These included the top 
up/downregulated genes in the in vitro profile, such as SERPINB2, IL8 and TFPI2 
(fold change 60, 30, and 26 times respectively), as well as IFIT1, KIT and HLTF 
(fold change -9, -7, and -6.8 times respectively) (Table 3.1, Table 3.2). It suggested 
that the dramatic gene expression changes occurred during the early contraction 
were at least partly due to a response to serum. Nevertheless, the majority of the 
genes in the early contraction profile were not related to the serum response, 
suggesting that they were specifically related to contractile activity. 
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Figure 3.5 Functional annotation by DAVID of the first 1000 genes up/downregulated 
during early contraction from day0 to 3. 
(a) The top 10 functional clusters of the first 1000 upregulation genes during early 
contraction according to enrichment score (p<0.01). (b) The top 10 functional clusters of the 
first 1000 downregulation genes during early contraction according to enrichment score 
(p<0.01). The first 10 most regulated genes of each cluster were listed below the score bar. 
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Figure 3.6 Paired comparisons of the fibroblast serum responsive (SR) genes (genes 
that were identified in a study of transcriptional profile of human foreskin fibroblasts 
in response to serum (Iyer et al., 1999)) that were regulated dynamically during the in 
vitro contraction. 
87 and 141 SR genes were up/downregulated in the early contraction from day0 to 3, whilst 
107 and 95 SR genes were up/downregulated in the late contraction from day3 to 5 
respectively. 55 genes upregulated from day0 to 3 were downregulated from day3 to 5, and 
72 genes downregulated from day0 to 3 were upregulated from day3 to 5. 1 gene that was 
upregulated consistently was CYP1B1, and 10 genes that were downregulated consistently 
were FOS, SYNPO2, PARD3B, SVEP1, ARID5B, C1R, MID1, ZFP36L2, CRABP2 and 
DAAM1. 
 
 
3.3 Late contraction gene expression profile 
In the later contraction from day3 to 5, the hyperactive early activation profile clearly 
receded. 3143 genes were found upregulated and 2721 downregulated during this 
stage. More than half of the genes were the ones that being up or downregulated 
from day0 to 3 going back to their original expression levels from day3 to 5 (Figure 
3.4). The first 100 genes up/downregulated during late contraction are listed in 
(Table 3.3) and (Table 3.4), which showed that most of the extremely upregulated 
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genes in early contraction were downregulated, and those that significantly 
downregulated from day0 to 3 were upregulated again. Also, 202 serum response 
genes were found expressed in the late contraction. More than half of them (127 
genes) were up or downregulated in the early contraction and being regulated to the 
opposite direction in the late contraction (Figure 3.6), suggesting that the active 
serum stimulation response rested. One serum response gene that was upregulated 
throughout the contraction was CYP1B1, which relates to oxidative homeostasis, 
ultrastructural organisation and the function of trabecular meshwork tissue in the 
eye (Bejjani et al., 1998). Ten genes that were downregulated consistently included 
FOS, SYNPO2, PARD3B, SVEP1, ARID5B, C1R, MID1, ZFP36L2, CRABP2 and 
DAAM1.  
 
The functional annotation analysis of the first 1000 genes up/downregulated during 
late contraction by DAVID showed a reverse image of that of the early contraction. 
Gene groups that related to cytokine and growth factors, wound healing response, 
protein kinase and transcription activities were largely turned down, and the ones 
that related to oxidation reduction, steroid biosynthesis, mitochondrion and 
peroxisome were re-activated. Moreover, 63 genes were upregulated and 113 
downregulated respectively in the early contraction from day0 to 3, and in the late 
contraction from day3 to 5 (Figure 3.4). The genes that involved in collagen 
degradation (MMP1, 3, 16), modulation of extracellular space (VEGFC, SERPINE2, 
AKR1B1) and vesicle mediated transport (NEDD4, SYTL5, PCLO) were promoted 
all the time; and the ones that related to glycoprotein (A2M, PZP, MASP1), EGF-like 
calcium binding (MATN2, F10, SVEP1) and cell adhesion (MATN2, COL14A1, 
TNXB) were supressed consistently (Figure 3.7). 
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Table 3.3 The symbol, definition and fold change of the first 100 genes upregulated in 
the late contraction from day3 to 5 (fold change>2 times, p value<0.05). 67 of them 
were the reverse-backs from the downregulation genes in the early contraction. The 
ones that were not regulated in the early contraction (fold change≤2 times, p 
value<0.05) were coloured in blue. The serum response genes (genes that were 
identified in a study of transcriptional profile of human foreskin fibroblasts in 
response to serum (Iyer et al., 1999)) were labelled in bold character (5 genes).  
Symbol Definition FoldChng 
TAC1 tachykinin, precursor 1  12.36 
AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 9.37 
GLRB glycine receptor, beta  8.35 
C5orf30 chromosome 5 open reading frame 30  8.12 
ENPP5 
ectonucleotide pyrophosphatase/phosphodiesterase 5 
(putative)  7.75 
DHCR7 7-dehydrocholesterol reductase  7.55 
GPR125 G protein-coupled receptor 125 7.26 
EYA2 eyes absent homolog 2 (Drosophila)  6.92 
PTGR2 prostaglandin reductase 2  6.65 
SKP2 
S-phase kinase-associated protein 2, E3 ubiquitin protein 
ligase  6.62 
ZNF737 zinc finger protein 737 6.60 
NFXL1 nuclear transcription factor, X-box binding-like 1  6.54 
SC5D sterol-C5-desaturase  6.24 
KCND2 
potassium voltage-gated channel, Shal-related subfamily, 
member 2  6.16 
CCRL1 chemokine (C-C motif) receptor-like 1  6.16 
RGS12 regulator of G-protein signaling 12  6.16 
TMEM155 transmembrane protein 155  6.13 
RP3-
509I19.1 n/a 6.13 
TM7SF2 transmembrane 7 superfamily member 2  6.10 
CEP57L1 centrosomal protein 57kDa-like 1  6.05 
SLC6A6 
solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6  6.05 
B3GALNT1 
beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside 
blood group)  5.81 
DTNB dystrobrevin, beta 5.79 
PCBP4 poly(rC) binding protein 4  5.75 
DEPTOR DEP domain containing MTOR-interacting protein 5.71 
OSBPL10 oxysterol binding protein-like 10  5.69 
AFP alpha-fetoprotein  5.69 
CC2D2A coiled-coil and C2 domain containing 2A  5.61 
CLGN calmegin  5.56 
HLTF helicase-like transcription factor  5.37 
PARP4 poly (ADP-ribose) polymerase family, member 4  5.35 
GPR63 G protein-coupled receptor 63 5.28 
COG6 component of oligomeric golgi complex 6  5.21 
FAM8A1 family with sequence similarity 8, member A1 5.20 
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PIR pirin (iron-binding nuclear protein)  5.18 
ZNF141 zinc finger protein 141  5.18 
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase  5.09 
DCDC1 doublecortin domain containing 1  5.01 
ANG angiogenin, ribonuclease, RNase A family, 5  4.99 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 4.95 
PGAP2 post-GPI attachment to proteins 2  4.94 
ENOX1 ecto-NOX disulfide-thiol exchanger 1  4.91 
TTC5 tetratricopeptide repeat domain 5  4.91 
PEX2 peroxisomal biogenesis factor 2  4.89 
TNFRSF11B tumour necrosis factor receptor superfamily, member 11b  4.89 
PLSCR4 phospholipid scramblase 4  4.85 
MSMO1 methylsterol monooxygenase 1  4.82 
TFAP2B 
transcription factor AP-2 beta (activating enhancer binding 
protein 2 beta)  4.82 
IMPACT impact RWD domain protein 4.78 
DDIT4L DNA-damage-inducible transcript 4-like  4.76 
RIN2 Ras and Rab interactor 2  4.74 
PTPN13 
protein tyrosine phosphatase, non-receptor type 13 (APO-
1/CD95 (Fas)-associated phosphatase)  4.74 
GPSM2 G-protein signaling modulator 2  4.70 
SNCA synuclein, alpha (non A4 component of amyloid precursor)  4.69 
NFRKB nuclear factor related to kappaB binding protein 4.65 
PDGFRL platelet-derived growth factor receptor-like 4.65 
PLXDC2 plexin domain containing 2  4.64 
C14orf1 chromosome 14 open reading frame 1  4.63 
USF1 upstream transcription factor 1  4.60 
ARRDC1 arrestin domain containing 1  4.56 
RFX5 regulatory factor X, 5 (influences HLA class II expression) 4.54 
GALNT5 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 5 (GalNAc-T5)  4.53 
COLEC12 collectin sub-family member 12  4.53 
HIBCH 3-hydroxyisobutyryl-CoA hydrolase  4.51 
TMEM97 transmembrane protein 97  4.48 
ADAM22 ADAM metallopeptidase domain 22 4.47 
UFSP2 UFM1-specific peptidase 2  4.46 
TP53TG1 TP53 target 1 (non-protein coding)  4.45 
FKBP7 FK506 binding protein 7  4.42 
SMIM11 small integral membrane protein 11  4.40 
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 4.40 
NAALADL1 N-acetylated alpha-linked acidic dipeptidase-like 1 4.37 
TMEM62 transmembrane protein 62  4.34 
DTWD2 DTW domain containing 2  4.33 
SPATA20 spermatogenesis associated 20  4.32 
APEH N-acylaminoacyl-peptide hydrolase  4.31 
CLCC1 chloride channel CLIC-like 1 4.30 
CNTN3 contactin 3 (plasmacytoma associated) 4.29 
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ACACB acetyl-CoA carboxylase beta  4.27 
KDELR3 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 3  4.25 
ACN9 ACN9 homolog (S. cerevisiae)  4.19 
CHSY3 chondroitin sulfate synthase 3 4.14 
COL10A1 collagen, type X, alpha 1 4.13 
HIST1H1C histone cluster 1, H1c  4.13 
GOLGA8O golgin A8 family, member O  4.11 
ARHGAP18 Rho GTPase activating protein 18 4.11 
ATRNL1 attractin-like 1  4.11 
TRIM2 tripartite motif containing 2  4.10 
GPX8 glutathione peroxidase 8 (putative)  4.09 
BCR breakpoint cluster region  4.08 
GLDN gliomedin  4.06 
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase)  4.05 
TMEM182 transmembrane protein 182  4.04 
AK5 adenylate kinase 5 4.04 
LMO3 LIM domain only 3 (rhombotin-like 2)  4.04 
KIT 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog  4.04 
GPER G protein-coupled estrogen receptor 1  4.03 
ZNF14 zinc finger protein 14  4.02 
CRYZ crystallin, zeta (Quinone reductase)  4.01 
TIMD4 T-cell immunoglobulin and mucin domain containing 4 4.00 
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Table 3.4 The symbol, definition and fold change of the first 100 genes downregulated 
in the late contraction from day3 to 5 (fold change>2 times, p value<0.05). Remarkably 
84 of them were the reverse-backs from the upregulation genes in the early 
contraction. The ones that were not regulated in the early contraction (fold change≤2 
times, p value<0.05) were coloured in blue. The serum response genes (genes that 
were identified in a study of transcriptional profile of human foreskin fibroblasts in 
response to serum (Iyer et al., 1999)) were labelled in bold character (10 genes).  
 
Symbol Definition FoldChng 
IL8 interleukin 8  -18.31 
NR4A2 nuclear receptor subfamily 4, group A, member 2  -17.21 
CXCR4 chemokine (C-X-C motif) receptor 4  -15.81 
MFSD2A major facilitator superfamily domain containing 2A -15.53 
CYP1A1 
cytochrome P450, family 1, subfamily A, 
polypeptide 1  -13.68 
LSMEM1 leucine-rich single-pass membrane protein 1  -13.51 
RAD54L RAD54-like (S. cerevisiae)  -13.48 
SERPINB2 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 2  -13.24 
C12orf50 chromosome 12 open reading frame 50  -13.04 
KIAA0226L KIAA0226-like  -13.03 
RASGRF1 
Ras protein-specific guanine nucleotide-releasing 
factor 1  -12.58 
IL33 interleukin 33  -12.54 
FOS FBJ murine osteosarcoma viral oncogene homolog  -12.47 
ICAM1 intercellular adhesion molecule 1  -12.29 
LIMD1-AS1 LIMD1 antisense RNA 1  -11.89 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64)  -11.80 
ATF3 activating transcription factor 3  -11.34 
ISG20 interferon stimulated exonuclease gene 20kDa -11.01 
RN7SL184P RNA, 7SL, cytoplasmic 184, pseudogene  -10.48 
SCUBE2 signal peptide, CUB domain, EGF-like 2  -10.13 
POLG2 
polymerase (DNA directed), gamma 2, accessory 
subunit  -9.81 
KRTAP3-2 keratin associated protein 3-2  -9.69 
NR4A3 nuclear receptor subfamily 4, group A, member 3  -9.35 
INHBA inhibin, beta A -9.32 
SLC22A3 
solute carrier family 22 (extraneuronal monoamine 
transporter), member 3 -9.19 
GUCY2C 
guanylate cyclase 2C (heat stable enterotoxin 
receptor)  -9.15 
EGR1 early growth response 1 -8.96 
CCL20 chemokine (C-C motif) ligand 20  -8.72 
TSLP thymic stromal lymphopoietin  -8.70 
TEX35 testis expressed 35 -8.49 
RNU4ATAC RNA, U4atac small nuclear (U12-dependent splicing)  -8.31 
REL 
v-rel reticuloendotheliosis viral oncogene homolog 
(avian) -8.21 
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EGR3 early growth response 3 -8.16 
ACTN2 actinin, alpha 2 -7.98 
PPP4R1L protein phosphatase 4, regulatory subunit 1-like  -7.97 
KB-1732A1.1 n/a -7.95 
RNA5SP242 RNA, 5S ribosomal pseudogene 242  -7.93 
CYP19A1 
cytochrome P450, family 19, subfamily A, 
polypeptide 1 -7.87 
RNU6ATAC33P RNA, U6atac small nuclear 33, pseudogene  -7.52 
NCKAP1L NCK-associated protein 1-like -7.43 
RNU6ATAC3P RNA, U6atac small nuclear 3, pseudogene  -7.38 
NFATC2 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2  -7.36 
LMCD1 LIM and cysteine-rich domains 1  -7.29 
A2M alpha-2-macroglobulin -7.29 
C5orf45 chromosome 5 open reading frame 45  -7.27 
BCL2L10 BCL2-like 10 (apoptosis facilitator) -7.21 
C9 complement component 9  -7.17 
HBEGF heparin-binding EGF-like growth factor  -7.15 
LRMP lymphoid-restricted membrane protein -7.06 
UTS2B urotensin 2B  -7.01 
RNU6ATAC2P RNA, U6atac small nuclear 2, pseudogene  -7.00 
IDI2-AS1 IDI2 antisense RNA 1  -6.97 
CXCL1 
chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha)  -6.87 
DUSP5 dual specificity phosphatase 5  -6.83 
POPDC2 popeye domain containing 2 -6.83 
PIK3CG 
phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit gamma  -6.79 
NEB nebulin  -6.78 
TMEM100 transmembrane protein 100 -6.74 
SORBS2 sorbin and SH3 domain containing 2  -6.73 
LIF leukaemia inhibitory factor  -6.69 
MIR103A2 microRNA 103a-2  -6.61 
DERL3 derlin 3  -6.53 
HIST2H3C histone cluster 2, H3c  -6.49 
CYP27B1 
cytochrome P450, family 27, subfamily B, 
polypeptide 1  -6.47 
PSG2 pregnancy specific beta-1-glycoprotein 2  -6.46 
PRKCH protein kinase C, eta  -6.40 
IDI2 isopentenyl-diphosphate delta isomerase 2  -6.38 
EGR2 early growth response 2 -6.37 
TAGLN3 transgelin 3 -6.30 
GEM 
GTP binding protein overexpressed in skeletal 
muscle  -6.28 
CREB5 cAMP responsive element binding protein 5  -6.27 
CSPG4 chondroitin sulfate proteoglycan 4  -6.22 
MT1G metallothionein 1G  -6.20 
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PLEKHA8P1 
pleckstrin homology domain containing, family A 
member 8 pseudogene 1  -6.16 
SIK1 salt-inducible kinase 1  -6.15 
SNHG1 
small nucleolar RNA host gene 1 (non-protein 
coding)  -6.11 
BACH2 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 2  -6.10 
MIR222 microRNA 222  -6.07 
MTFR2 mitochondrial fission regulator 2  -6.06 
RCC1 regulator of chromosome condensation 1  -6.02 
ZC3H12C zinc finger CCCH-type containing 12C  -6.02 
HSPA6 heat shock 70kDa protein 6 (HSP70B') -6.01 
SLC30A1 
solute carrier family 30 (zinc transporter), member 
1  -5.96 
RPL31P57 ribosomal protein L31 pseudogene 57  -5.92 
RP3-393E18.2 n/a -5.91 
FCGR1C 
Fc fragment of IgG, high affinity Ic, receptor (CD64), 
pseudogene  -5.91 
PLEK2 pleckstrin 2  -5.86 
CCDC15 coiled-coil domain containing 15  -5.84 
TNRC6C trinucleotide repeat containing 6C -5.82 
TNFAIP3 tumour necrosis factor, alpha-induced protein 3  -5.81 
MOGAT1 monoacylglycerol O-acyltransferase 1 -5.79 
ZC3H4 zinc finger CCCH-type containing 4  -5.78 
RNU6ATAC10P RNA, U6atac small nuclear 10, pseudogene -5.78 
LINC01270  long intergenic non-protein coding RNA 1270 -5.78 
KDM6B lysine (K)-specific demethylase 6B  -5.70 
HOMER1 homer homolog 1 (Drosophila) -5.70 
STX11 syntaxin 11  -5.68 
MAP7D2 MAP7 domain containing 2  -5.68 
FOSB FBJ murine osteosarcoma viral oncogene homolog B  -5.64 
SYPL2 synaptophysin-like 2  -5.63 
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Figure 3.7 Functional annotation of the genes regulated throughout the whole 
contraction process.  
Functional annotation analysis by DAVID showing the top 5 gene clusters upregulated (a) 
and 10 downregulated (b) throughout the in vitro contraction according to enrichment score. 
The most regulated genes (or the first 10 of them) of each cluster were listed below the 
score bar. 
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3.4 Gene expression profile changes induced by NSC23766 treatment  
Previous study showed that transient treatment with the Rac1 inhibitor NSC23766 
was sufficient to block long-term tissue contraction in vitro and ex vivo (Tovell et al., 
2012), suggesting that the inhibitor could block a major activation signal that is 
necessary for the fibroblasts to engage in the contraction process. Importantly, this 
activation signal appeared to be transient, suggesting that it could be linked to a 
short, temporary activation of signalling pathways downstream of small GTPases. 
Indeed, the above analysis of the gene expression changes during the early and 
late contraction phases confirmed the transient nature of the contraction activation 
signal. It was also clear from the PCA plot (Figure 3.2) and the hierarchical 
clustering heatmap (Figure 3.3) that the NSC23766 treated samples, and 
particularly Day3NSC, clustered close to the untreated samples at day 5 where the 
transient hyperactivation phase has receded. Looking at the individual gene profiles, 
there was a strong overlap between the genes upregulated during early contraction 
and the genes downregulated by NSC23766 treatment at day3, and the genes 
downregulated during early contraction and the genes upregulated by NSC23766 
treatment at Day3, respectively (Figure 3.8). The significantly up/downregulated 
genes were particularly affected (Table 3.1, Table 3.2), indicating that most of the 
early contraction signals were suppressed by NSC23766. 
  
To further characterise the gene modulation upon NSC23766 treatment, DAVID 
functional annotation analysis was performed on the first 500 genes 
up/downregulated in early contraction respectively and those that were reversely 
regulated by NSC23766 at day3. Notably, a major downregulation of gene function 
by NSC23766 was focused on the transcription activity, and the upregulation 
modulation was made on oxidation-reduction, coenzyme metabolism and ion 
binding (Figure 3.9).  
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Figure 3.8 Venn diagrams showing that majority of the early contraction gene 
signalling were suppressed by NSC23766 treatment.  
(a) 1894 out of 2849 upregulation genes in the early contraction were downregulated by 
NSC23766 treatment. (b) 1677 out of 2805 downregulation genes in the early contraction 
were upregulated by NSC23766 treatment.  
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Figure 3.9 Functional annotation analysis by DAVID showing the modulations of 
NSC23766 made on the early contraction gene signalling. 
 (a) The top 10 gene functional clusters of the first 500 upregulation genes in the early 
contraction that were suppressed by NSC23766 treatment at day3. (b) The top 10 gene 
functional clusters of the first 500 downregulation genes in early contraction that were 
upregulated by NSC23766 treatment at day3. The most regulated genes (or the first 10 of 
them) of each cluster were listed below the score bar. 
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3.5 Relevance to in vivo contraction profile 
The fibroblast-populated collagen lattices have been used widely as a classical 
model for tissue contraction in the context of ocular scarring, providing invaluable 
insights into disease mechanisms as well as a tool for identifying drugs with anti-
scarring potential (Ehrmann and Gey, 1956, Porter et al., 1998, Daniels et al., 2003, 
Kottler et al., 2005). However, there is little information on how well this in vitro 
assay recapitulates the in vivo scarring. To further assess the compatibility and 
reliability of the gene expression profile of our in vitro contraction model to a real 
wounding event, we compared it to the raw data obtained from a pilot microarray 
study in the classical model of conjunctival scarring in rabbits following glaucoma 
filtration surgery. Conjunctiva samples were taken from un-operated control eye and 
operated eye respectively on the same rabbit 5 days after the surgery (stage of 
active wound response), and RNA was extracted from the samples for the 
subsequent microarray. The array was performed with the Agilent two-colour 
microarray system using a custom designed rabbit chip (Agilent AMADID# 017130) 
with 7328 annotated genes. The data was analysed by the LIMMA package within 
Bioconductor (Ritchie et al., 2015), and a modest t-test was applied using a 
Bayesian approach (the in vivo microarray was performed by Dr. Daniel Paull, and 
the data analysis was performed by Dr. Jian-Liang Li). 
 
As a result, 479 genes were found upregulated in the operated samples comparing 
to the control ones, and 459 genes were downregulated (fold change >1.2 times, p 
value<0.05). DAVID functional annotation analysis was applied on these genes 
respectively and identified that gene clusters including cytoplasmic vesicle, protein 
folding and response to wounding were upregulated, whilst the ones related to 
oxidation reduction, vesicular fraction, ion binding and cofactor binding being 
downregulated (Figure 3.10). Notably, the functional clusters of ‘respond to 
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wounding’ and ‘cofactor binding’ were also observed in the in vitro early contraction 
up and downregulation profiles respectively.  
 
Also, the comparison between the in vivo and in vitro array profiles indicated that 
about one third of the genes altered during the in vivo wound healing were common 
to the ones observed in the in vitro profiles, with a slightly stronger similarity to the 
early contraction profile, matching the expected wound response (Figure 3.11). It 
suggested that the in vitro contraction model mimics well the wound healing 
response in vivo and possibly the very early stage of scarring. The main genes 
whose expression increased dramatically in the in vitro early contraction including 
IL1A, TNFAIP6, MMP1 and PMEPA1, as well as those that decreased significantly 
such as FMO2, LANCL1 and NLGN1 were also found up or downregulated 
respectively in the in vivo profile (Table 3.5,Table 3.6). Notably, 5 genes regulated 
consistently in the same way throughout the in vitro contraction were also presented 
in the in vivo profile, including MMP1 and MMP3 that were upregulated all the time; 
and A2M, IL1R1 and ACE, which were downregulated constantly in vitro and in vivo. 
 
297 upregulated and 298 downregulated genes were expressed exclusively in the in 
vivo profile (Figure 3.11), with an expression profile particularly matched to 
epithelium or inflammatory cells. For example, the epithelial markers KRT6A and 
GKN1, lymphoblast marker HBB, neuron-derived factor C4or31, dendritic cell 
marker LILRA4 and immune response regulators S100A8/9 were found upregulated 
(Table 3.7). The muscle proteins including MYL1, TNNI2, ACTA1 and LPL, neuron 
filament NEFL, leukocyte derived chemotaxin LECT1 and the cytochrome P450 
superfamily of monooxygenases were downregulated (Table 3.8).This expression 
profile was expected as the in vivo samples contained a mixture of cells and with 
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the presence of inflammation, and they possibly had contaminations of epithelium 
and muscle. In addition, the gene expression profile of the in vivo array and the 
profile of human fibroblasts in response to serum (Iyer et al., 1999) were also 
compared. However, only 4% genes from the in vivo array (23 upregulated genes 
and 18 downregulated genes, data not shown) matched the serum stimulation 
profile, suggesting that our 3D collagen contraction model was a better match to the 
in vivo wounding behaviour than the 2D serum stimulation model. 
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Figure 3.10 Characterisation of the functional gene clusters regulated during the in 
vivo wound healing study. 
(a) The top 10 functional gene clusters upregulated in the in vivo wound healing study 
analysed by DAVID functional annotation analysis according to the enrichment score. (b) 
The top 10 functional gene clusters downregulated in the in vivo wound healing study 
analysed by DAVID functional annotation analysis according to the enrichment score. The 
most regulated genes (or the first 10 of them) of each cluster were listed below the score 
bar. 
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Figure 3.11 Paired comparisons of the gene expression profiles of the in vivo and in 
vitro wounding models. 
(a) 102 and 82 out of 479 upregulation genes in the in vivo microarray were in common with 
the in vitro early and late contraction upregulation profiles respectively. The two genes 
upregulated both in vivo and throughout the in vitro contraction were MMP1 and MMP3. (b) 
127 and 37 out of 459 downregulation genes in the in vivo microarray were in common with 
the in vitro early and late contraction downregulation profiles respectively. The three genes 
downregulated both in vivo and throughout the in vitro contraction were A2M, IL1R1 and 
ACE. 
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Table 3.5 The gene symbol, definition and fold changes of the first 20 common 
upregulation genes in the in vitro early contraction and in vivo profiles (fold 
change>1.2, p<0.05). 
 
 
Table 3.6 The gene symbol, definition and fold changes of the first 20 common 
downregulation genes in the in vitro early contraction and in vivo profiles (fold 
change>1.2, p<0.05). 
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Table 3.7 The gene symbol, definition and fold change of the first 20 upregulated 
genes expressed exclusively in the in vivo wounding model (fold change>2, p<0.05).  
  
Table 3.8 The gene symbol, definition and fold change of the first 20 downregulated 
genes expressed exclusively in the in vivo wounding model (fold change>2, p<0.05). 
 
 106 
 
3.6 Relevance to ocular fibrotic disease profile 
To further characterise the relevance of our in vitro contraction gene expression 
profile to a real wounding/fibrotic event, the early and late contraction profiles were 
compared to the profiles of human ocular fibrotic diseases including trachoma 
(Kechagia et al., 2016) and thyroid-associated orbitopathy (TED) (Ezra et al., 2012), 
both of which are associated to fibroblast-mediated contractile scarring (Figure 
3.12). Trachoma is a conjunctiva scarring disease, whose scarring consequences 
are characterised by the presence of a highly fibrotic conjunctiva/tarsal plate with 
increased matrix deposition and a compact a-vascular stroma, mainly composed of 
fibroblasts and inflammatory cells (Abu el-Asrar et al., 1998). TED is caused by 
thyroid autoimmune disease, with manifestations including extraocular muscle 
inflammation and fibrosis, upper eyelid retraction and proptosis. Orbital fibroblasts 
are believed to play important roles in the TED, as they produce proinflammatory 
cytokines that activate genes regulating adipocyte proliferation (Naik et al., 2010, 
Kumar et al., 2004).  
 
As a result, over one third of the genes upregulated in trachoma were also found in 
the in vitro profile, including 18 genes upregulated in the early contraction, including 
the inflammatory-responsible genes IL6, TNFSF4, PTGER3 and OLR1, apoptosis 
related genes RASGRF2, GATA6 and HSPB8, and transcription regulators TSHZ2 
and DUXA. 23 trachoma signature genes were found upregulated in the late 
contraction, for example SEMA6A, DMD and UCHL1 (morphogenesis), KCND2, 
PLOD2, PLXDC2 and FLT1 (signal transduction), and MAP6 and APBB1IP 
(cytoskeleton) (Table 3.9). Meanwhile, more than half of the downregulated genes 
in trachoma were found downregulated in the in vitro model, such as glycoproteins 
CPM, NOG, KCNT2 and COLEC12 that were downregulated in early contraction, 
and signal peptides MYOC, WISP3 and SERPINA3, which were downregulated in 
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late contraction. Also, CLEC3B, which regulates fibrinolysis and related to calcium 
ion binding, was found to be suppressed both in trachoma and in vitro contraction 
(Table 3.10). 
 
Moreover, for the gene expression profile of the thyroid-associated orbitopathy 
(TED), over one third of the upregulated genes were captured in the in vitro profile, 
including SGK1, IL7R, JUN and SLC2A14 that were transiently activated in early 
contraction and receded in the late contraction; and SLC20A1, CLEC11A and 
ST8SIA4, which were upregulated exclusively in the late contraction (Table 3.11). 
Two thirds of the downregulated genes of the disease were also downregulated in 
vitro, which included 13 genes that decreased in the early contraction and six of 
which reactivated later at day5, such as CMBL, FOXL2 and FABP4; and genes that 
were only downregulated in the early contraction, such as ADH1B, IGSF10, ERAP2 
and ITGBL1. In addition, five downregulated genes of the TED were recorded in the 
late contraction, with three of which were suppressed consistently throughout the in 
vitro contraction, involving COL12A1, SFRP4 and DAAM1; and C14orf180 and 
IGFBP6 that were only downregulated from day3 to 5 (Table 3.12). The functional 
annotation clustering analysis of these common up/downregulated genes between 
the in vitro contraction and trachoma, and the ones of the in vitro contraction and 
TED suggested that the gene expression features of the inflammation and fibrotic 
progressions of the diseases’ are replicated in the in vitro contraction model (Figure 
3.13). 
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Figure 3.12 Venn diagrams showing the common genes expressed between the in 
vitro contraction and trachoma, and the in vitro contraction and the thyroid-
associated orbitopathy (TED).  
(a) 47 out of 128 upregulations and (b) 22 out of 46 downregulation genes in Trachoma were 
expressed in the in vitro contraction profile. (c) 8 out of 21 upregulations and (d) 15 out of 24 
downregulation genes in the thyroid-associated orbitopathy (TED) were captured in the in 
vitro profile.  
 
 
 
 
 
 109 
 
Table 3.9 The gene expression profiles of the common upregulated trachoma 
signature genes (genes that were identified to be expressed significantly in trachoma 
(Kechagia et al., 2016)) in the in vitro early (day0-3) and late (day3-5) contraction 
stages (fold change>1.2 times, p<0.05). ‘─’ represents no gene expression change 
detected. 
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Table 3.10 The gene expression profiles of the common downregulated trachoma 
signature genes (genes that were identified to be expressed significantly in trachoma 
(Kechagia et al., 2016)) in the in vitro early (day0-3) and late (day3-5) contraction 
stages (fold change>1.2 times, p<0.05). ‘─’ represents no gene expression change 
detected. One gene that was downregulated consistently in trachoma and in vitro is 
highlighted in pink. 
 
 
Table 3.11 The gene expression profiles of the common upregulated thyroid-
associated orbitopathy (TED) signature genes (genes that were identified to be 
expressed significantly in the TED (Ezra et al., 2012)) in the in vitro early (day0-3) and 
late (day3-5) contraction stages (fold change>1.2 times, p<0.05). ‘─’ represents no 
gene expression change detected.  
 
 
 111 
 
Table 3.12 The gene expression profiles of the common downregulated thyroid-
associated orbitopathy (TED) signature genes (genes that were identified to be 
expressed significantly in the TED (Ezra et al., 2012)) in the in vitro early (day0-3) and 
late (day3-5) contraction stages (fold change>1.2 times, p<0.05). ‘─’ represents no 
gene expression change detected. Genes that were downregulated consistently in the 
TED and in vitro contraction were highlighted in pink. 
 
 
 
Figure 3.13 Annotated gene functional clusters (analysed by DAVID) of the common 
up/downregulated genes between the in vitro contraction and trachoma (a), and the 
ones of the in vitro contraction and TED (b).  
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3.7 Validation of the in vitro contraction profile signatures    
To validate the signature gene profiles of the early and late contraction stages, a 
number of gene candidates were selected from the in vitro and in vivo microarray 
analysis, and in combination with the expression profiles of human ocular fibrotic 
diseases trachoma (Kechagia et al., 2016), thyroid-associated orbitopathy (TED) 
(Ezra et al., 2012) and floppy eye syndrome (FES) (Ezra et al., 2010). The early 
contraction signature candidates were selected because they were significantly 
upregulated in vitro from day0 to 3, and/or upregulated in vivo (Table 3.13). 
Similarly, the late contraction signature genes were chosen for validation as they 
were significantly upregulated from day3 to 5 in vitro; and/or upregulated in 
trachoma, thyroid-associated orbitopathy (TED) or floppy eyelid syndrome (FES) 
(Table 3.14), as we hypothesised that genes upregulated after the receding of the 
hyperactivation early phase would be involved in the acquisition of the fibrotic 
phenotype. The gene expression profiles were validated using qPCR with 
conjunctival fibroblast line HTF7071 (the original line used in the in vitro microarray 
study) and HTF9154 (another primary fibroblast line from a different donor) in the 
standard collagen contraction culture at day0, 3 and 5. All the early contraction 
candidate genes showed clear upregulation from day0 to 3 in both fibroblast cells, 
with MMP1, 3 and 10, and IL8 being the most upregulated genes (Figure 3.14). The 
expression levels of the gene candidates of the late contraction were also validated 
using qPCR with HTF7071 and HTF9154 at day0, 3 and 5 during contraction. In 
HTF9154 all the genes were upregulated from day0 to 3, and increased further from 
day3 to 5; whilst in HTF7071 the genes were upregulated from day0 to 3, and most 
of which kept around the similar expression levels from day3 to 5 (Figure 3.15), 
suggesting that the expression levels of these genes can vary between fibroblasts 
from different donors.  
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Table 3.13 Early contraction gene candidates selected for validation. 
 
 
Table 3.14 Late contraction gene candidates selected for validation. 
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Figure 3.14 Validation of the in vitro early contraction profile signatures by qPCR. 
qPCR validation of the early contraction candidates in two human conjunctival fibroblasts (a) 
HTF7071 and (b) HTF9154 (n≥2 experiments ± SEM). All the genes showed clear 
upregulation from day0 to 3 in both fibroblasts, with MMP1, 3 and 10, and IL8 being the most 
upregulated genes.  
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Figure 3.15 Validation of the in vitro late contraction profile signatures by qPCR. 
qPCR validation of late contraction candidates in two human conjunctival fibroblasts (a) 
HTF7071 and (b) HTF9154 (n≥2 experiments ± SEM). In HTF9154 all the genes were 
upregulated from day0 to 3, and increased further from day3 to 5; whilst in HTF7071 they 
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were upregulated from day0 to 3, and most of which kept around the similar expression 
levels from day3 to 5, suggesting that the expression levels of these genes can vary 
between fibroblasts from different donors.  
 
 
3.8 Discussion 
A comprehensive analysis was performed on the full gene expression profile of 
fibroblast-mediated contraction in vitro with the purpose of understanding the 
molecular mechanisms involved in fibroblast-mediated tissue contraction. The in 
vitro contraction was characterised by a dramatic, but transient, hyperactive early 
phase that initiated the entire contractile activity, and as the contraction slowed 
down at the later stage, the “activation” profile receded to a more “resting” 
phenotype. The dynamically regulated process reflected and matched the actual 
wound healing process in vivo, as after fibroblasts being activated in response to 
the injury and breach of the local tissue tension, the activation calms down and 
eventually terminates (Brown et al., 1998). In addition, the treatment with 
NSC23766 efficiently blocked the activation phase of contraction, and arrested the 
cells in the quiescent stage directly, suggesting that the signalling through Rac1 
activity is critical in the early stage of contraction, as supported by the previous 
study (Tovell et al., 2012).   
 
The genes that were significantly upregulated during the early contraction involved 
many inflammatory mediators. For example IL1RN and F2RL1, which positively 
modulate immune and inflammatory responses (Tamassia et al., 2010, Carvalho et 
al., 2010), CXCR4 that plays an essential role in vascularisation and endows potent 
chemotactic activity for lymphocytes (Rahimi et al., 2010, Pavlasova et al., 2016), 
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SERPINB2, a coagulation factor that contributes to the regulation of adaptive 
immunity (Kruithof et al., 1995, Medcalf and Stasinopoulos, 2005, Heit et al., 2013), 
IL8, a major inflammation regulator that attracts neutrophils, basophils and T-cells 
(Larsen et al., 1989, Baggiolini, 2015), and HBEGF that displays mitogenic and 
migratory effects to both fibroblasts and keratinocytes, as well as promoting 
angiogenesis (Shirakata et al., 2005). These stimuli are involved in intercellular 
signalling in vivo (Iyer et al., 1999), not only for the fibroblasts to interpret, amplify 
and broadcast signals that provoke inflammation, but also purposing to recruit other 
participant cells such as lymphocytes and macrophages. These cells enter the 
wounding site to provide both innate and antigen-specific defences against wound 
infection, and recruit the phagocytic cells to clear out the debris during the 
remodelling of the wound. The fact that the profile was captured in the in vitro profile 
demonstrated that our collagen contraction model is a good system to replicate at 
least partly some of the pathways of local inflammation in the wound healing 
response in vivo. Furthermore, the most downregulated gene clusters in the early 
contraction were the ones that related to sterol metabolic process and cofactor 
binding, which were activated again in the late contraction. The suppression of 
these pathways in the early contraction might be explained as a feedback response 
of fibroblasts to serum stimulation (that provided external lipid and cholesterol), 
which in turns brought down the endogenous cholesterol biosynthesis (Iyer et al., 
1999).  
 
The application of NSC23766 reversed the gene expression profile of early 
contraction as the activation of immune response, wound healing and transcription 
activity was suppressed, and the pathways controlling oxidation reduction, cofactor 
binding and lipid metabolism were promoted. The same pattern was observed in the 
late contraction, in which the cells were rested or appeared to have reduced 
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contraction status, suggesting that the upregulation of redox reaction, coenzyme 
activity and sterol metabolism signalling might be associated with reduction of 
contractile properties. Indeed, it has been reported that dermal fibroblasts 
expressing a strong upregulation of lipid and fatty acid metabolism signature genes 
exhibited a ‘normal-like’ non-fibrotic feature compared to the fibrotic ones in 
systemic sclerosis pathogenesis (Milano et al., 2008, Johnson et al., 2015), which 
hypothesised a potential anti-fibrotic function linked to these pathways. However, 
the detailed mechanisms are awaiting further investigation.   
 
A coordinated and multi-faced gene program that modulates tissue homeostasis, 
cell migration, inflammation and angiogenesis, is induced by fibroblast in response 
to serum stimulation (Iyer et al., 1999, Chang et al., 2004). In the in vitro early 
contraction profile, the serum-responsive genes captured matched the gene groups 
that were significantly upregulated between 4-8hrs after serum stimulation (Iyer et 
al., 1999), including those implicated in inflammation (IL8, PTGS2, ICAM1, IL6), 
coagulation and homeostasis (THBD, TFPI2, PLAUR), angiogenesis (VEGFA, 
FGF2) and tissue remodelling (PLOD2, CDH2), as well as the downregulated ones, 
such as those related to lipid synthesis (ACACA, FADS2, SQLE, PSAT1), cell 
adhesion (SVEP1, THBS2, FAT4), cell cycle arrest (CDKN1C, CDKN2C, 
ARHGAP20) and actin cytoskeleton binding (SPTBN1, DAAM1, EPB41L2), 
suggesting that the fibroblast-mediated contractile activity is at least partially 
induced by an early response to serum stimuli. In total about two thirds of the serum 
response genes were expressed during the in vitro contraction, demonstrating that 
our in vitro model well replicated the physiological response of fibroblasts to serum 
stimulation. However, as our study was using fibroblasts from a different tissue 
(conjunctiva vs. foreskin), harvesting at different time points (5-day period vs. 24hr 
period) and culturing in a different experimental environment (3D collagen gel vs. 
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2D tissue culture flask), our serum response profile was expected to be slightly 
different from the one of the previous study of fibroblast in response to serum (Iyer 
et al., 1999). Most importantly, majority of the genes expressed in our profile are not 
related to serum stimulation, which are possibly linked to contractile activity. 
 
Whilst the in vitro microarray has provided an in depth understanding of the gene 
modulation during fibroblast-mediated tissue contraction, numerous other cells 
contribute to the wound healing process in vivo, such as neutrophils, macrophages 
and lymphocytes (Clark, 1996, Martin, 1997). The in parallel pilot study of the in vivo 
wounding model in rabbit has given an insight into the inflammatory exponents of 
wound healing. Our collagen gel contraction assay can be used as an accelerated 
model of the wound healing program in vivo, which is a much longer process. In the 
rabbit eye undergoing glaucoma filtration surgery, the time point accessed in this 
study (5-day) represents an early stage of the tissue repair when the bleb is closed 
by filled granulation tissue and the contraction by migratory fibroblasts being 
observed (Geggel et al., 1984, Miller et al., 1989). Thus we expected the in vivo 
gene expression profiling to match closely the in vitro contraction profile. Indeed, we 
have shown that one third of the genes regulated in the in vivo contraction were 
altered in the same manner in the in vitro assay, and the ones that were not 
presented in the in vitro profile were likely related to other cellular participants (such 
as epithelial cells and inflammatory cells). Moreover, our in vitro array recapitulated 
many more of the genes regulated in vivo than the assay of the fibroblasts in 
response to serum stimulation (Iyer et al., 1999), indicating that the 3D collagen 
contraction model is a better match to the in vivo wound healing behaviour than the 
2D serum stimulation model. Notably, ACTA2, which encodes α-SMA that is a major 
constituent of the contractile apparatus and commonly used as a marker of 
myofibroblast formation (Sappino et al., 1990, Desmouliere, 1995), was upregulated 
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exclusively in the in vivo profile. The differentiation of the myofibroblast population at 
the wound site usually occurs in a later stage of the wound healing (Miller et al., 
1989, Midwood et al., 2004). The fact that ACTA2 was not found regulated in the in 
vitro contraction suggested that the in vitro assay, as expected, does not 
recapitulate all aspects of the contraction.  
 
Through the comparison of the gene expression profiles of trachoma and thyroid-
associated orbitopathy (TED), we have shown that some of the genes identified as 
associating to the fibrotic features were captured in our in vitro assay, with the 
expression profile slightly leaning towards late contraction. It suggested that the late 
contraction may represent the cells leading towards the progression of fibrosis. 
Moreover, more trachoma signature genes were expressed in the in vitro profile 
than that of TED, which is possibly because trachoma is a conjunctival fibrotic 
disease (Abu el-Asrar et al., 1998) that is much closer to our model, whilst the study 
of TED was using orbital fibroblasts rather than the conjunctival ones. Besides, the 
causes of the TED involve not only fibrosis but also adipogenesis (Naik et al., 2010). 
Nevertheless, the fact that there were still some common genes being identified 
between the TED and the in vitro contraction profile indicated that TED may be 
fundamentally associated with fibrosis, independent of the cause of the disease.  
 
Finally, the signature genes verified in the study of the in vitro contraction are not 
only limited to the ocular fibrotic diseases, but also applied to a wide variety of 
fibrotic associated pathogenesis from different locations (Table 3.15). It is 
recognised that these candidates represent only a part of the gene signatures of the 
in vitro contraction, and more studies are needed to understand the gene 
interactions and signalling pathways underlying fibroblast-driven matrix contraction 
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and tissue repair. Moreover, the downregulated gene signatures of the contraction 
will need to be characterised in the future work. Nevertheless, the comprehensive 
analysis presented has provided a ‘molecular portrait’ of the fibroblast-mediated 
contraction in vitro, which will be a powerful tool assisting future anti-scaring and 
fibrosis research in a wide range of fibrotic related diseases. 
 
 
Table 3.15 Examples of the implications of the in vitro contraction signature genes in 
various fibrotic diseases and cancers. The early contraction signature genes are 
coloured in blue, and the late contraction signature genes are coloured in pink. MMP1 
and MMP3 are highlighted in yellow as they were upregulated throughout the whole 
contraction process. 
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Chapter 4 The involvement of the Rho GTPases in contraction 
 
 
4.1 The variable response of fibroblasts to NSC23766 treatment 
In the previous chapter, we have discussed how Rac1 appeared to be a major 
regulator in fibroblast-mediated tissue contraction, as a transient 24hrs 
downregulation of Rac1 by its inhibitor NSC23766 altered gene expression and 
prevented the initiation of the contraction. The original results were obtained with 
one conjunctival fibroblast line (HTF7071) from one donor. During the validation of 
the in vitro microarray candidates by qPCR, we used an additional line from a 
different donor (HTF9154), which showed a different response to the treatment with 
NSC23766. Thus, in the current chapter, the effects of NSC23766 and other 
commercially available Rac inhibitors on the contractile activity of a few primary 
conjunctival fibroblasts that originated from different donors were characterised. We 
also investigated the modulations of contraction by other Rho GTPases and MAPK 
signalling. The results would provide useful information in assisting the future study 
of Rac-mediated cellular functions in the in vivo models of ocular scarring, and also 
for the development of anti-scarring therapeutics in the clinics.  
 
The primary human conjunctival fibroblast cells used in this study and their donor 
information were recorded in Chapter 2 (2.1.1). The differential responses of 
fibroblasts to NSC23766 treatment were firstly evaluated in the collagen contraction 
experiment using HTF7071, HTF9154, HTF2489 and HTF2493 treated with 50µM 
NSC23766 for the first 24hrs (Figure 4.1). The results showed that at day2, 
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NSC23766 treatment led to a 50% reduction of contraction in HTF7071, HTF2489 
and HTF2493, and about 30% reduction of contraction in HTF9154 comparing to 
the untreated contraction. At day7, NSC23766 treatment suppressed 30% 
contraction in HTF7071, and about 10% contraction in HTF9154, HTF2489 and 
HTF2493 comparing to the untreated contraction, suggesting a variable response of 
fibroblasts to the treatment of NSC23766. In particular, HTF9154 was not sensitive 
to the NSC23766 treatment, suggesting that it might utilise other signalling 
pathways rather than Rac1 to sustain contraction.   
 
 
4.2 The Characterisation of other Rac inhibitors 
NSC23766 was initially identified as a small molecule that binds to a putative 
binding pocket in the surface groove of Rac1. It interacts with the Rac-specific GEFs 
Trio and Tiam1 without affecting the closely related Cdc42 or RhoA binding or 
activation by their respective GEFs (Gao et al., 2004). Although NSC23766 was 
widely used in in vitro studies as a moderately active Rac inhibitor, its relatively high 
IC50 of 50-100μM in fibroblasts restricts its potential of being used as a therapeutic 
agent in the clinic. Therefore, for the purpose of evaluating alternative Rac 
inhibitors, especially with the focus on their short transient inhibitory ability that will 
benefit the potential future clinical application, four commercially available 
compounds were selected. They included W56, which selectively inhibits Rac1 
interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1 (Gao et al., 2001), 
Z62954982, a cell-permeable isoxazolyl-benzamide compound that interferes Rac1-
Tiam1 interaction, while exhibiting no effect toward cellular Cdc42 and RhoA 
activation or Rac1 interaction to its effector Pak1 (Ferri et al., 2009), EHT1864, an 
inhibitor of Rac family GTPases by direct binding to Rac1, Rac1b, Rac2 and Rac3 
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(Shutes et al., 2007), and Ehop-016, which was synthesized based on the structure 
of NSC23766 but with an IC50 of 1.1µM that is 100 times lower than NSC23766 
(Montalvo-Ortiz et al., 2012). Also, Simvastatin, a clinical proved cholesterol-
lowering drug that is widely used in the prevention and treatment of atherosclerotic 
cardiovascular disease, was selected for its ability of blocking Rac1-mediated 
signalling events by depletion of the lipid attachments that are required by the Rho 
GTPases (Negre-Aminou et al., 2001, Miller et al., 2011). The Rho-associated 
protein kinase (ROCK) inhibitor H1152 and the broad MMP inhibitor GM6001 were 
applied for their known effect of preventing fibroblast-mediated matrix contraction 
(Martin-Martin et al., 2011), and NSC23766 was used as a base line control. The 
inhibitors were added to the collagen contraction medium of fibroblast HTF9154, 
which did not respond well to 50µM 24hrs NSC23766 treatment. The concentrations 
of the inhibitors applied were set to be 10µM for 7 days and 50µM for 24hrs 
respectively (except GM6001 that was used at a concentration of 100µM (Martin-
Martin et al., 2011)), as in comparison with the standard 50µM 24hrs dosage of 
NSC23766 (Figure 4.2). As a result, 10 and 20µM of 7-day application of W56, and 
10, 25µM 7-day and 50µM 24hrs applications of Z62954982 barely affected the 
contraction, whilst 50µM of Simvastatin and EHT1864 notably inhibited 1/3 of the 
contraction respectively with a transient 24hrs application. Significantly, the 7-day 
10µM or  50µM 24hrs application of Ehop-016 completely suppressed the whole 
contraction activity for 7 days, making it the most efficient Rac inhibitor among all. 
Furthermore, as expected, the ROCK inhibitor and broad MMP inhibitor both had 
good inhibitory effect on the contractile activity of HTF9154 with a consistent 7-day 
application of 10µM and 100µM concentrations respectively.  
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Figure 4.1 The variable responses of fibroblasts to NSC23766 treatment. 
Collagen contraction kinetics of four primary conjunctival fibroblasts HTF7071 (a), HTF9154 
(b), HTF2489 (c) and HTF2493 (d) treated with NSC23766 for the first 24hrs ((a), (b): mean 
± SEM, n=3 experiments with triplicate wells; (c), (d): mean ± SEM, n=2 experiment with 
triplicate wells). The primary fibroblast line of HTF7071 was going to an end at the time of 
performing the experiment, thus its contraction curve was lower than the others.  
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Figure 4.2 Characterisation of the inhibitory efficiency of a range of Rac inhibitors 
including NSC23766, W56, Z62954982, EHT1864 and Ehop-016, as well as the broad 
MMP inhibitor GM6001 and the Rho-associated protein kinase (ROCK) inhibitor H1152 
(labelled as ‘ROCK’) on fibroblast-mediated collagen gel contraction.  
7-day contraction kinetics of HTF9154 treated with a range of Rac inhibitors including (a) 
NSC23766 10µM and 50µM, for 7 days and 24hrs respectively; (b) W56 10µM and 20µM, 
for 7 days; (c) Z62954982 10µM and 25µM for 7 days, and 50µM for 24hrs; (d) Simvastatin 
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50µM, for 7 days and 24hrs; (e) EHT1864 10µM and 50µM, for 7 days and 24hrs 
respectively; and (f) Ehop-016 10µM and 50µM, for 7 days and 24hrs respectively. The 
broad MMP inhibitor GM6001 (g) and the Rho-associated protein kinase (ROCK) inhibitor 
H1152 (h) were also applied for 100µM and 10µM respectively, both for 7 days (Mean ± 
SEM, n=3 experiments with triplicate wells). DMSO was used as solvent control in the W56 
and Simvastatin treated groups, and its concentrations used was kept the same with W56 or 
Simvastatin respectively. 
 
 
Moreover, Simvastatin, EHT1864 and Ehop-016 were further tested in the collagen 
contraction assay with seven primary fibroblast cell lines originated from different 
donors, with unrelated age and sex spectrum respectively. We used 50µM 24hrs 
treatment for Simvastatin and EHT1864, and 10µM 24hrs treatment for Ehop-016, 
as 10µM of Ehop-016 already showed a great efficiency in inhibiting contraction 
(Figure 4.2). The ROCK inhibitor, GM6001 and NSC23766 were also used as 
reference (Figure 4.3). The results showed that 24hrs treatment of 50µM 
Simvastatin reduced 20-30% contraction of most of the fibroblasts, with HTF7071 
being the most sensitive one to the drug, and HTF1818 and HTF0748-1 being the 
most insensitive ones. HTF7071 and HTF1785R were sensitive to the NSC23766 
treatment, which managed to reduce 40% of the contraction on HTF0104 and 
HTF2320 but only for the first three days, suggesting that a reapplication of the 
inhibitor for these cells may be necessary. Furthermore, treatment with 50µM of 
EHT1864 resulted in a good suppression of contraction of all the fibroblasts for the 
first two to three days, which indicated that a reapplication of the drug at day3 would 
be desirable as the efficiency gradually drew back afterwards. By contrast, 24hrs 
treatment of 10µM Ehop-016 significantly blocked the contractile activity of most of 
the fibroblasts tested, especially for the ones that were not responsive to 
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NSC23766, such as HTF9154 and HTF1818. HTF0748-1 only responded well to the 
ROCK inhibitor, suggesting that it may use a different mechanism for contraction.  
 
To determine whether the inhibitory effect of the inhibitors was due to their effect on 
contraction or toxicity, the cell viability upon the treatment was evaluated using 
AlamarBlue reagent in the culture medium of four contracting fibroblasts including 
HTF7071, HTF9154, HTF1785R and HTF0041 at day2 and day7 respectively 
(Figure 4.4). The results showed that the inhibitors had variable effects on different 
fibroblasts. Broadly, Simvastatin, NSC23766, the ROCK inhibitor H1152 and 
GM6001 did not result in much reduction on cell viability of all the cells, whereas 
EHT1864 and Ehop-016 appeared to be more toxic. They caused a 20% drop of the 
cell viability at day2 and a 30% drop at day7 on HTF9154, HTF1785R and 
HTF0041, and a 50% decrease of the cell viability on HTF7071 at both day2 and 
day7, suggesting that HTF7071 was extremely sensitive to the treatment, and also 
the inhibitory effect of EHT1864 and Ehop-016 on contraction may partly due to 
their toxicity to the cells.  
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Figure 4.3 Characterisation of the inhibition efficiency of the Rac inhibitors 
Simvastatin, NSC23766, EHT1864 and Ehop-016, as well as the broad MMP inhibitor 
GM6001 and the Rho-associated protein kinase (ROCK) inhibitor H1152 (labelled as 
‘ROCK’) on collagen contraction with eight different conjunctival fibroblasts. 
Collagen contraction assay of fibroblasts HTF7071 (a), HTF9154 (b), HTF1785R (c), 
HTF0041 (d), HTF1818 (e), HTF0748-1 (f), HTF0104 (g) and HTF2320 (h) were treated with 
inhibitors including Simvastatin 50µM, NSC23766 50µM, EHT1864 50µM and Ehop-016 
10µM respectively for 24hrs, or ROCK inhibitor H1152 10µM for 7 days, or the broad MMP 
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inhibitor GM6001 100µM for 7 days (Mean ± SEM, (a)-(b), n=3 experiments with triplicate 
wells, (c)-(h), n=2 experiments with triplicate wells).  
 
 
 
Figure 4.4 Cell viability assay performed on the inhibitors treated contracting 
fibroblasts at day2 and day7. 
Cell viability assay was performed by adding alamarBlue dye in the day2 and day7 
contraction medium of fibroblasts HTF7071 (a), HTF9154 (b), HTF1785R (c) and HTF0041 
(d) treated with inhibitors including Simvastatin 50µM, NSC23766 50µM, EHT1864 50µM, 
Ehop-016 10µM respectively for 24hrs, or the ROCK inhibitor H1152 10µM and the broad 
MMP inhibitor GM6001 100µM respectively for 7 days (mean ± SEM, n=2 experiments with 
triplicate wells). The fluorescence read was normalised to the read of day2 control sample. 
The inhibitors caused variable effects on the cell viability of these fibroblasts. EHT1864 and 
Ehop-016 appeared to reduce more viability than other inhibitors, especially at day7.   
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4.3 The role of Rho GTPases Rac1, Cdc42 and RhoA in contraction  
In the previous study, the involvement of Rac1 in serum-stimulated matrix 
contraction by human conjunctival fibroblast was investigated by siRNA knockdown 
and treatment with NSC23766, both of which significantly reduced the contraction 
by 70% in HTF7071 (Tovell et al., 2012). However, we have found that fibroblasts 
from different donors responded variably to the NSC23766 treatment, suggesting 
that the cells may apply other mechanisms to regulate contractile activity. We 
explored the contribution of Rac1, Cdc42 and RhoA in contraction by depleting the 
individual gene by siRNA technology, and seeding these knockdown cells into 
collagen contraction assay for three days. To verify the specificity of NSC23766 to 
Rac1, and also the modulation of Rac1 on contraction in the absence of Cdc42 or 
RhoA, we applied the 50µM NSC23766 treatment in the contraction medium for the 
first 24hrs (Figure 4.5). The experiment was performed with conjunctival fibroblasts 
HTF1785R, which were sensitive to the NSC23766 treatment, and exhibited a 
moderate sensitivity to other Rac inhibitors. The knockdown of Rac1, Cdc42 or 
RhoA in the cells was validated by Western blot, which proved a good depletion of 
the target proteins (Figure 4.5d). Surprisingly, depletion majority of the Rac1 protein 
by siRNA barely reduced the contraction, whilst the treatment of NSC23766 
decreased 30% of the contraction in both control and Rac1 knockdown cells, 
suggesting that the cells may use other signalling pathways to regulate contraction 
in the absence of Rac1, and NSC23766 may have other targets that played a role in 
contraction. Meanwhile, knocking down of Cdc42 or RhoA resulted in a significant 
30% or 25% of reduction of contraction respectively, indicating that Cdc42 and 
RhoA both played a regulatory role in contraction. However, treatment with 
NSC23766 further decreased the contractile activity of the Cdc42 or RhoA 
knockdown cells, suggesting that Cdc42 and RhoA partially regulated contraction, 
and they were not targeted by NSC23766.  
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Figure 4.5 Small Rho GTPases Rac1, Cdc42 and RhoA differently regulated the 
contractile activity of human conjunctival fibroblast HTF1785R.  
Fibroblast HTF1785R cells were treated with siRNA for Rac1, Cdc42 and RhoA respectively 
and then seeded into collagen contraction assay with transient treatment with NSC23766 for 
the first 24hrs. The 3-day contraction curve was plotted for Rac1 (a), Cdc42 (b) and RhoA 
(c) knockdown cells respectively (NT: non-targeting siRNA control. Mean ± SEM, n=3 
experiments with triplicate wells). (d) The validation of the Rac1, Cdc42 or RhoA siRNA-
knockdown cells by Western blot showed a good depletion of the target protein. The figure is 
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a representative of reproducible results (n≥3 experiments for each knockdown). (e) 
Averaged day3 contraction normalised to control contraction (Mean ± SEM, n=3 experiments 
with triplicate wells, t test between siRNA treated samples and control contraction, 
****p<0.0001, *p<0.05; t test between NSC23766 treated and non-treated samples within the 
same group, ****p<0.0001, **p<0.01, *p<0.05). 
 
 
4.4 Role of ERK, P38 MAPK and PI3K signalling in contraction 
After identifying that small Rho GTPases (mainly Cdc42 and RhoA) play a 
regulatory role in fibroblast-mediated contraction, we further explored the regulation 
of other signalling pathways in contraction, specifically the MAPK signalling 
including ERK and P38 MAPK, and the PI3K signalling pathway, and their links to 
GTPase activation. Rac1, Cdc42 or RhoA knockdown HTF1785R cells were seeded 
into 3-day collagen contraction assay and treated with the ERK inhibitor U0126 
10µM, P38 MAPK inhibitor SB203580 10µM and PI3K inhibitor Ly294002 25µM, 
respectively. The percentage of contraction was monitored daily, and the kinetics 
are shown in (Figure 4.6). The results demonstrated that the PI3K signalling played 
an important role in contraction, as treatment with Ly294002 depleted at least 40% 
of contraction in all the cells. Blocking of the P38 MAPK by SB203580 barely 
affected contraction, however upon inactivation of Cdc42, it significantly reduced 20-
30% of contraction, suggesting that the P38 MAPK signalling was downstream of 
Cdc42 and its participation in contraction was Cdc42 dependent. Notably, 
application of U0126 increased contraction in all the cells, indicating that the ERK 
signalling played an inhibitory role in contraction. The fact that inhibition of ERK 
counteracted the effect brought by inactivation of Cdc42 suggested that the 
modulation of contraction by Cdc42 was likely mediated through the suppression of 
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the ERK signalling. The prospective roles of these participators in contraction are 
modelled in Figure 4.7.  
 
 
4.5 Role of Rac2, Racgap1, Arhgap5 and Arhgef3 in contraction 
During the analysis of the in vitro microarray, we found that many regulators of the 
Rho GTPases were expressed differently in different stages of contraction, including 
the GTPase-activating proteins (GAPs) and Guanine nucleotide exchange factors 
(GEFs). Other members of the Rac superfamily, for example Rac2, was also found 
being regulated. We hypothesised that these genes may perform differential 
regulatory functions in different stages of the contraction via GTPase activity (Rac 
members), and activation (GEFs) or inactivation (GAPs) of the Rho GTPases that 
involved in the contraction modulation (such as Cdc42 and RhoA). Therefore, we 
selected four candidates for exploration, which included Rho GTPase Rac2 (Ras-
related C3 botulinum toxin substrate 2), Arhgap5 (Rho GTPase Activating Protein 5) 
whose GAP activity is preferentially towards RhoA (Matheson et al., 2006), 
Racgap1 (Rac GTPase Activating Protein 1) that strongly interacts with Cdc42 and 
Rac1 (Bastos et al., 2012) and Arhgef3 (Rho Guanine Nucleotide Exchange Factor 
3) that selectively activates RhoA and RhoB (Arthur et al., 2002). Both Rac2 and 
Arhgap5 were upregulated in the early contraction from day0 to 3, and then 
downregulated in the late contraction from day3 to 5, whilst Racgap1 and Arhgef3 
were downregulated from day0 to 3, and upregulated oppositely from day3 to 5 
(Table 4.1). Notably, the expression patterns of all four genes’ were completely 
reversed by the NSC23766 treatment at day3, suggesting that Rac2 and Arhgap5 
might be functional in promoting contraction, whereas Racgap1 and Arhgef3 played 
a negatively part. Herein, to verify the roles of these genes in contraction, we 
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inactivated the individual gene in HTF1785R using siRNA technology (Figure 4.8), 
and seeded the knockdown cells in 3-day collagen contraction assay with/without 
the treatment of NSC23766 (Figure 4.9). As a result, knocking down of Rac2 
significantly blocked contraction, indicating that its activity performed a vital function 
in mediating contraction. Depletion of Racgap1 increased contractile activity, 
suggesting that it suppressed the contraction possibly via inactivation of Cdc42 and 
Rac1. Blocking of Arhgap5 significantly inhibited contraction, which matched its 
expression profile in the in vitro microarray. We supposed that Arhgap5 might be 
required for contraction through other signalling pathways, as its modulation on 
contraction cannot be explained by its GAP activity towards RhoA. Inhibition of 
Arhgef3 completely inhibited contraction. We did not find Arhgef3 knockdown to be 
lethal to the cells, thus speculated that similar to Arhgap5, Arhgef3 was possibly 
involved in other signalling event whose activity was needed for the activation of 
contraction. Moreover, no statistical difference was found between the NSC23766 
treated and untreated Rac2 knockdown cells, which suggested that these cells 
mainly utilised Rac2 to mediate contraction. Also, it was possible that the sensitivity 
of the fibroblasts in response to NSC23766 treatment was a reflection of the ratio of 
Rac1/Rac2 within them. The fact that suppression of Racgap1 counteracted the 
effect of NSC23766 treatment, suggesting that Racgap1 negatively regulated the 
contraction mainly through inactivation of Cdc42.   
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Figure 4.6 The ERK, P38 MAPK and PI3K signalling differently regulated the 
contractile activity of human conjunctival fibroblast HTF1785R. 
(a)-(e) 3-day contraction kinetics of Rac1, Cdc42 or RhoA-knockdown HTF1785R cells 
treated with the ERK inhibitor U0126 10µM, P38 MAPK inhibitor SB203580 10µM and PI3K 
inhibitor Ly294002 25µM, respectively (NT: non-targeting siRNA control. Mean ± SEM, n=3 
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experiments with triplicate wells). (f) Averaged day3 contraction normalised to the control 
contraction (Mean ± SEM, n=3 experiments with triplicate wells, t test between the same 
inhibitor treated samples in the siRNA knockdown group and control group, ***p<0.001, 
**p<0.01, *p<0.05; t test between non-treated and inhibitor-treated samples within the same 
group, ••p<0.01, •p<0.05). 
 
 
 
Figure 4.7 Illustrative diagram showing the potential regulatory roles of Rac1, Cdc42 
and RhoA, and ERK, PI3K and P38 signalling in contraction.  
The prospective roles of Rac1, Cdc42 and RhoA, and ERK, P38 MAPK and PI3K signalling 
in contraction were showed in the illustration. The size of the protein icon represents the 
importance of the protein to contraction. Upon serum stimulation, Cdc42, RhoA and PI3K 
signalling are activated to promote contraction, whilst the contribution of active Rac1 to 
contraction is small. The activation of ERK plays an inhibitory role, which is suppressed by 
Cdc42 activity. The P38 MAPK signalling positively regulates contraction downstream of 
Cdc42.  
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Table 4.1 Gene expression fold changes of Rac2, Racgap1, Arhgap5 and Arhgef3 in 
the in vitro microarray of fibroblast-mediated contraction at day0-3, day3-5 and 
NSC23766 treated samples at day3 (p<0.05).  
 
 
 
 
Figure 4.8 Validation of the siRNA knockdown of Rac2, Racgap1, Arhgap5 and 
Arhgef3 respectively in HTF1785R using Western blot.  
Western blot results confirmed that the protein expression of (a) Rac2, (b) Racgap1, (c) 
Arhgap5 and (d) Arhgef3 respectively was successfully depleted following the siRNA 
treatment in human conjunctival fibroblast HTF1785R (NT: non-targeting siRNA control. 
Figure represented reproducible results n≥3).   
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Figure 4.9 Collagen gel contraction kinetics of the Rac2, Racgap1, Arhgap5 and 
Arhgef3 knockdown HTF1785R cells respectively treated with/without NSC23766.  
3-day collagen contraction curves of fibroblast HTF1785R treated with siRNA for Rac2 (a), 
Racgap1 (b), Arhgap5 (c) and Arhgef3 (d) respectively, with/without treatment with 
NSC23766 for the first 24hrs (NT: non-targeting siRNA control. Mean ± SEM, n=3 
experiments with triplicate wells). (e) Averaged day3 contraction normalised to the control 
contraction (Mean ± SEM, n=3 experiments with triplicate wells, t test between siRNA 
treated samples and control contraction, ****p<0.0001, ***p<0.001; t test between 
NSC23766 treated and non-treated samples within the same group, ****p<0.0001, *p<0.05).  
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4.6 Discussion  
We have demonstrated that a transient application of Rac1 inhibitor NSC23766 on 
human conjunctival fibroblast cells HTF7071 altered gene expression, which 
prevented the cells from entering the contractile phenotype as a whole, suggesting 
that inhibition of Rac1 activity could be a promising approach in the treatment of 
conjunctival scaring after glaucoma surgery. However, by enlarging the sample size 
for validation in this study, it was shown that approximately half of the fibroblasts 
from different donors did not respond to the NSC23766 treatment, suggesting that 
these cells utilised additional signalling pathways to mediate contraction. Also, the 
sensitivity of the fibroblasts to the NSC23766 treatment were not related to the sex 
or age of the donors. 
 
We have evaluated the efficiency of a range of Rac inhibitors in contraction, and 
found that treatment with Z62954982 or W56 barely suppressed contraction. By 
contrast, transient treatment with 50µM Simvastatin had a moderate inhibitory effect 
that decreased 30% of the contraction at day7 of most of the fibroblasts, whilst a 
consistent exposure to the drug at the same concentration showed better results, 
suggesting a persistent administration was required. The advantage of using 
Simvastatin is that it has already been proved to use clinically for treating 
atherosclerosis. Also, its pleiotropic effects including regulating actin cytoskeleton 
dynamics via Rac or RhoA/ Rac1 pathways (Kang et al., 2016, Serra et al., 2015, 
Baba et al., 2008, Caceres et al., 2011), which make it potentially to be beneficial in 
a wide range of therapeutic settings.  
 
Transient treatment with 50µM of EHT1864 exhibited a good inhibitory effect on gel 
contraction, especially within the first 3 days, suggesting that a reapplication of the 
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drug at day3 will be desirable. However, a study has reported that the application of 
EHT1864 and NSC23766 at 100µM respectively affected directly the activation of 
the Rac1 effectors PAK1 (p21-activated kinase 1) and PAK2 (p21-activated kinase 
2) (Dutting et al., 2015), which raised questions about the off-target effects at such 
concentration.  
 
Significantly, Ehop-016, with an application of 10µM for 24hrs, completely blocked 
the contractile activity, which makes it the most efficient drug among all. It has been 
demonstrated to block Rac activity in MDA-MB-231 cells, as well as inhibiting 
mammary tumour growth and metastasis in a nude mice model (Dharmawardhane 
et al., 2013, Castillo-Pichardo et al., 2014), and recently been patented for Rac1 
inhibition in treating metastatic breast cancer cells 
(https://www.google.com/patents/US8884006), showing that it could be a promising 
agent in the prevention of contractile scarring. Ehop-016 was reported to have no 
effect on the cell viability of mammary epithelial cells (MCF-10A) and reduced only 
20% of cell viability of MDA-MB-435 cells at concentrations of < 5 µM (Montalvo-
Ortiz et al., 2012). We used a higher concentration (10 µM) in our assay and 
observed about 40% reduction of cell viability at day7, suggesting that a transient 
10µM treatment of Ehop-016 was tolerable to our cells, though the effect of the drug 
on gel contraction might be partly due to toxicity.  
 
One surprising finding of the study was that depletion majority of the Rac1 protein in 
the cells by siRNA knockdown did not suppress fibroblast-mediated contraction. It 
explained the reason by which Rac1 specific inhibitors (Z62954982 and W56) had 
no effect in reducing contraction, whilst the effective ones may have achieved the 
target by inhibiting other regulators of contraction. For example, Simvastatin impairs 
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the RhoA/Rho-kinase signalling pathway (Serra et al., 2015, Laufs et al., 2002), 
EHT1864 blocks the closely related Rac1b, Rac2 and Rac3 isoforms and the Rac-
dependent transformation caused by Tiam1 or Ras (Shutes et al., 2007), and Ehop-
016 inhibits Cdc42 at concentrations above 10µM (Dharmawardhane et al., 2013), 
whilst Rac2, Cdc42 and ROCK signalling were all  showed to play important 
regulatory roles during contraction in the study. Rac1 inhibition has been shown to 
reverse the phenotype of fibrotic fibroblasts cultured from lesional areas of 
scleroderma (Xu et al., 2009), and delayed cutaneous wound closure in vivo with 
reduced collagen production and myofibroblast formation (Liu et al., 2009). Its 
inefficacy in our model might be explained as the fibroblasts we used are from 
normal conjunctival tissue rather than fibrotic origins, or it is due to a tissue specific 
effect of conjunctiva. Moreover, our results suggested that NSC23766 is not Rac1 
specific. It may suppress contraction via inhibition of other effectors, such as Rac2 
or even RhoA, as NSC23766 was found to be a competitive antagonist at 
muscarinic acetylcholine receptors (mAChRs), which concomitantly suppressed the 
carbachol-induced RhoA activation (Levay et al., 2013).  
 
We found that Cdc42 and RhoA were both involved in regulating fibroblast-mediated 
contraction, especially Cdc42, which activated the contraction possibly through 
suppression of ERK signalling. The regulatory role of Cdc42 in ERK pathway was 
also reported by recent studies in human keratinocytes and pulmonary endothelial 
cells (Rohani et al., 2014, Lv et al., 2017). Interestingly, we showed that activation of 
ERK signalling negatively regulated contraction, which was different from that 
observed in other models, such as scleroderma fibroblasts, proximal epithelial cells 
and osteoblast-like MG-63 cells, in which ERK pathway contributed to the 
overexpression of fibrotic proteins and enhanced contractile activity (Chen et al., 
2008, Saenz-Morales et al., 2009, Parreno and Hart, 2009), suggesting that ERK 
 143 
 
signalling performs differential functions in contraction in different cells. 
Furthermore, some studies pointed out that Cdc42 deficiency decreased collagen 
gel contraction of primary mouse embryonic fibroblasts, which associated with 
altered cell-matrix interaction and reduced focal adhesion complex formation. This 
was linked to the interaction between Cdc42 and p21-activated kinase (PAK) that 
was known to affect contraction (Sipes et al., 2011, Rhee and Grinnell, 2006), 
suggesting that Cdc42 have more downstream effectors to regulate contraction 
apart from ERK. By contrast, the participation of RhoA in contraction was observed 
to be consistent in different models. For example, it was reported to mediate 
lysophosphatidic acid (LPA) induced retraction of fibroblast dendritic network 
(Grinnell et al., 2003), and was shown to regulate airway smooth muscle contraction 
through modulating actin polymerisation, via catalysing the assembly and activation 
of membrane adhesome signalling modules, such as paxillin, vinculin and focal 
adhesion kinase (FAK) (Zhang et al., 2015, Zhang et al., 2010). 
   
Meanwhile, the intervention of the p38 MAPK signalling only subtly reduced 
contraction. However, treatment with SB203580 in the Cdc42 knockdown cells 
significantly reduced contraction comparing to the untreated control, suggesting that 
the activation of the pathway positively contributed to contraction in a Cdc42-
dependent way. The P38 signalling was also reported to play a modest regulatory 
role in contraction in osteoblasts-like cells (Parreno and Hart, 2009). Furthermore, 
we found that the PI3K signalling was vitally involved in the activation of contraction. 
Consistently, PI3K was shown to mediate human recombinant basic fibroblast 
growth factor (bFGF)-stimulated matrix contraction of dermal fibroblasts, and 
platelet-derived growth factor (PDGF)-mediated contraction of retinal pigment 
epithelial (RPE) cells (Abe et al., 2007, Bando et al., 2006). Although its 
downstream mechanisms are awaiting further investigation, the intervention of the 
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PI3K signalling pathway could be of therapeutic benefit in preventing fibroblast-
mediated contraction.  
 
Lastly, our study characterised that Rac2 may be a master regulator of conjunctival 
fibroblast-mediated contraction, which has not been mentioned by any other study 
before. The activity of Rac2 was linked to integrin-directed migration in 
macrophages, although in fibroblasts this signalling was thought to be compensated 
by Rac1 (Pradip et al., 2003). Rac2 was required for the postnatal neovascular 
response and αvβ3/ α4β1/α5β1 integrin-dependent migration in endothelial cells (De 
et al., 2009), however its function in the three-dimensional cultured cells has not yet 
been studied. Our results demonstrated that conjunctival fibroblasts utilised Rac2 to 
mediate contraction, and we proposed that Rac2 can be a promising target in the 
prevention of conjunctival scarring. We also for the first time explored the regulatory 
roles of a few regulators of Rho GTPases’ in contraction. Racgap1 that is functional 
critically in driving cytokinesis and cell proliferation (Warga et al., 2016, Sahin et al., 
2016, Neubauer et al., 2016), was found to negatively regulate contraction possibly 
via inactivation of Cdc42. Arhgap5, which regulates fibroblast focal adhesion, 
cytoskeletal organisation and migration, and maintains the tensional homeostasis 
and functional composition of the mesenchymal microenvironment through 
inactivating of RhoA (Barker et al., 2004, Ponik et al., 2013, Raman et al., 2013), 
and Arhgef3 that activates RhoA and RhoB (Arthur et al., 2002), may be both 
required by independent signalling pathways that were compulsory for contraction 
activation. Arhgap5 is regulated by β3 integrin/EGFR pathway (Balanis et al., 2011), 
and it interacts with focal adhesion kinase (FAK) and p120RasGAP (Tomar et al., 
2009) to regulate cell polarity. Arhgef3 regulates a number of genes in bone cells 
including ACTA2 (Mullin et al., 2014), and interacts with mTORC2 (Mammalian 
target of rapamycin complex 2) and Akt (Khanna et al., 2013) independently of its 
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GEF activity. The detailed mechanisms by which they modulated contraction are 
awaiting further characterisation. Nevertheless, our study has provided novel 
prospective roles for these regulators of Rho GTPases’ in contraction, which offers 
new possibilities for the future therapeutic interventions.  
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Chapter 5 Matrix metalloproteinase 1 (MMP1) in the 
contraction 
 
5.1 The expression of matrix metalloproteinases (MMPs) during in vitro 
contraction 
Matrix metalloproteinases (MMPs) play a vital part in all major cell behaviours such 
as proliferation, migration and differentiation, due to their essential ability to degrade 
extracellular matrix (ECM) proteins. MMP1 (collagenase I) cleaves fibrillar collagens 
type I, II and III, and is upregulated in many diseases and cancers that associated 
with dysregulation of ECM degradation. Previous work showed that transient 
treatment with Rac1 inhibitor NSC23766 efficiently prevented matrix degradation in 
vitro and ex vivo, and led to a significant reduction of MMP1 mRNA and protein 
expression during the in vitro contraction of HTF7071 (Tovell et al., 2012). 
Therefore, we proceeded to explore the link between Rho GTPase activation and 
MMP1 expression in contracting conjunctival fibroblasts. 
 
MMP family members were found to be strongly upregulated during in vitro  
contraction, especially MMP1, 3 and 10 in early contraction from day0 to 3, and 
MMP1 and 3 in late contraction from day3 to 5. Other MMPs, such as MMP16, 14, 
27, 12 and 2 were all found upregulated (Table 5.1), suggesting they perform 
important roles during the process. Only MMP10 was found downregulated in the 
late contraction. However, despite the observation that transient NSC23766 
treatment significantly reduced tissue contraction and matrix degradation in both in 
vitro and ex vivo models (Tovell et al., 2012), the in vitro microarray profile showed 
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that the inhibitor did not suppress the upregulation of MMPs but further increased 
their expression levels (Table 5.2). 
 
Table 5.1 The gene expression fold changes of Matrix metalloproteinases (MMPs) 
regulated during (a) early contraction from day0 to 3 and (b) late contraction from 
day3 to 5.  
 
 
Table 5.2 The gene expression fold changes of MMPs regulated in the NSC23766 
treated samples at (a) day3 and (b) day5 compared to untreated control samples.  
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5.2 Effect of NSC23766 treatment on MMPs’ expression and enzymatic 
activity 
To validate the gene expression profile of MMPs during contraction, the mRNA 
levels of the most upregulated MMPs including MMP1, 3 and 10 were quantified 
using qPCR with two conjunctival fibroblasts HTF7071 and HTF9154, which were 
originated from different donors (Figure 5.1). The results showed the gene 
expressions of MMP1, 3 and 10 were significantly upregulated during fibroblast-
mediated gel contraction, especially in HTF9154 that the mRNA levels of MMP1 and 
10 both increased over 100 times at day3 peak contraction rate. The expression 
patterns of these MMPs varied between the two fibroblasts. MMP1 and 10 in 
HTF7071, and MMP3 in HTF9154 further upregulated after day3, whereas MMP3 in 
HTF7071, and MMP10 in HTF9154 dropped back in late contraction at day5, 
suggesting a natural variation between the two fibroblasts. However, the treatment 
with NSC23766 did not suppress the overexpression of these MMPs.  
 
To determine the effect of NSC23766 treatment on MMPs secretion and activity, we 
measured the MMPs’ enzymatic activities released in the culture medium during 
contraction at day0, 3 and 5 with/without 24hrs transient treatment with NSC23766 
using HTF7071, HTF9154, HTF1785R and HTF0041 (Figure 5.2). The total amount 
of MMPs activity released was measured by incubating the samples with APMA (4-
aminophenylmercuric acetate) for 3hrs at 37ºC to active all the MMPs. The results  
confirmed that a large amount of MMPs were released in the medium throughout 
the contraction, matching the in vitro microarray profile. However, comparing to the 
total MMPs produced, only a small portion of MMPs were released in their active 
form, which only significantly increased at day5. For all the fibroblasts tested, 
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treatment with NSC23766 significantly abrogated total MMPs activity in the medium 
from day3 to day5, and active MMPs activity at day5.  
 
 
 
Figure 5.1 mRNA expression levels of MMP1, 3 and 10 were upregulated during 
contraction, independently of treatment with NSC23766.  
The mRNA expressions for MMP1, 3 and 10 during contraction (with/without transient 
treatment with NSC23766) were validated using qPCR. Two different primary human 
conjunctival fibroblasts were used:  HTF7071 (a, b, c) and HTF9154 (d, e, f) (n=2 
experiments, mean ± SEM).  
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Figure 5.2 Transient treatment with NSC23766 significantly inhibited total MMP 
activity in the contraction medium. 
Measurements of total (a, c, e, g) and active (b, d, f, h) MMP enzymatic activities in the 
medium of fibroblasts HTF7071 (a, b), HTF9154 (c, d), HTF1785R (e, f) and HTF0041 (g, h) 
contracting at day0, 3 and 5 with/without transient treatment with NSC23677. The activities 
were measured using MMP activity assay, and APMA (4-aminophenylmercuric acetate) was 
applied to stimulate all the MMPs in the medium (for total activity) (Mean ± SEM, n=2 
experiments with triplicate wells). The active MMP activity of NSC23766 treated cells at day5 
of HTF1785R (f) and day3 and 5 of HTF0041 (h) were under detectable level.  
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5.3 Treatment with NSC23766 altered MMP1 expression and secretion 
The above results demonstrated that NSC23766 treatment regulated MMP 
expression on protein release, rather than a direct inhibition on the gene expression. 
As MMP1 was the most upregulated MMP in the in vitro early contraction, whose 
significant upregulation at mRNA level was validated by qPCR in different 
fibroblasts, it was selected as an example to study the relation between its 
intracellular protein expression and extracellular secretion upon NSC23766 
treatment. The protein expressions of MMP1 in contracting fibroblasts HTF7071 and 
HTF1785R was detected by performing Western blot on cell lysates extracted from 
collagen gels at day0, 3 and 5 with/without transient NSC23766 treatment for the 
first 24hrs. The amount of MMP1 protein secreted into the contraction medium at 
the matching time points was identified using MMP1 ELISA. The results confirmed 
that MMP1 was massively secreted into the extracellular medium during contraction 
of both fibroblasts tested, and treatment with NSC23766 significantly suppressed its 
secretion (Figure 5.3). By contrast, MMP1 intracellular protein levels were 
increased following NSC23766 treatment, matching the previously observed 
increase in mRNA expression (Figure 5.4). This suggested that treatment with 
NSC23766 did not affect MMP protein levels in the cells but rather prevented its 
release to the extracellular space.  
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Figure 5.3 NSC23766 significantly blocked MMP1 protein released in the culture 
medium during contraction. 
MMP1 protein released in the medium of gel contraction at day 0, 3 and 5 (with/without 
transient NSC23766 treatment) of two human conjunctival fibroblasts HTF7071 (a) and 
1785R (b) was detected by MMP1 ELISA (mean ± SEM, n=2 experiments with triplicate 
wells). (c), (d) showing the matching contraction kinetics.  
 
 
  
Figure 5.4 NSC23766 increased MMP1 intracellular protein expression.  
Detection of MMP1 protein expression in fibroblasts HTF7071 (a) and 1785R (b) extracted 
from contraction gels at day 0, 3 and 5 (with/without transient NSC23766 treatment) by 
Western blot. (representative figures of reproducible results, n≥3 experiments).  
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5.4 NSC23766 treatment led to intracellular accumulation of MMP1 in both 
2D- and 3D-cultured cells 
5.4.1 MMP1 expression and secretion in 2D- and 3D-cultured fibroblasts 
We used fluorescence staining to detect where MMP1 was localised in the cells. 
Due to the complexity of processing and quantifying fluorescence signal from 
fibroblasts embedded in 3D collagen matrices in projected images, the alternative 
model of 2D cell culture was investigated. We firstly determined whether the 
transient application of NSC23766 inhibited the extracellular secretion of MMP1 in 
monolayer-cultured fibroblasts to the same extent as in 3D culture using HTF1785R. 
MMP1 intracellular protein levels were detected using Western blot on cell lysates 
extracted from 3D and 2D cell cultures respectively, and the release of MMP1 in the 
culture medium was measured in parallel using ELISA (Figure 5.5). The results 
suggested that NSC23766 treatment led to accumulation of MMP1 within the cells 
under both culturing conditions. Although the effect was less profound in 
monolayers, there was still over 3 times more MMP1 protein detected in the 
NSC23766 treated cells comparing to the untreated control, suggesting that the 
modulation of NSC23766 on MMP1 expression and secretion in fibroblasts could be 
alternatively studied in the 2D cell culture.  
 
To confirm this result using immunofluorescence staining, human conjunctival 
fibroblast HTF1785R cells seeded on coverslips with/without transient treatment 
with NSC23766 were fixed at day3 and stained for MMP1. The fluorescence signal 
was measured using ImageJ. The cells were traced manually for the calculation of 
the integrated density and cell size. The corrected integrated density (CID) was 
calculated based on the equation listed on Chapter 2 (2.11.1) (Figure 5.6). 
NSC23766 treated cells had about 2 times more MMP1 fluorescence signal than 
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control ones, which was consistent with the Western blot measurements in Figure 
5.5. Besides, treatment with NSC23766 led to a significant increase of cells size, 
which was about 1.5 times bigger than the untreated ones.  
 
5.4.2 The localisation of MMP1 in the cells  
Next we used immunofluorescence staining to localise MMP1 in the cells during 
contraction. Collagen contraction gels of fibroblasts HTF7071 and HTF9154 treated 
with/without transient NSC23766 treatment respectively were fixed at day3 and 
double-stained for MMP1 (Abcam ab38929 anti-MMP1 antibody) and actin 
cytoskeleton. The gels were imaged using Biorad Radiance laser scanning confocal 
microscope with a long working distance objective (ZEISS LD plan- Neofluoar 
63x0.75). The untreated control cells were in starlike shape that reflected a strong 
protrusive activity, whereas the NSC23766 treated ones were sat in a more 
quiescent stage. The difference was shown more obviously in HTF7071, which 
matched its sensitivity to NSC23766 treatment, as discussed in the previous 
chapter. A significant amount of MMP1 released into the extracellular matrix by 
control fibroblasts were captured in the image, shown as hazy-green little dots 
surrounding the cell. The secretion of MMP1 was almost completely suppressed in 
the NSC23766 treated cells (Figure 5.7).   
 
This experiment, using the Abcam anti-MMP1 antibody Ab38929, revealed a 
unspecific staining in centre of the cells (Figure 5.7 top panel), which was 
unexpected. To investigate whether MMP1 was localised in the nucleus, we 
changed to use an in-house produced anti-MMP1 primary antibody that was kindly 
provided by Dr. Yoshi Itoh from Oxford University. We fixed the collagen contraction 
gels of fibroblast HTF1785R treated with/without transient NSC23766 at day3 and 
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stained them with this antibody. The imaging was performed using Nikon Eclipse Ti 
confocal microscope with 20x objective (20x S Plan Fluor ELWD 0.45 Ph1). The 
images were acquired with z-stacks of 2µm per layer and projected using Nikon NIS 
elements software (Figure 5.8). The images showed that NSC23766 treated 
fibroblasts had brighter fluorescence signal comparing to untreated control, which 
suggested that the cells treated with NSC23766 had more intracellular MMP1. Also, 
MMP1 was found to be localised mostly in the cytoplasm area. Furthermore, the 
accumulation of MMP1 in 2D-cultured cells was determined by Western blot 
performed on fractionated cytoplasm and nuclear lysates of monolayer-cultured 
HTF1785R cells with/without transient NSC23766 treatment (Figure 5.9). The 
results suggested that the accumulation of intracellular MMP1 led by NSC23766 
treatment was mostly cytoplasmic, which was consistent with the observation in 3D.  
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Figure 5.5 NSC23766 treatment led to accumulation of intracellular MMP1 in 
HTF1785R, which was stronger in collagen gels (3D) comparing to monolayers (2D). 
 (a) Western blot results showing MMP1 protein expression in fibroblast HTF1785R cells 
extracted from collagen gels (3D) at day3 contraction or tissue culture of monolayer (2D) at 
day3 both with/without treatment with 50uM NSC23766 at first 24hr. (b) The quantitation of 
the Western blot results (mean ± SEM, n=5 experiments, t test between 3D and 2D cultured 
NSC23766-treated samples, **p<0.05). (c) MMP1 ELISA of culture medium from 2D-
cultured control and NSC23766 treated cells at day3 (mean ± SEM, n=2 experiments, 
**p<0.05). 
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Figure 5.6 Immunofluorescence staining of MMP1 expression in HTF1785R cells 
cultured on tissue culture flask (2D).  
Immunofluorescence staining of MMP1 expression in the non-treated control (a) or 24hrs 
NSC23766 treated (b) fibroblast cells HTF1785R cultured on coverslips at day3 (scale 
bar=100um). (c) Averaged fluorescence corrected integrated density (CID) for MMP1 in 
control and NSC23766 treated cells (mean ± SEM, n=4 experiments, 3 of which used 
Abcam ab38929 anti-MMP1 antibody, and 1 used the in-house produced anti-MMP1 
antibody provided by Dr. Y. Itoh from Oxford University. Totally more than 200 cells were 
counted, ****p<0.0001). (d) Corresponding averaged cell area of control and NSC23766 
treated cells (mean ± SEM, n=4 experiments, with more than 200 cells were counted, 
***p<0.001). 
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Figure 5.7 Immunofluorescence staining of MMP1 in fibroblast cells HTF7071 and 
HTF9154 contracting in collagen gels at day3. 
Contracting fibroblasts HTF7071 and HTF9154 in collagen gels at day3 with/without 24hrs 
transient NSC23766 treatment were fixed and stained with Abcam ab38929 anti-MMP1 
antibody (green) for MMP1 and Phalloidin (red) for actin cytoskeleton (scale bar x axis=16 
µm, y axis=36 µm). The red arrows pointed out MMP1 release in the extracellular space. 
The images were taken using Biorad Radiance confocal microscope with a long working 
distance objective (ZEISS LD plan- Neofluoar 63x0.75), and the projections were made 
using Velocity software.  
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Figure 5.8 Immunofluorescence staining of MMP1 in fibroblast cells HTF1785R 
contracting in the collagen gels at day3. 
Contracting fibroblast cells HTF1785R in day3 collagen gels with/without transient 
NSC23766 treatment were fixed and stained with an in-house produced anti-MMP1 antibody 
(green) that was kindly provided by Dr. Y. Itoh from Oxford University. The images were 
taken with z-stacks of 2µm per layer using Nikon Eclipse Ti confocal microscope with 20x 
objective (20x S Plan Fluor ELWD 0.45 Ph1), and projected using the Nikon NIS elements 
software (scale bar=50µm).   
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Figure 5.9 NSC23766 treatment led to MMP1 accumulation in the cytoplasm. 
(a) The protein expression of MMP1 detected by Western blot on fractionated cytoplasm and 
nuclear lysates of monolayer-cultured fibroblast cells HTF1785R with/without transient 
treatment with NSC23766 at day3. The untreated whole cell lysates were used as control. 
LaminA and β-tublin were used as markers of the nuclear and cytoplasm proteins 
respectively. The extra bands of MMP1 in the NSC23766 treated samples might be 
dimerised full length and active form of MMP1, and were both counted in the measurements. 
The figure is a representative of reproducible results (n=3 experiments). (b) Quantitation of 
the fractionation Western blot results (the cytoplasmic MMP1 was normalised to β-tublin, 
and then normalised to β-tublin-normalised whole cell control. The nuclear MMP1 was 
normalised to LaminA, and then normalised to LaminA-normalised whole cell control. Mean 
± SEM, n=3 experiments). 
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5.5 The effect of NSC23766 treatment on MMP1 secretion was not due to a 
direct inhibition of GTPase dynamin 
In a recent study, a novel invadopodia-independent matrix degradation process was 
identified in stromal fibroblast. It reported that inhibition of dynamin family member 2 
(Dyn2) caused a marked upregulation of stromal matrix degradation, which was 
mediated by augmented surface expression of MT1-MMP that stimulated MMP2 
activity (Cao et al., 2016). Dynamin is a GTPase responsible for endocytosis in the 
eukaryotic cells. It is a member of the ‘dynamin superfamily’, which includes 
classical dynamins, dynamin-like proteins (Dlps), Myxovirus resistance proteins, 
Atlastins, mitofusins, Optic atrophy 1 (OPA1) and the guanylate-binding proteins 
(GBPs) (Faelber et al., 2013). Dynamins are principally involved in the scission of 
newly formed vesicles both at the membrane as well as at the Golgi apparatus 
(Urrutia et al., 1997, Henley et al., 1999), and they have been extensively studied in 
the context of clathrin-coated vesicle budding from the cell membrane (Praefcke 
and McMahon, 2004). It was the first time that Cao et al revealed that the 
deactivation of a dynamin member triggered upregulation of fibroblast-mediated 
matrix degradation, suggesting a link between the dynamins and the modulation of 
MMP release. Coincidentally, another member of dynamins, dynamin 1 like 
(DNM1L), was found 1.4 times upregulated from day3 to 5 in our in vitro contraction 
expression profile. Also, it was 1.54 times upregulated following the NSC23766 
treatment at day3. Therefore, we hypothesised that the upregulation of DNM1L by 
NSC23766 might contribute to the regulation of MMP1 secretion. Herein, we used a 
dynamin inhibitor Dynasore that interferes with GTPase activity of dynamin 1, 
dynamin 2 and DNM1L (Macia et al., 2006) to investigate the possible modulation of 
dynamin/DNM1L on MMP1 expression and secretion. 
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Fibroblast cells HTF1785R were embedded in gels and contraction was allowed to 
proceed following the treatment with NSC23766 (24hr), Dynasore (24hr and 5-day 
respectively) and NSC23766 (24hr) plus Dynasore (24hr and 5-day respectively), 
respectively. The day3 and 5 contraction gels were analysed for the examination of 
in-cell MMP1 expression by Western blot. The culture medium was harvested at the 
same time points for the detection of MMP1 secretion by ELISA (Figure 5.10). The 
results showed that treatment with Dynasore did not interfere with the contraction 
kinetics of the fibroblasts, but it significantly suppressed MMP1 protein release in 
the medium, whether used for only 24hr or continuously for 5 days. The inhibitory 
effect was not as strong as that of NSC23766 treatment, and applying both 
inhibitors together did not result in a further reduction of MMP1 release. However, 
Dynamin inhibition did not lead to any increase of MMP1 protein expression, 
suggesting that the pathways that NSC23766 and Dynasore applied to modulate 
MMP1 secretion partially overlapped. Moreover, there were a lot more MMP1 
expressed following NSC23766 treatment than that of treatment with Dynasore 
alone, suggesting that NSC23766 targeted more pathways than just inhibiting 
dynamin.  
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Figure 5.10 Dynamin inhibition significantly suppressed MMP1 protein secretion.  
Fibroblast cells HTF1785R were treated with NSC23766 (50µM for 24hr), Dynasore (80µM 
for 24hr and 5-day respectively), and NSC23766 (50µM for 24hr) plus Dynasore (80µM for 
24hr and 5-day respectively) respectively in collagen contraction assay. MMP1 protein 
expression in the cells and secretion in the culture medium at day3 and 5 were detected by 
Western blot and ELISA respectively. (a) 5-day gel contraction kinetics (mean ± SEM, n=3 
experiments with triplicate wells). (b) MMP1 ELISA assay on contraction medium at day3 
and 5 (mean ± SEM, n=2 experiments with triplicate wells). (c) The detection of MMP1 in-cell 
protein expression in the HTF1785R cells extracted from contraction gels at day3 and 5, 
normalised to protein expression of Gapdh loading control. (d) Quantitation of the Western 
blot results. (c) and (d) are representative figures of reproducible results (n=3 experiments). 
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5.6 Small Rho GTPases Rac1, Cdc42 and RhoA differentially regulated MMP1 
expression and secretion  
To investigate the role of small Rho GTPases on MMP1 production in human 
conjunctival fibroblasts, immunofluorescence staining was performed to evaluate 
MMP1 protein expression in Rac1, Cdc42 or RhoA knockdown HTF1785R cells 
cultured on 2D cover slips. Silencing of the Rho GTPases led to a 1.5 (Rac1 or 
Cdc42, p<0.0001) to 2 times (RhoA, p<0.0001) fold increase of MMP1 fluorescence 
in the cells. In addition, RhoA inhibition led to a 1.5 times increase in cell size 
(Figure 5.11).   
 
We next explored the regulation of MMP1 protein expression and extracellular 
release by Rho GTPases in fibroblasts cultured in 3D collagen gels. The Rac1, 
Cdc42 or RhoA siRNA knockdown fibroblast cells HTF1785R were seeded in 
collagen contraction assay with/without 24hrs transient treatment with NSC23766. 
The cells were extracted from the gels at day3 and lysed for the extraction of RNA 
and protein respectively. The culture medium was collected at the same time for the 
detection of MMP1 release by MMP1 ELISA. The mRNA levels of MMP1 in the Rho 
GTPase knockdown cells were quantified by qPCR, whilst the protein expression 
levels of MMP1 were determined by Western blot. Silencing each of Rac1, Cdc42 or 
RhoA resulted in a significant upregulation of MMP1 mRNA expression in 
contracting fibroblasts, which was not affected by NSC23766 treatment (Figure 
5.12a). Moreover, knockdown of Rac1, Cdc42 or RhoA respectively led to a 
significant increase of MMP1 protein expression in the cells (from 5 (Rac1, p<0.01) 
to 10 times (RhoA, p<0.01)) (Figure 5.12b). Silencing of Rac1 did not suppress the 
release of MMP1 statistically. However, considering that more MMP1 were 
produced intracellularly upon Rac1 inhibition, it was likely that the release was 
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affected to some extent. Knockdown of Cdc42 remarkably augmented MMP1 
secretion by 2 fold (p<0.001), whereas inhibition of RhoA radically depleted MMP1 
release in the medium by almost 70% (p<0.0001) (Figure 5.12c). NSC23766 
treatment counteracted the overexpression of MMP1 in the cells led by silencing of 
Cdc42, which also brought the MMP1 protein release back to normal, suggesting 
that the regulation of MMP1 expression by Cdc42 was possibly reliant on signalling 
through Rac. By contrast, NSC23766 treatment on the Rac1-knockdown cells 
notably reduced MMP1 release in the medium, suggesting that other targets of 
NSC23766 (for example Rac2, as discussed in Chapter 4) played a regulatory role 
in controlling the release of MMP1. Moreover, in the RhoA-knockdown cells, 
NSC23766 further increased MMP1 expression and suppressed its release, 
suggesting that the signalling through RhoA also contributed vitally to the 
modulation of MMP1 expression and release, which did not overlap with the one 
that NSC23766 applied.  
 
In addition, inhibition of the Rho-associated protein kinase (ROCK), a downstream 
effector of RhoA in contracting HTF1785R cells using the ROCK inhibitor H1152 
also increased MMP1 protein production in the cells, but had no effect on its 
secretion (Figure 5.13). It suggested that MMP1 expression might be triggered by a 
major downstream signalling event led by ROCK inhibition (such as changes in 
actin polymerisation), although signalling through ROCK was not essential for the 
extracellular release of MMP1.  
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Figure 5.11 Silencing of Rac1, Cdc42 or RhoA increased MMP1 expression. 
(a-e) Immunofluorescence staining of MMP1 in Rac1, Cdc42 or RhoA knockdown 
HTF1785R cells cultured on coverslips respectively (scale bar=100μm, used Abcam 
Ab38929 anti-MMP1 antibody). (f) Averaged fluorescence corrected integrated density (CID) 
for MMP1 in the Rac1, Cdc42 or RhoA knockdown cells and (g) corresponding cell area 
(n=4 experiments counting in total >200 cells per group, t test between control and 
knockdown cells, and between knockdown cells ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05). (h) The validation of the protein depletion of Rac1, Cdc42 or RhoA following siRNA 
treatment by Western blot (figure is a representative of repeatable results, n=4 experiments).   
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Figure 5.12 Downregulation of Rac1, Cdc42 or RhoA increased MMP1 production, 
whilst only RhoA inhibition significantly prevented MMP1 secretion. 
(a) MMP1 mRNA expression levels of Rac1, Cdc42 or RhoA knockdown cells extracted from 
day3 contraction gels measured by qPCR. (b) MMP1 protein expression in Rac1, Cdc42 or 
RhoA knockdown cells extracted from day3 contraction gels measured by Western blot (n>3 
experiments, t test between control and knockdown expression, and NSC23766 treated and 
non-treated samples. *p<0.05, **p<0.01, ****p<0.0001). (c) Detection of MMP1 protein 
secreted in the day3 contraction medium by MMP1 ELISA (n=3 experiments with triplicate 
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wells, t test between control and knockdown secretion, and NSC23766 treated and non-
treated samples. *p<0.05, ***p<0.001, ****p<0.0001).  
  
 
 
Figure 5.13 The inhibition of ROCK, a downstream mediator of RhoA, also increased 
MMP1 protein production in the cells, but had no effect on its secretion. 
(a) MMP1 detection by Western blot on HTF1785R cells extracted from day3 collagen 
contraction gels treated with/without 10μM ROCK inhibitor H1152. (b) Quantitation of the 
Western blot results (mean ± SEM, n=2 experiments). (c) MMP1 ELISA performed on day3 
control and ROCK inhibitor treated gel contraction medium (mean ± SEM, n=2 experiments 
with triplicate wells). 
 
 
5.7 ERK, P38 MAPK and PI3K signalling differentially regulated MMP1 
expression and secretion  
The small Rho GTPases are activated by signalling downstream of activated 
integrins and growth factors, so are the mitogen-activated protein kinases (MAPKs), 
which are involved in regulating various major cell functions (Miyamoto et al., 1995). 
It has been reported that activation of ERK1/2 or P38 MAP kinase pathway was 
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able to induce transcription from MMP1 promoter in human primary fibroblasts 
(Brauchle et al., 2000). The activation of ERK1/2 stimulated MMP1 production in 
human skin fibroblasts and keratinocytes, which was shown to be Cdc42 dependent 
(Deroanne et al., 2005, Rohani et al., 2014), consistently with our results in Figure 
5.12. In addition, the PI3K (phosphoinositide-3-kinase) signalling pathway was also 
reported to be involved in the regulation of MMPs in fibroblasts (Liao et al., 2003), 
suggesting that these signalling pathways potentially participated in the regulation of 
MMP production. Here we aimed to identify the implication of ERK, P38 MAPK and 
PI3K signalling on MMP1 expression and secretion in contracting human 
conjunctival fibroblasts with relation to the Rho GTPases activation.  
 
We investigated the role of the ERK1/2, p38 MAPK and PI3K pathways in mediating 
MMP1 expression and secretion in the Rho GTPases-silenced fibroblasts using 
pharmacological inhibition. The Rac1, Cdc42 or RhoA siRNA knockdown 
HTF1785R cells were seeded in collagen contraction gels and treated with U0126 
(ERK inhibitor), SB203580 (P38 MAPK inhibitor) and Ly294002 (PI3K inhibitor) 
respectively. The cells and culture medium were harvested at day3 for MMP1 
immunoblotting and ELISA respectively (Figure 5.14). The results demonstrated 
that inhibition of ERK1/2 significantly reduced MMP1 release in the medium of all 
experiment conditions, which was possibly due to the deactivation of MMP1 
promoter (Brauchle et al., 2000), implying that MMP1 secretion was ERK-
dependent. By contrast, inhibition of P38 MAPK signalling did not lead to significant 
changes in MMP1 expression or secretion, suggesting that it did not perform a 
major role in regulating MMP1 production. Furthermore, inhibition of PI3K notably 
increased MMP1 accumulation in the cells but remarkably suppressed its secretion 
in all conditions, indicating that it played an important role in the modulation of 
MMP1 expression and secretion.   
 170 
 
 
Figure 5.14 The ERK, P38 MAPK and PI3K signalling differentially regulated MMP1 
expression and secretion. 
(a) Averaged MMP1 expression in Rac1, Cdc42 or RhoA knockdown fibroblast cells 
HTF1785R extracted from day3 contraction gels treated with ERK inhibitor U0126 10μM, 
P38 MAPK inhibitor SB203580 10μM or PI3K inhibitor Ly294002 25μM respectively 
(normalised to day3 untreated control expression, n=3 experiments, mean ± SEM, t test 
against non-treated control within the same sample group, **p<0.01). (b) Averaged MMP1 
secretion at day3 of Rac1, Cdc42 or RhoA knockdown fibroblast cells HTF1785R treated 
with the ERK inhibitor U0126 10μM, P38 MAPK inhibitor SB203580 10μM or PI3K inhibitor 
Ly294002 25μM respectively (normalised to day3 untreated control secretion, n=3 
experiments with duplicate wells, mean ± SEM, t test against non-treated control within the 
same sample group, ****p<0.0001, ***p<0.001, *p<0.05).  
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5.8 Regulation of GTPases activation in MMP1 secretion 
In the previous chapter, it has been demonstrated Arhgap5, Racgap1, Arhgef3 and 
Rac2 were expressed differently during the in vitro contraction (Figure 4.8) and 
performed differential regulatory roles in contractile activity (Figure 4.9). To further 
characterise signalling pathways that regulate MMP1 expression and secretion, 
HTF1785R were transfected with siRNA targeting Rac2, Arhgap5, Racgap1 or 
Arhgef3 to silence their respective gene expressions, and then seeded into collagen 
gels with/without transient treatment with NSC23766. The gels were terminated at 
day3, following with the extraction of the cells for the detection of MMP1 expression 
using Western blot. The culture medium was collected at the same time for 
measuring MMP1 release by ELISA (Figure 5.15). Silencing each of the gene 
caused a significant increase of MMP1 protein expression in the cells, suggesting 
that MMP1 production might be induced as a result of changes in actin 
polymerisation caused by activation/deactivation of Rho GTPases. Silencing of 
Rac2, Racgap1 or Arhgef3 notably increased MMP1 secretion in the culture 
medium, whereas with NSC23766 treatment the effect was counteracted, 
suggesting that none of the gene was functional in controlling MMP1 release. By 
contrast, inhibition of Argap5 significantly suppressed MMP1 secretion, which was 
further reduced by NSC23766 treatment, suggesting that Arhgap5 was vital in 
regulating the extracellular release of MMP1.  
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Figure 5.15 Silencing of Rac2, Arhgap5, Racgap1 or Arhgef3 increased MMP1 
expression in the cells but differently regulated its release in the medium. 
(a) Averaged MMP1 protein expression in the Rac2, Racgap1, Arhgap5 or Arhgef3 
knockdown HTF1785R cells extracted from day3 collagen contraction gels with/without 
transient NSC23766 treatment for the first 24hrs (normalised to day3 control expression, n≥3 
experiments mean ± SEM, t test between knockdown expression and control expression, 
and also between NSC23766 treated and non-treated samples within same group. 
****p<0.0001, **p<0.01, *p<0.05). (b) Averaged MMP1 secretion in the day3 contraction 
medium of Rac2, Racgap1, Arhgap5 or Arhgef3 knockdown HTF1785R cells with/without 
transient NSC23766 treatment for the first 24hrs (normalised to day3 control secretion, n≥3 
experiments with triplicate wells, mean ± SEM. t test against control secretion, and 
n****p<0.0001, ***p<0.001, **p<0.01, *p<0.05).  
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5.9 Discussion 
Members of the MMPs family were among the most upregulated gene groups 
during conjunctival fibroblast-mediated in vitro contraction, especially MMP1, which 
was expressed over 38 times on gene level in early contraction, and upregulated all 
the way throughout the whole contraction process. Elevated expression of MMP1 
has been reported in many diseases associated with dysregulation of ECM 
remodelling, as well as tumour invasion and metastasis (Lemaitre and D'Armiento, 
2006). Multiple studies showed that in addition to degrading ECM, MMP1 cleaves 
signalling molecule precursors, such as pro-TGFα, EGF-like ligands, and TGFβ 
from cell surfaces or extracellular matrix. It processes several important mediators 
including pro-TNFα, IL-1β, L-selectin (CD62L), α1-antiprotease inhibitor, C1q, 
connective tissue growth factor (CTGF), and insulin growth factor-binding proteins 1 
(IGFBP1) and 3 (IGFBP3) (Rajah et al., 1995, Hatfield et al., 2010, Page-McCaw et 
al., 2007, Kessenbrock et al., 2010). MMP1 also activates PAR-1, which is a 
proteinase-activated receptor that promotes migration and invasion of tumour-
infiltrating fibroblasts in the model of breast carcinoma (Boire et al., 2005), vascular 
smooth muscle cell dedifferentiation and arterial stenosis (Austin et al., 2013). 
These findings suggest that by working in both proteolytic and non-proteolytic 
manners, MMP1 has important and complex roles in regulating matrix turnover, 
disease progression and signal transduction. However, knockdown of MMP1 by 
siRNA that caused an 85% decrease of the protein release in the medium only 
reduced 50% contraction at day2 and 20% contraction at day7 (Figure 5.16). It 
suggests that a small amount of MMP1 secreted in the medium may be enough to 
stimulate contraction, or MMP1 may not play a major functional role in contraction. 
Alternatively, other MMPs, such as MMP3 or 10, may cover the role of MMP1 in its 
absence.   
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Figure 5.16 Silencing of MMP1 by siRNA in conjunctival fibroblasts only mildly 
affected contraction.  
Fibroblast HTF1785R cells were treated with siRNA targeting MMP1 for 72hrs, and then 
seeded into collagen contraction gels for 7 days. The culture medium at day3 and 5 were 
collected for the application of MMP1 ELISA. (a) Western blot results showing after 72hr of 
siRNA treatment, MMP1 protein expression was significantly decreased in the cells. (NT: 
non-targeting control siRNA). (b) 7-day contraction kinetics of the control and MMP1-
knockdown HTF1785R cells (mean ± SEM, assay performed with triplicate wells). (c) ELISA 
results demonstrated that MMP1 secretion was significantly reduced in day3 and 5 
contraction medium of MMP1 knockdown cells (mean ± SEM, n=2 experiments with 
duplicate wells). (a), (b) are representative figures of reproducible results (n=2 experiments).    
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The large quantity of MMP1 produced during the contraction process makes it a 
good model to investigate the post-translational modulation of its secretion by the 
Rho GTPases. However, it was difficult to locate where MMP1 was produced within 
the cells, due to the lack of reliable anti-MMP1 primary antibody for 
immunofluorescence staining. The subsequent quantification of MMP1 signal 
intensity in fibroblasts embedded in 3D collagen matrix had technical restriction as 
well. The anti-MMP1 antibody used for most of the study was the commercially 
available Abcam ab38929, which worked efficiently in Western blotting but showed 
a strong non-specific nucleus signal in immunofluorescence staining that was 
dependent on batch variations. Although MMP1 was reported to accumulate in the 
mitochondria and nuclei within the cells during the mitotic phase of the cell cycle 
(Limb et al., 2005), and in the nuclei of breast tumour cells with a slight additional 
staining in the cytoplasm (Kohrmann et al., 2009), by performing Western blot on 
fractionated cytoplasm and nuclear lysates of contracting fibroblasts, we confirmed 
MMP1 localised mainly cytoplasmic in our model. The application of a more specific 
in-house produced anti-MMP1 antibody, which was kindly provided by Dr. Itoh from 
Oxford University, confirmed the results. Also, the experiments performed on the 
2D-cultured fibroblasts showed that they exhibited an identical expression pattern of 
MMP1 comparing to the 3D-cultured cells, but with a less profound production of the 
protein.  
 
The mechanisms by which MMP1 is expressed and released in the cells are yet 
unclear. Previous studies showed that disruption of actin cytoskeleton, initiated by 
binding of soluble antibody to α5β1 integrin, led to an increased expression of 
MMP1 gene in rabbit synovial fibroblasts that was dependent on Rac1 activation 
(Kheradmand et al., 1998). The Rho family of small GTPases are activated 
downstream of integrin activation, which tightly control the organisation and 
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dynamics of the various structures that constitute the actin cytoskeleton. Rac1, 
Cdc42 and RhoA are reported to differently regulate MMP1 expression in several 
cell types from different origins (Kheradmand et al., 1998, Deroanne et al., 2005, 
Rohani et al., 2014, Ferri et al., 2007, Igata et al., 2010). However, our work is the 
first study that investigated the role of Rho GTPases in regulating MMP1 protein 
expression and extracellular release.  
 
The modulation of Rho GTPases on MMP1 production varies depending on different 
cell types. In our model, inhibition of Cdc42 significantly augmented MMP1 
secretion that was caused by overexpression of the protein in the cells, which was 
possibly through the activation of ERK1/2, consistently with previous findings 
(Kheradmand et al., 1998, Rohani et al., 2014). Notably, the treatment with 
NSC23766 abolished Cdc42-dependent MMP1 overexpression and secretion, 
suggesting that NSC23766 may suppress ERK activity, which was also mentioned 
in the study of human skin fibroblasts (Deroanne et al., 2005).  
 
The regulatory roles that Rac1 and RhoA performed on MMP1 expression and 
release are distinct in our cells from the ones of other cell types. The activation of 
Rac1 was required for the production of MMP1, and blocking of Rac1 resulted in a 
reduction of MMP1 expression at both gene and protein levels in the rabbit synovial 
fibroblasts, human smooth muscle cells and the in vivo mice model (Kheradmand et 
al., 1998, Ferri et al., 2007, Bopp et al., 2013). In conjunctival fibroblasts, we found 
that Rac1 downregulation did not greatly interfered with the secretion of MMP1, but 
increased its expression in the cells. Furthermore, we showed that downregulation 
of RhoA significantly reduced MMP1 secretion, which was very different from the 
results found in keratinocytes and dermal fibroblasts (Deroanne et al., 2005, Rohani 
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et al., 2014). RhoA inhibition led to a remarkable accumulation of MMP1 within the 
cells, whereas blocking of the RhoA downstream effector ROCK pathway failed to 
prevent MMP1 from being released, suggesting that signalling through activated 
RhoA but not ROCK, is essential for MMP1 protein secretion in conjunctival 
fibroblasts (Table 5.3).   
 
 
Table 5.3 Summary of the changes of MMP1 protein expression and secretion upon 
siRNA knockdown (KD) of small Rho GTPases Rac1, Cdc42, RhoA and Rac2, and 
GAPs and GEFs including Arhgap5, Racgap1 and Arhgef3. ‘≈’ represents no 
statistically significant change detected. ‘↑’ and ‘↓’ represent up and downregulation 
respectively, ‘↑↑’ represents over 2 times upregulation in protein secretion 
characterised and ‘↓↓’ represents a significant reduction of contraction kinetics. 
 
 
Several studies have demonstrated the involvement of MARK signalling in MMP1 
expression. Activation of the ERK1/2 or P38 MAP kinase pathway was found to 
induce transcription from MMP1 promoter in primary human fibroblasts (Brauchle et 
al., 2000), and activation of ERK1/2 signalling induced MMP1 protein expression in 
human dermal fibroblasts, keratinocytes and epithelial cells, as well as in the ex vivo 
model of lung tissue (Mercer et al., 2004, Deroanne et al., 2005, Rohani et al., 2014, 
Jian et al., 2011). Inhibition of the p38 MAP kinase increased MMP1 expression in 
dermal fibroblasts but had no effects in keratinocytes (Deroanne et al., 2005, 
Rohani et al., 2014), suggesting that the modulation of the P38 MAPK signalling on 
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MMP1 expression is cell-type and model dependent. It was reported that the 
divergent regulatory role that P38 MAPK played in MMP1 expression in contracting 
human fibroblasts was depend on the level of p38α kinase activity in response to 
biomechanical signals (Xu et al., 2001). In our model, inhibition of ERK signalling 
remarkably reduced MMP1 produced by the cells, whilst blocking of P38 MAPK 
signalling had no significant effect on MMP1 expression and secretion, suggesting 
that it did not play a key role in the regulation (Table 5.4).  
 
Furthermore, inhibition of the PI3K signalling by its inhibitor LY294002 was reported 
to suppress the secretion of MMP2 and 9 in mouse embryo fibroblasts, colorectal 
cancer cells and macrophages (Liao et al., 2003, Ordonez et al., 2016, Ren et al., 
2016), but had no effect on MMP1 expression in dermal fibroblasts (Rohani et al., 
2014). We showed that treatment with LY294002 significantly increased MMP1 
expression but reduced its secretion (Table 5.4), which led to a great accumulation 
of MMP1 within the cells that was similar to the effect of downregulating RhoA. PI3K 
signalling (specific PI3Kα, Akt1 and Akt2 isoforms) was reported to act as upstream 
regulator of RhoA in osteosarcoma MG-63 and U2OS cells (Zhang et al., 2017), 
suggesting that its regulation on MMP1 expression and secretion may be (at least) 
partially through modulating of RhoA activity.  
 
Table 5.4 Summary of the regulation of the inhibitors of ERK (U0126), P38 MAPK 
(SB203580) and PI3K (LY294002) pathways on MMP1 expression and secretion 
respectively in contracting conjunctival fibroblasts HTF1785R. ‘≈’ represents no 
statistically changes detected, ‘↑’ and ‘↓’ represent up and downregulation 
respectively.  
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Besides, our results showing that fibroblasts cultured in 3D collagen gels produced 
significantly more MMP1 than 2D monolayer-cultured cells is consistent with the 
previous studies, suggesting that fibroblasts spread on a rigid substrate express low 
levels of MMP1 than cells grown on polymerized collagen or in-gel (Kheradmand et 
al., 1998, Ferri et al., 2007, Lambert et al., 2001). The possible explanations are that 
contracting floating collagen lattices induced the expression of Nuclear factor-
kappaB (NF-κB), a previously identified positive regulator of MMP1 expression (Xu 
et al., 1998), and ligation to collagen induced the activation of ERK signalling, which 
triggered the expression of MMP1 (Rohani et al., 2014).  
 
Our study for the first time characterised the role of Rac2, Racgap1, Arhgap5 and 
Arhgef3 in regulating MMP1 expression and secretion (Table 5.3). We found that 
silencing any of these genes led to an upregulation of MMP1 expression in the cells. 
Unlike Rac1, downregulation of Rac2 significantly increased MMP1 secretion, 
showing that Rac2 activity may participate in the rate-limiting control of MMP1 
release. Arhgap5 (P190BRhoGAP) is an important regulator of RhoGTPase activity 
in mammalian cells, with a catalytic activity preferentially towards RhoA (Matheson 
et al., 2006). It was reported to regulate proteolysis through MMP14 and MMP2 
expression in endothelial cells, via modulating on these MMPs’ mRNA levels 
(Guegan et al., 2008), suggesting that its regulation on MMP1 expression might be 
on the mRNA level. Silencing of Arhgap5 decreased MMP1 secretion, suggesting 
that its activity may be required for signalling pathways that regulate MMP1 
secretion. Racgap1 is a crucial modulator in cytokinesis that shows strong GAP 
activity towards Rac1 and Cdc42, and less towards RhoA (Bastos et al., 2012, 
Warga et al., 2016). Blocking of Racgap1 resulted in an augmented MMP1 release 
led by increased protein expression, suggesting that Racgap1 was involved in 
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signalling pathways that regulate MMP1 expression. Lastly, Arhgef3 is a RhoGEF 
that selectively activate RhoA and RhoB (Arthur et al., 2002). It was reported to 
regulate transferrin uptake in erythroid cells through activation of RhoA (Serbanovic-
Canic et al., 2011), suggesting that it plays a role in the secretory processes. In our 
model, inhibition of Arhgef3 did not result in the same result as that of inhibiting 
RhoA, suggesting that Arhgef3 is functional in modulating MMP1 release that is 
independent of its GEF activity towards RhoA. In addition, treatment with 
NSC23766 counteracted the secretion of MMP1 to the level of control in Rac2, 
Racgap1 and Arhgef3 knockdown cells, and further reduced MMP1 release in 
Arhgap5 knockdown cells. In correlation with the changes in MMP1 expression, it 
suggested that Rac1 activity is required for the expression of MMP1 (in Rac2 and 
Arhgap5 knockdown cells); or for the rate-limiting regulation of MMP1 release into 
the extracellular space (in Racgap1 and Arhgef3 knockdown cells). 
 
In summary, this study demonstrated that inactivation of small Rho GTPases and 
their modulators induced the production of MMP1 in the cells, though only RhoA or 
Arhgap5 downregulation significantly inhibited MMP1 secretion (Table 5.3, Table 
5.4), suggesting their important and differential roles in the regulation of MMP1 
manufacture in contracting conjunctival fibroblasts. It is proposed that the rate-
limiting step for modulating MMP1 during the tissue contraction is the release of the 
protein in the extracellular medium rather than its expression levels. Also, it is highly 
possible that this mechanism is applicable to other MMPs that exhibited 
upregulation during the contraction, hence drawing some interesting new prospects 
for future therapies. 
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Chapter 6  Discussion and future directions 
 
 
To characterise the molecular pathways underlying conjunctival fibrosis and 
scarring, we utilised a genome wide microarray study to investigate gene 
expression changes during human conjunctival fibroblast-mediated contraction. 
Unlike the previous microarray studies that have been carried out in animals or 
small cohort of patients with mixed cell populations (Esson et al., 2004, Popp et al., 
2007, Mahale et al., 2015), our work is the first study that performed with in vitro 3D 
contraction model that contained only fibroblasts. Through a comprehensive 
analysis that combined a pilot parallel study of an in vivo wounding model in rabbit 
following glaucoma filtration surgery, and previously obtained microarray data of 
human ocular fibrotic diseases such as trachoma and thyroid-associated 
orbitopathy, we identified that the contraction process consisted of two phases: the 
early phase, exhibited a classic serum/wound response profile with upregulation of 
genes related to inflammation, matrix remodelling and transcription activation; and a 
late stage when the hyperactive signal receded and the gene profile progressed to 
promote fibrosis. Furthermore, we found that an early transient inhibition of Rac1 by 
its inhibitor NSC23766 was efficient to suppressed the gene expression changes 
that initiated the contraction in fibroblasts HTF7071. Importantly, our results 
demonstrated that small Rho GTPases Rac2, Cdc42 and RhoA, and their regulators 
including Arhgap5, Racgap1 and Arhgef3 differently regulated the contractile 
activity. They also differently regulated matrix remodelling by modulating the 
expression and secretion of MMP1. The uncovered regulators of the contraction that 
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we identified and the rate-limiting model of MMP1 secretion that we proposed will 
draw some interesting new prospects for the future research and therapies. 
 
 
6.1 Signalling pathways characterised in contraction 
Our analysis has provided novel insights into the signalling pathways that 
contributed to the activation or inhibition of the cellular contractile activity, by 
characterising the annotated functional gene clusters being dynamically modulated 
during the contraction in vitro and in vivo (Figure 6.1). We confirmed the 
participation of some expected signalling events such as ‘Respond to wounding’, 
‘transcription regulation’ and ‘cytokine activity’ that are closely related to wound 
healing (Iyer et al., 1999). We also proposed the involvement of gene clusters that 
have not been directly linked to tissue contraction before, for example, the gene 
cluster of ‘Cadmium ion binding’ was found to be related to the upregulation of 
contraction. Cadmium was reported to induce translocation of proteins to cellular 
compartments, particularly cytoskeleton (Liu et al., 2014). It acted on the disruption 
of focal adhesions, as well as shifting the actin polymerisation-depolymerisation in 
favour of depolymerisation by activation of Ca(2+)-dependent proteins in the studies 
of rat, mouse, and human mesangial cells (Templeton and Liu, 2013), which 
suggested that the uptake of Cadmium ion potentially regulated actin cytoskeleton, 
which may facilitate the contraction.  
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Figure 6.1 Conclusion of the annotated functional gene clusters that are associated 
with the activation or inhibition of the contractile activity.  
The figure concludes the annotated functional gene clusters that are related to the positive 
regulation (activation) or negative regulation (inhibition) of the contractile activity. They are 
selected as they were among the top 10 up or downregulated gene clusters in the in vitro 
early contraction from day0-3 or late contraction from day3-5, day3 NSC23766 treated 
samples, or the in vivo contraction, and also being similarly regulated in at least two other 
sample groups that are identically related to the activation or inhibition of contraction. The 
different colour blocks following the cluster name represent its expression patterns in 
different sample groups. The explanation of each colour block is listed in the figure legend.  
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Similarly, functional clusters that were identified underlying negative regulation of 
the contraction, such as ‘oxidation reduction’, ‘coenzyme metabolic processes’ and 
‘steroid biosynthesis’, have not been recognised by any other studies before. 
However, gene that regulate cholesterol biosynthesis were showed to be 
suppressed in the previous study of the transcriptional program of fibroblasts in 
response to serum (Iyer et al., 1999). Lately, the expression profile of strongly 
upregulated lipid and fatty acid metabolism signature genes was found to be 
associated with a less contractile phenotype in human dermal fibroblasts in vitro 
(Milano et al., 2008, Johnson et al., 2015). Also, rats with a higher body fat 
constituent were identified with a higher levels of lipid peroxidation and significantly 
delayed wound contraction (Paulino do Nascimento and Monte-Alto-Costa, 2011), 
suggesting that enhanced lipid metabolism may be linked to or result from the 
inhibition of the contractile activity. Still, the detailed mechanisms by which these 
signalling events affected contraction are awaiting further investigation, our work 
has expanded a wider view of the current event and suggested more possibilities for 
the future direction of the research.  
 
 
6.2 A model for the role of small GTPases in contraction 
One surprising finding of the study was that the small Rho GTPase Rac1 may not 
play an essential role in regulating conjunctival fibroblast-mediated contraction. 
Following the published study of Tovell et al (Tovell et al., 2012), it was 
hypothesised that Rac1 is a master regulator of tissue contraction in conjunctiva. 
However, our results suggested that Rac2, but not Rac1, may be a major regulator 
of contraction, indicating that Rac2 can be a promising target in the future 
therapeutics of conjunctival scarring. Similar to Rac1, Rac2 was found to regulate 
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actin dynamics through interacting with cofilin and Arp2/3 (Sun et al., 2007). It may 
also act with DIAP3 or other downstream effectors to perform a dominant regulatory 
role of actin despite the presence of Rac1. 
 
Here we proposed a model by which the contractile activity of conjunctival fibroblast 
is regulated by the Rho GTPases and other regulators that we characterised in the 
study (Figure 6.2). Following serum stimulation, Rac2 is activated and performs a 
vital role in mediating contraction. Activation of Cdc42 promotes contraction via 
inhibition of the ERK signalling, whose activity suppresses contraction. Cdc42 may 
also facilitate contraction by activating the P38 MAPK signalling pathway. The 
activation of RhoA promotes contraction, whilst the contribution of active Rac1 to 
contraction is small. The PI3K signalling pathway plays an important role in 
promoting contraction. Activation of Racgap1 suppresses contraction through 
inactivation of Cdc42. The inhibition of Arhgap5 or Arhgef3 significantly decreases 
contraction, suggesting that their activities are required for the signalling pathways 
that are essential to the contraction, which makes them novel targets for the 
prevention of contraction. Our work revealed that Rho GTPases and numerous 
signalling pathways contribute to the contraction in which they perform distinct 
regulatory roles, and several GAPs and GEFs also play vital functions in regulating 
the process.  
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Figure 6.2 Illustrative diagram showing the potential regulatory roles of numerous 
modulators in the conjunctival fibroblast-mediated contraction. 
The potential regulatory roles of small Rho GTPases Rac1, Cdc42, RhoA and Rac2, and 
their regulators including Racgap1, Arhgap5 and Arhgef3, and the ERK, P38 MAPK and 
PI3K signalling pathways are illustrated in the figure. The size of the icon represents the 
importance of the participator in the contraction. The black arrows represent positive 
regulation, and the red arrows represent inhibition. Upon serum stimulation, Rac2 is 
activated and performs a vital role in contraction. Cdc42 promotes contraction by inactivation 
of ERK. The P38 MAPK signalling facilitates contraction downstream of Cdc42. The PI3K 
signalling plays an important role in mediating contraction. The activation of RhoA or Rac1 
promotes contraction, though the contribution of Rac1 is small. Activation of Racgap1 
suppresses contraction through inactivation of Cdc42 and Rac1, especially Cdc42. The 
inhibition of Arhgap5 or Arhgef3 significantly decreases contraction, suggesting that their 
activities are required for the signalling pathways that are essential for the contraction.  
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Moreover, other Rho GTPases, for example RhoB and RhoD, were also found 
being differently regulated during the in vitro contraction. RhoB holds a conserved 
‘effector domain’ like RhoA and has the potential to interact with the same 
downstream effectors (Ridley, 2013). RhoB was shown to regulate actin dynamics 
via modulating β1 integrin surface levels and activity, thereby stabilising 
lamellipodial protrusions (Alfano et al., 2012, Vega et al., 2012). RhoB was 
downregulated 1.5 times by NSC23766 treatment at day3, and downregulated 2.1 
times from day3 to 5, suggesting that it may be functional in a way to promote early 
contraction. RhoD was thought to have cellular functions that are antagonistic to 
RhoA, as introduction of constitutively active form of RhoD into fibroblasts resulted 
in disassembly of actin stress fibres and focal adhesions (Tsubakimoto et al., 1999). 
RhoD was downregulated 2 times from day0 to 3, and upregulated 3 times from 
day3 to 5, suggesting that RhoD-dependent pathways may negatively affect the 
contraction. It will be interesting to further investigate the roles that RhoB and RhoD 
perform in contraction.  
 
 
6.3 A model for the regulation of MMP1 expression and secretion during 
contraction 
Another surprising result suggested by the study was that 85% depletion in the level 
of MMP1 protein released in the culture medium was not able to stop contraction. It 
is suspected a small amount of MMP1 was enough to facilitate contraction, or that 
other MMPs, such as MMP3 and MMP10 that were also significantly upregulated 
during the contraction, shared the same function with MMP1. It will be interesting to 
explore that if a complete suppression of MMP1, or depleting MMP1, 3 and 10 
altogether could prevent the contraction. Also, overproduction of MMP1 was not 
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able to overcome the loss of cellular contractility led by deactivation of vital 
regulators of contraction, such as Rac2 in our model, suggesting that cell-mediated 
protrusive activity and MMP1-mediated matrix degradation are independent events 
in conjunctival fibroblast-mediated contraction.  
 
We for the first time proposed a model of potential mechanisms by which the 
expression and release of MMP1 are regulated during contraction in conjunctival 
fibroblasts (Figure 6.3). We found that the expression of MMP1 is triggered by 
inactivation of the small Rho GTPases Rac2, RhoA, Cdc42 or Rac1. Cdc42 inhibits 
MMP1 expression by suppression of the ERK signalling, which upon activation 
promotes MMP1 production. The activation of ERK may require the participation of 
active Rac1. The PI3K signalling negatively regulate MMP1 expression possibly via 
activating RhoA, whose downstream effector ROCK serves to inhibit MMP1 
expression. Arhgef3 also reduces MMP1 expression via activation of RhoA, whilst 
Racgap1 and Arhgap5 inhibit MMP1 expression through other signalling pathways 
other than their GAP activity towards Cdc42, Rac1 or RhoA. In terms of the export 
of MMP1, RhoA, Rac1 and Arhgap5 perform important regulatory roles in controlling 
the release of MMP1 to the extracellular spaces. Our work revealed that the rate-
limiting regulation of MMP1 is on the protein release rather than its expression 
levels, suggesting some promising new strategies for the future therapeutics. 
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Figure 6.3 A model for the potential mechanisms by which the expression and release 
of MMP1 are regulated during the conjunctival fibroblast-mediated contraction.   
The expression of MMP1 is triggered by inactivation of the small Rho GTPases Rac2, RhoA, 
Cdc42 or Rac1. Cdc42 suppresses MMP1 expression by inhibition of the ERK signalling, 
which upon activation promotes MMP1 production, and may require the participation of 
active Rac1. The PI3K signalling negatively regulate MMP1 expression possibly by 
activating RhoA, whose downstream effector ROCK serves to inhibit MMP1 expression. 
Arhgef3 reduces MMP1 expression via activation of RhoA, whilst Racgap1 and Arhgap5 
inhibit MMP1 expression through unknown signalling pathways other than their GAP activity 
towards Cdc42, Rac1 or RhoA. RhoA, Rac1 and Arhgap5 perform important regulatory roles 
in controlling the release of MMP1 to the extracellular spaces.  
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6.4 Future direction 
The mechanisms by which the small Rho GTPases especially RhoA and Rac1 
controlled the rate-limiting secretion of MMP1 during the contraction are worth being 
further characterised. The Rho GTPases are known to be critical players in the 
process of vesicle trafficking. Together with their regulators, Rho GTPases 
modulate and/or trigger exocytosis, and induce the squeezing of the post-exocytic 
vesicles through promoting the remodelling of the cytoskeleton around the fused 
vesicle (de Curtis and Meldolesi, 2012). Although most of the molecular pathways 
involved in the process are still unclear, emerging evidence suggest that RhoA may 
be an important regulator. RhoA controls the coordination of actin and microtubule 
cytoskeleton modulation, as well as vesicle trafficking and fusion, via interacting with 
the exocyst complex, which is a multi-subunit tethering complex involved in the 
regulation of cell-surface transport and cell polarity in various cell systems (Pathak 
and Dermardirossian, 2013). Rac1 is also reported to participate in the modulation 
of actin cytoskeleton for vesicle release (Williams et al., 2009, Humeau et al., 2002). 
Other vital regulators of exocytosis, such as the Rab and Ral family of GTPases that 
are functional in exocyst assembly and vesicle-tethering processes (Wu et al., 
2008), are also found to be dynamically regulated during the in vitro contraction. We 
hypothesise that RhoA and to a less extent of Rac1, modulate MMP1 secretion 
through their regulatory roles in vesicle trafficking in cooperation with other small G 
proteins like Rab and Ral family of proteins (Figure 6.4). The interactions between 
these regulators in MMP1 exocytosis are waiting to be further characterised.  
 
In summary, this study has provided comprehensive and in-depth views of the gene 
expression patterns and signalling pathways underlying conjunctival fibroblast-
mediated contraction, which will assist as a powerful tool in the research of 
preventing conjunctival fibrosis and scarring. Also, the characterisation of the 
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regulatory roles that Rho GTPases and their regulators performed on cellular 
contractile activity and MMP1-mediated matrix remodelling has offered unique 
insights and novel targets for the future development of new therapeutics.  
 
 
 
Figure 6.4 A putative model for the regulation of MMP1 trafficking by RhoA and Rac1, 
in cooperation with the Rab, Ral and Rap family of proteins. 
MMP1 vesicles that bound with Rab, Ral and/or Rap families of proteins and exocyst 
components are transported to the plasma membrane using microtubule as tracks. At the 
plasma membrane, RhoA is activated and recruited to the exocyst complex. With the aid of 
Rac1, RhoA regulates the exocyst function by affecting the complex formation which 
promotes the opening of actin filaments and fusion of the vesicles with the membrane. 
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Appendix 
Gene symbols and descriptions 
A2M alpha-2-macroglobulin        
ACACA acetyl-CoA carboxylase alpha        
ACE angiotensin I converting enzyme       
ACTA1 actin, alpha 1, skeletal muscle        
ACTA2 actin, alpha 2, smooth muscle, aorta       
ADAM22 ADAM metallopeptidase domain 22       
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide     
AKR1B1 aldo-keto reductase family 1 member B       
APBB1IP amyloid beta precursor protein binding family B member 1 interacting protein   
ARHGAP20 Rho GTPase activating protein 20       
ARID5B AT-rich interaction domain 5B        
C14orf180 chromosome 14 open reading frame 180       
C1R complement C1r         
CD34 CD34 molecule         
CDH2 cadherin 2         
CDKN1C cyclin dependent kinase inhibitor 1C       
CDKN2C cyclin dependent kinase inhibitor 2C       
CLEC11A C-type lectin domain family 11 member A      
CLEC3B C-type lectin domain family 3 member B       
CMBL carboxymethylenebutenolidase homolog      
COL12A1 collagen type XII alpha 1 chain        
COL14A1 collagen type XIV alpha 1 chain       
COLEC12 collectin subfamily member 12       
CPM carboxypeptidase M        
CRABP2 cellular retinoic acid binding protein 2       
CXCR4 C-X-C motif chemokine receptor 4       
CYP1B1 cytochrome P450 family 1 subfamily B member 1      
DAAM1 dishevelled associated activator of morphogenesis 1     
DMD dystrophin         
DUXA double homeobox A        
EPB41L2 erythrocyte membrane protein band 4.1 like 2      
ERAP2 endoplasmic reticulum aminopeptidase 2      
F10 coagulation factor X         
F2RL1 F2R like trypsin receptor 1        
FABP4 fatty acid binding protein 4        
FADS2 fatty acid desaturase 2        
FAT4 FAT atypical cadherin 4        
FGF2 fibroblast growth factor 2        
FGFR2 fibroblast growth factor receptor 2       
FLT1 fms related tyrosine kinase 1        
FOS Fos proto-oncogene, AP-1 transcription factor subunit     
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FOXL2 forkhead box L2         
GATA6 GATA binding protein 6        
GKN1 gastrokine 1         
HBEGF heparin binding EGF like growth factor       
HLTF helicase like transcription factor       
HSPB8 heat shock protein family B (small) member 8      
ICAM1 intercellular adhesion molecule 1       
IFIT1 interferon induced protein with tetratricopeptide repeats 1     
IGFBP6 insulin like growth factor binding protein 6      
IGSF10 immunoglobulin superfamily member 10      
IL11 interleukin 11         
IL1R1 interleukin 1 receptor type 1        
IL1RN interleukin 1 receptor antagonist       
IL36B interleukin 36, beta         
IL6 interleukin 6         
IL7R interleukin 7 receptor        
ITGBL1 integrin subunit beta like 1        
JUN Jun proto-oncogene, AP-1 transcription factor subunit     
KCND2 potassium voltage-gated channel subfamily D member 2     
KCNT2 potassium sodium-activated channel subfamily T member 2     
KIT KIT proto-oncogene receptor tyrosine kinase      
KRT6A keratin 6A         
LDLR low density lipoprotein receptor       
LECT1 leukocyte cell derived chemotaxin 1       
LIF leukemia inhibitory factor        
LILRA4 leukocyte immunoglobulin like receptor A4      
LPL lipoprotein lipase         
MAP6 microtubule associated protein 6       
MASP1 mannan binding lectin serine peptidase 1      
MATN2 matrilin 2          
MID1 midline 1          
MMP1 matrix metallopeptidase 1        
MMP10 matrix metallopeptidase 10        
MMP16 matrix metallopeptidase 16        
MMP3 matrix metallopeptidase 3        
MYL1 myosin light chain 1         
MYOC myocilin          
NEFL neurofilament, light polypeptide       
NOG noggin          
OLR1 oxidized low density lipoprotein receptor 1      
PARD3B par-3 family cell polarity regulator beta       
PCLO piccolo presynaptic cytomatrix protein       
PEX2 peroxisomal biogenesis factor 2       
PLAUR plasminogen activator, urokinase receptor      
PLOD2 procollagen-lysine,2-oxoglutarate 5-dioxygenase 2      
PLXDC2 plexin domain containing 2        
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PSAT1 phosphoserine aminotransferase 1       
PTGER3 prostaglandin E receptor 3        
PTGS2 prostaglandin-endoperoxide synthase 2       
PTHLH parathyroid hormone like hormone       
PZP PZP, alpha-2-macroglobulin like       
RASGRF2 Ras protein specific guanine nucleotide releasing factor 2     
SEMA6A semaphorin 6A         
SERPINA3 serpin family A member 3        
SERPINB2 serpin family B member 2        
SERPINE2 serpin family E member 2        
SFRP4 secreted frizzled related protein 4       
SGK1 serum/glucocorticoid regulated kinase 1       
SLC20A1 solute carrier family 20 member 1       
SLC2A14 solute carrier family 2 member 14       
SMAD2 SMAD family member 2        
SMAD3 SMAD family member 3        
SPTBN1 spectrin beta, non-erythrocytic 1       
SQLE squalene epoxidase        
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4     
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1   
SYNPO2 synaptopodin 2         
SYTL5 synaptotagmin like 5        
TFPI2 tissue factor pathway inhibitor 2       
TGFBR3 transforming growth factor beta receptor 3      
THBD thrombomodulin         
THBS2 thrombospondin 2         
TNFSF4 tumor necrosis factor superfamily member 4      
TNNI2 troponin I2, fast skeletal type        
TNXB tenascin XB         
TSHZ2 teashirt zinc finger homeobox 2       
UCHL1 ubiquitin C-terminal hydrolase L1       
VEGFA vascular endothelial growth factor A       
VEGFC vascular endothelial growth factor C       
WISP3 WNT1 inducible signaling pathway protein 3      
ZFP36L2 ZFP36 ring finger protein like 2       
 
 
